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The Human Immunodeficiency Virus (HIV) pandemic still remains a major public
health concern worldwide. The World Health Organization (WHO) estimates that
approximately over 70% of people living with HIV in the world are in sub-Saharan
region. Malawi is one of the worst affected countries in sub-Saharan Africa with
prevalence reaching up to 16% in some areas. Recent study reports, largely in
Africa, comparing outcomes for HIV patients with Kaposi’s sarcoma (HIV/KS)
and HIV patients without KS indicate poor prognosis and poor health outcomes
amongst HIV patients with KS. While efforts are being made to improve the
management and care for the HIV/KS patient group, there is also need for contin-
ued efforts to better understand the survival patterns in this patients. The work
presented in this thesis attempts to investigate the survival patterns in different
patient subgroups in HIV cohorts in Malawi by using advanced and novel statist-
ical techniques with an ultimate aim of informing targeted patient treatment and
management practices.
In this thesis, we aim to address the following four objectives; (1) to identify
risk factors for mortality among HIV patients diagnosed with Kaposi’s sarcoma
during routine initiation of ART, (2) to model the survival pattern among HIV
patients diagnosed with KS, (3) to model local geographical variations in survival
among HIV patients on ART, (4) to quantify transition dynamics in HIV and TB
co-infection using multi-state modelling.
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For the first two objectives, we considered extended Cox models and parametric
models. We also used a novel approach of accounting for high attrition in cohorts in
which we used a ’gold-standard’ data to compare survival in our cohort. Sensitivity
analyses indicated consistencies in our approach providing an insight into how
model results change when using this comparison approach. Overall We noted
an early mortality with most patients dying in the first five months after starting
HIV treatment. Patients with TB and the patients who started in the early era
of ART were significantly at risk of dying. The model diagnostics indicated that
(i) a random effects Cox/Log-Gaussian frailty model and (ii) a flexible parametric
proportional hazards model, describe the risk of mortality in the HIV/KS patients
well.
For the third objective, spatial survival models were considered. The study showed
existence of possible residual spatial variation in survival after adjusting for age,
sex, KS status, TB status and unobserved individual frailties. To further aid our
understanding, we used the choropleth maps to indicate areas with substantially
high probability of mortality risk at different cut-off values. These results highlight
the local geographical variations in survival in HIV populations, an element more
often ignored in most studies on HIV data.
For the last objective, we considered the homogeneous continuous time multistate
Markov models. In this study we found that patients in TB free status had a
relatively higher probability of transitioning to being diagnosed with TB compared
to dying while in TB free status. However, the cumulative transition hazards for
the ’TB free → death’ transitions compared to the "TB free → TB infection"
transitions were only higher during the early days of HIV treatment. This result
emphasize how early periods after starting HIV treatment is crucial to ensure
better prognosis. We also noted significant gender differences in the ’TB-free →
death’ transitions.
It is anticipated that the findings in this thesis will help to inform treatment and
management practices of HIV patients. The findings provide clear outcome path-
ways taken by HIV/TB patients before experiencing a terminal outcome. More
vimportantly, the findings could help inform policies aimed at improving overall
survival in HIV cohorts by establishing targeted patient management and treat-
ment strategies and also formulating a more efficient triage system for care and
treatment of particular group of patients.
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The work in this thesis was motivated by the growing challenges and burden of the
HIV pandemic, especially in the resource-limited settings. Though HIV and AIDS
is a global disease, but recent program progress reports by The Joint United Na-
tions AIDS Program (UNAIDS) indicate disproportional burden of morbidity and
AIDS-related deaths, with the sub-Saharan Africa region being worst affected. In
the light of this, our work seeks to contribute to the overall understanding of sur-
vival and mortality in HIV patients with application to data from Zomba, Malawi.
Furthermore, we also study and quantify the impact of co-infection from other dis-
ease such as Kaposi’s sarcoma (KS) and Tuberculosis (TB) on HIV patients that
are initiated on a life-long HIV treatment (the antiretroviral therapy, ART).
Our work in this thesis is divided into three main parts; Part I - the introduct-
ory chapters (research proposal, epidemiological and statistical methods reviews),
Part II comprising of three epidemiological studies on survival and mortality in
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HIV patients routinely enrolled in HIV treatment program in Zomba, Malawi and
Part III which comprises of a summary discussion and conclusions.
In Part I, there are three chapters, this thesis introduction and outline being
the first chapter. In Chapter 2, we describe the overall objectives, provide a
detailed description of all the datasets used in this thesis including definitions of
variables. The introductory part also comprises of detailed literature review on
the epidemiology of diseases studied in this work; HIV/AIDS, KS, and TB. In
Chapter 4, we end this first part by providing a concise introduction to the all
statistical methods used in this thesis. The focus in this review is on the methods
used in the analyses in this work and references are provided for further details on
mathematical proofs and computation procedures.
In Part II, we present three (3) separate epidemiological studies based on our HIV
data and the summary of discussions and conclusions from these three analyses.
In Chapter 5, the objective is to quantify the mortality risk among HIV patients
on ART using the patient covariates available in our the dataset. To do this,
we use standard survival methods to study mortality in a subgroup population
of ART patients, focusing on HIV patients that are also diagnosed with KS at
the time of starting the HIV treatment. In Chapter 6, we extend the non-spatial
frailty models fitted in Chapter 5 by replacing the patient-level frailties with the
spatial frailties. The aim in this chapter is to study how survival can vary geo-
graphically and to highlight the use of spatial statistics in understanding disease
epidemiology. We use spatial survival methods for point pattern data to study the
hazards of death in the general HIV cohort in our study region (regardless of KS
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and TB). This analysis could potentially help health planners and policy-makers
in identifying areas with high risk of death as well as identifying areas requiring
extra resources to improve access to health services. Lastly in Chapter 7, the
focus is on quantifying the transition probabilities between two pairs of TB states
among patients diagnosed with TB in addition to the HIV/AIDS. The data in this
analysis are commonly categorised as multistate, and we take advantage of recent
analysis tools for analysing these data (especially those available as open-source
R-Software packages).
In Part III, we provide a general summary of discussions and conclusions of results
presented from Chapter 5 to Chapter 7. Based on our results and experience in this
work, we also suggest potential areas of further research that could be considered:
both methodological and epidemiology research.
In conclusion, through out this thesis, we have made efforts to address the items lis-
ted in the main reporting guidelines for epidemiological studies, with emphasis on
cohort studies. We solely used STROBE guidelines and our efforts are documented
in the appendix by making reference to the page numbers where a STROBE item




Research proposal and Data
description
Summary
This chapter contains the research proposal and a comprehensive review of the
literature on HIV and HIV-related diseases with emphasis on cancer and tuber-
culosis (TB). We also summarize main methods used to address each objective
although these methods are separately reviewed and discussed in detail later in
chapter 4 and subsequent chapters.
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2.1 Motivation Statement
The acquired immunodeficiency syndrome (AIDS) which is a progressive Human
Immunodeficiency Virus (HIV), is one of the main leading causes of mortality
globally (UNAIDS, 2016). Africa has the highest proportion of HIV-infected pop-
ulations with over 70% of the global HIV population living in the sub-Saharan
region. The Joint United AIDS programme estimates about 1.1 millions AIDs-
related deaths globally in 2015 alone, of which 74% were in Africa (UNAIDS,
2016).
Due to the compromised immunity, patients with HIV become vulnerable to many
opportunistic illnesses (CDC, 2016). Some of the most common opportunistic ill-
nesses in HIV patients are TB and cancer. With a rapidly growing era of provision
of a lifelong HIV treatment the highly active antiretroviral therapy (ART), recent
studies have shown that provision of this treatment has a preventive effect on op-
portunistic diseases (Velásquez et al., 2015; Johansson, Robberstad and Norheim,
2010). As such, it is recommended that all patients suffering from these opportun-
istic illnesses are tested for HIV and started on HIV treatment for the remainder
of their lives.
However, while on treatment there are many factors that may influence prognosis
in HIV patients and consequently increase their mortality risk. These factors
include patient behavioural and biological characteristics, multiple co-infections,
treatment-seeking and adherence to medication prescription, among others. For
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example, studies by Takarinda et al., (2015), Vijay et al., (2011), Chu, Mahlan-
geni et al., (2010) and Mwinjiwa et al., (2013) and Makombe, Harries and al,
(2008) highlight the disproportional co-morbidity burden and poor patient out-
comes among HIV patients with KS.
In the light of the above, there is a substantial interest in conducting research
in HIV programmes in order to constantly evaluate treatment and care practices.
The work in this thesis was motivated on this basis: to make a contribution to
scientific understanding of these opportunistic diseases in ART cohorts. Our data
focuses on the data from the sub-Saharan African country of Malawi.
2.2 Research Questions and Objectives
In this project, we aim to make use of advanced statistical analysis methodologies
to help better understand Kaposi’s sarcoma (KS) and Tuberculosis (TB) epidemi-
ology in HIV-infected patients. The main research questions to be investigated
are;
1. What are the risk factors for mortality amongst HIV/KS patients?
2. Can spatial statistical methods add to our understanding of the epidemiology
of KS among HIV patients by characterising the geographical distribution?
Do geographical determinants unexplained part of the observed variation in
risk?
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3. Which state transition paths are common in patients that are diagnosed with
TB in addition to HIV?
Specifically, we will address the following objectives in three separate chapters;
1. Understand the relationship between individual risk factors for mortality
amongst HIV/KS patients. Also, we will provide an approximate lower
bound on the proportion of patients recorded as lost to follow-up that are
really deaths.
2. Adjusting for individual-level covariate data, investigate the geographic vari-
ation in survival prognoses in the Zomba district.
3. Using multistate survival models, investigate the different infection pathways
for individuals with both TB and HIV.
2.3 Study Design
This is a retrospective cohort study. We used the HIV patient data that was
routinely captured at an ART clinic in Zomba Malawi from 2004 to 2014. We
only considered patients that started ART from 2004 to 2011 but followed them




In order to answer the research questions above, the models to be fitted will use
the following as response variables (outcomes);
• Survival (dead or alive) amongst HIV patients with KS.
• Time to death amongst HIV patients with KS (<5yrs, >=5yrs after HIV
treatment initiation).
2.5 Study setting and population
In 2008, our the study area Zomba district was estimated to be home to a pop-
ulation of approximately 700,000 with over 90% of people living in rural areas
(Malawi NSO, 2008). The district has one of the highest adult HIV prevalence
(around 16%) in Malawi. Since 2004, the Malawi Ministry of Health has scaled
up ART provision and decentralization of most HIV services such as HIV testing,
prevention of transmission of HIV virus from pregnant and breastfeeding mother
to a child. This has resulted into increase increased early HIV testing and uptake
of ART services (Malawi Ministry of Health, 2011).
By the end of 2011, over 18, 000 HIV positive patients were cumulatively enrolled
in HIV care in the district from 2004, of which approximately 3% are estimated to
either have already, or later develop cancer (with KS being common) (Mwinjiwa
et al., 2013; Malawi Ministry of Health, 2011). In this study, we used data from
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all adult HIV patients diagnosed with KS enrolled in HIV care between 2004 and
September 2011 under routine programme of HIV treatment provision. By the
end of 2011, the adult prevalence of tuberculosis (HIV-TB co-infection) in this
ART cohort was at around 15% (calculated from the our data). Figure 2.1 shows
the map of study district, Zomba district and its location on the map of Malawi.
Figure 2.1: The Map of Zomba district. On the bottom right corner is the
Map of Malawi, with Zomba district in yellow colour [Source: Zomba District
Socio-Economic Profile Report(2009-2002)].
2.6 Data Description and management
There are two types of datasets used in this work. The main data was sourced
from Dignitas International (an international non-government organisation) in col-
laboration with the Malawi Ministry of Health, Zomba district office.
The cohort data from Zomba Malawi was routinely collected in an HIV programme
from 2004 to 2014. This is the data of all HIV patients that were initiated on ART
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after testing positive to HIV. By end of 2011, the main cohort data comprised 18,
275 HIV positive patients (cumulatively) that were enrolled in the HIV clinic
care in Zomba from during this period. Three percent (615) of these patients
were diagnosed with Kaposi’s Sarcoma (skin tumour) during the screening process
to determine ART eligibility (Malawi Ministry of Health, 2011). The following
variable were available;
• Recruitment Date. This is the date at which HIV patients were initiated
on a lifelong ART. This variable was categorised in two periods: 2004-2007
and 2008-2011. This is because most ART scale-up activities started after
late 2007 and we wanted to compare patient outcomes before and after scale-
up of ART in the district.
• Age. This is defined as recruitment or baseline age, i.e age (in years) at
which patients started HIV ART. With the aging effect, the age of a patients
is an important factor and has been used in many studies to adjust any
confounding effect on the outcome of interest (Chu, Misinde et al., 2010;
Chu, Mahlangeni et al., 2010)
• Sex. Sex of patients as declared at recruitment time. Two sexes were recor-
ded as either male or female. Some studies have reported gender differences
in survival in patients taking ART (Takarinda et al., 2015).
• Name of village/traditional authority (TA). The name of a village
where patients were residing at the time of ART initiation. For confidential-
ity issues, geo-coordinates for special features near their residences were used
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such as home of village head person within each village, churches, market
places, schools, dams, hospitals, military and police stations. The data on
the geo-coordinates were obtained from the National Statistical Association
of Malawi and were matched to each patient’s address as indicated on their
clinic form.
• Distance. Using the village coordinates, we calculated the euclidean dis-
tance from the village point to Zomba HIV clinic. This variable is interesting
in two perspectives; the issue of accessibility to the clinic as a predictor of
survival, and spatial variation in survival outcomes.
• Occupation status. The type of occupation at ART initiation time. This
had the following categories; student, self-employed (includes farmers and
business persons), employed (teachers, health care workers, security person-
nel etc) and other (occupation not specified at baseline). We hypothesised
that different occupation status have different exposure to risk of HIV pro-
gression and we wanted to quantify this risk in our cohort.
• TB status. This information was updated at every HIV clinic visit. The
possible status categories recorded were; TB-free/ no TB, with TB and on
TB treatment, TB treatment completed but awaiting ascertainment of TB
status and also death. The patients that are categorised as "‘TB completed"’
are those patients whose the TB test results after completing TB treatment
was inconclusive. We considered all forms of TB whether pulmonary TB
(PTB), Extra pulmonary TB (EPTB), or multi-drug resistant (MDR) TB.
Data on TB diagnosis tool (whether smear or X-ray etc) was not captured
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in data collection tools which were used in HIV clinics but this information
was available in TB clinics. The challenge was that it was impossible to link
and merge data from TB and HIV clinics as they were collected separately.
There is documented evidence on the link between TB and HIV/AIDS and
this was included in the models as a confounder (Fenner et al., 2013; Collins
et al., 2010).
• ART outcome. This information was updated at each HIV clinic at the end
of every three months. The possible outcomes recorded were; alive (active
follow-up), dead and lost to follow-up.
• Time. This was defined as time from the recruitment date to the date of
ART outcome in chapter 5 and chapter 6. This definition was changed in
chapter 7 as time to the different TB status as considered.
2.6.1 Ethics Clearance and Study Oversight
We obtained ethics clearance to use patient data from the the Faculty of Health
and Medicine Research Ethics Committee (FHMREC) at Lancaster University
and also from the National Health Sciences Research Committee (NHSRC - 1278),
Lilongwe Malawi. The data were stored in password protected folders and access
was restricted to the researcher only.
As Principal Investigator, the research student had primary responsibilities for
the study with support from three academic supervisors in the department of
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Lancaster Medical School at Lancaster University: Dr Benjamin Taylor, Professor
Peter Diggle and Dr Thomas Keegan.
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Chapter 3
Literature review of HIV, KS and
TB Epidemiology
Summary
In this chapter, we present a comprehensive review of the epidemiology of HIV,
KS and TB. The relationship between these diseases are also explained with the
use of available literature. The review is focussed on studies and program reports
from Africa especially the sub-Saharan region because our data is from this region.
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3.1 HIV Epidemiology
The HIV and AIDS pandemic still remains a major public health problem world-
wide. Global HIV prevalence has remained at the current rate of at 0.8 % [0.7 -
0.9] for the past five years. There are large regional variations in HIV prevalence
(WHO, 2014b). Figure 3.1 shows disproportional burden of HIV with African
being worst hit by the epidemic. Other continents with high burden of HIV are
America and Europe.
Figure 3.1: Regional variations of adult HIV prevalence[Source: http://www.
who.int/gho/hiv/epidemic_status/prevalence/en/, accessed March 2014]
The World Health Organization (WHO) estimates that approximately over 70%
of people living with HIV in the world are in the sub-Saharan (SSA) region (World
Health Organisation, 2016). Within the SSA region, HIV prevalence is highest in
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females in Swaziland and Lesotho up to 37% and 31% respectively . With heavy
disease burden and limited resources, most countries in SSA region have weak
and fragile health systems. However, in the last decade the region has benefited
from the increased funding in HIV programmes targeting low and middle-income
countries, currently estimated at over $19 billion (UNAIDS, 2016). Thanks to
this huge funding, free HIV treatment ART is now provided in many developing
countries but treatment coverage is still below the 2020 treatment goals of 90-90-
90 set by the Joint United Nation AIDS Programme in 2015; 90% of HIV positive
people tested, 90% of HIV positive people started on ART, 90% of HIV patients
on HIV treatment having suppressed viral load (UNAIDS, 2014).
Malawi is one of the countries in southern Africa with high HIV prevalence. In
2008, the Malawi national adult HIV prevalence was estimated at 12% and as high
as 23% in rural areas (Malawi NSO, 2008). However, current research by the Joint
United Nation AIDS Programme estimates the prevalence in adults 15-49 years to
be at 9.1% [8.4% - 9.9%] (UNAIDS, 2015). The most common ways in which the
HIV is transmitted in Malawi is through sexual intercourse and through vertical
transmission from the mother to a child. Approximately 10% of HIV population
in the Malawi are children (Malawi Ministry of Health, 2011).
The provision of free highly active ART in Malawi dates back to 2004, when ter-
tiary government hospitals started offering free treatment the HIV positive patients
(Malawi Ministry of Health, 2008). Following the provision of HIV treatment, most
HIV related services including HIV testing and counselling, prevention of vertical
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transmission of HIV from mothers to babies (pregnant and breast feeding), tuber-
culosis prevention and treatment, were greatly expanded. The aim of expansion
and decentralisation of HIV services was to ensure that HIV infected patients had
timely access to treatment and care. A standardised treatment screening tool is
used in order to establish patients that are eligible to start ART. For example
between 2004 and 2011, HIV patients were started on ART if their CD4 count
was less than 250 cells/µL, or if they had TB or one of a list of stage 4 clinical
conditions as defined by WHO HIV clinical Staging (Malawi Ministry of Health,
2011; World Health Organisation, 2016).
HIV treatment provides protection against opportunistic illnesses and also boosts
patients’ immunity. For instance, Makombe, Harries, Yu et al., (2007) reported
improved treatment outcomes for HIV patients co-infected with TB. Johansson,
Robberstad and Norheim, (2010) reported significant differences in terms of sur-
vival between patients that started ART immediately and those that ART was
delayed, with patients that started early having an expected net benefit of 14.5
life years per patient. The national HIV programme in Malawi reports a declines
in HIV/AIDS-related deaths since the introduction of free ART in 2004. Fig-
ure 3.2 shows the gradual decline of all-cause deaths in HIV population in Malawi.
However, population level age-specific AIDS mortality rates are not available in
Malawi.
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Figure 3.2: National death trends in patients on HIV treatment[Source:
(Malawi Minstry of Health, 2014a)]
3.2 Epidemiology of HIV-related Cancer
Cancer is one of the leading causes of death globally, with 13% of deaths attributed
to cancer and 63% of these deaths occurring in developing countries. In addition,
56% of global new cases are registered in developing nations (World Health Organ-
ization, 2011b). The World Health Organization projects that by 2030, new cases
of cancer will increase by 69% from 12.7 million in 2011 to 21.4 million in 2030.
In addition, the number of deaths will increase by 72% from 7.6 million to 13.2
million deaths. Despite these overwhelming figures, cancer diseases have received
low priority from health care services in Sub-Saharan Africa (Sitas, Parkin et al.,
2006). One of the reasons is undoubtedly the overwhelming burden of infectious
diseases such as HIV and Malaria which have received undivided attention by
governments and NGOs. The continued implementation of expanded HIV/AIDS
programs in the SSA has resulted in a considerable drop in HIV/AIDS related
deaths (World Health Organization, 2008). With decreases in HIV/AIDS related
deaths, there is a steady shift of burden in the SSA region from infectious diseases
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to non-communicable diseases such as cardiovascular disease and cancer. This de-
crease could be due to demographic transition, as there access to health and social
services is improved over time. Amongst the common cancer types in Africa are;
Kaposi’s sarcoma (KS), cervical cancer, lymphomas, oesophageal cancer, liver can-
cer, breast cancer, lung cancer, and prostate cancer, (Kendiga et al., 2013; Wabing
et al., 2000; Chokunonga et al., 1999; Sitas, Bezwoda et al., 1997). The patterns
of these cancers vary greatly in different regions within Africa. However due to
limited finances and resources, very few African governments have made efforts
to curb these diseases as the majority do not have national cancer programs and
population-based cancer data . As a result many people die or are diagnosed late
when the disease has already progressed (World Health Organization, 2011a).
At the time of this study, population-based cancer data were not available in
Malawi which could be used to ascertain national prevalence for different cancer
types. Also in a recent nationwide cross-sectional health facility-based survey by
Msyamboza et al., (2012) in Malawi, approximately 18, 946 new cancer cases were
recorded between 2007 and 2010. Of 18, 946 cases, it was found that the top five
common cancers in Malawi were KS (34%), cancer of cervix (25%), oesophagus
(12%), non-Hodgkin lymphoma (6%), and urinary bladder (3%). Approximately
half (52%) of all cancer cases identified were from southern region, 34% from cent-
ral region and 13% from northern region (regional population of 45%, 42% and
13% respectively). These reported regional statistics correspond to HIV prevalence
figures in these three regions, which are 18%, 10% and 8% in northern, central
and southern regions respectively (since majority of cancer types in Malawi are
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HIV-related) (Malawi NSO, 2008). Kaposi’s sarcoma and cervical cancer were
found to be more prevalent in HIV infected populations, consistent with the lit-
erature that indicate that with the rise of HIV/AIDS in Africa, KS has become
the most frequently reported cancer in many sub-Saharan countries (Rohner et
al., 2014). By 2010, there were a total of 84 facilities (including public, research
and non-governmental facilities) providing either cancer laboratory diagnosis, or
treatment, palliative care, or referral services. Surgery, where undertaken was com-
pleted in all referral public hospitals which are: Queen Elizabeth Central Hospital
and Zomba Central Hospital in the southern region, Kamuzu Central Hospital in
central region, and Mzuzu Central Hospital in the northern region (Msyamboza
et al., 2012). Until recently, the majority of cancer treatment in Malawi has been
palliative (chemotherapy) and poor patient outcomes for cancer have been repor-
ted in sub-Saharan Africa (Kendiga et al., 2013; Sankaranarayanan et al., 2010).
For the rest of this section, we review literature on KS epidemiology with a focus
on its occurrence in HIV populations.
Kaposi’s sarcoma (KS) is a tumour caused by Human Herpes virus 8 (KSHHV)
(Minhas and Wood, 2014). The virus is common amongst the people whose im-
mune system have been severely weakened, for example people infected with HIV.
Studies have shown that highly active antiretroviral therapy (HAART), a treat-
ment given to HIV positive patients, has preventive effects on KS and it is recom-
mended being the first line treatment for patients (David, 2014). The most com-
mon transmission modes for Kaposi’s sarcoma Human Herpes-virus (KSHHV) are
sexual contract, blood transfusion, and saliva contact (Minhas and Wood, 2014).
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The epidemiology of KSHHV varies greatly geographically with more endemic re-
gions being sub-Saharan Africa, the Mediterranean, and north-west China. How-
ever, the United States of America and Western Europe have a low prevalence
(Minhas and Wood, 2014; Sankaranarayanan et al., 2010; Wu et al., 2014). In the
regions where KSHHV is not endemic, the virus is more prevalent among men who
have sex with men (MSM). This being the case, there are no comparable studies
from this area looking at the KS in the general HIV population because MSM
is largely unrecognisable in endemic KS areas. A systematic review proposed by
Rohner et al., (2014) is one of the studies reporting the global trend of KSHHV.
Since the introduction of HAART, the incidence of KS has been declining in the
general HIV populations and fewer people with advanced conditions are start-
ing HIV treatment; this trend is also observed elsewhere in HIV populations on
HAART (Gbabe et al., 2014). The most common treatment for KS in Africa
is chemotherapy as opposed to radiotherapy which is more often available in de-
veloped countries (Dedicoat, Vaithilingum and Newton, 2003). In their systematic
review of African studies, Gbabe et al., (2014) reaffirms the role of HAART and
chemotherapy in delaying disease progression in HIV patients with KS. Figure 3.3
shows the decline in the percentages of deaths in patients who are staged in WHO
HIV clinical stage 4 in Malawi. Kaposi’s sarcoma is one of the conditions in this
stage 4. From this figure, we also note a significant declining trend of proportion
of patients starting treatment in advanced stage from about 23% in 2004 to 5% in
2014.
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Figure 3.3: Trends in all-cause mortality amongst patients starting HIV treat-
ment in advanced HIV stage (WHO Stage 4)[Source: (Malawi Minstry of Health,
2014a)]
Table 3.1 shows some of the risk factors of mortality in HIV populations with KS.
These factors are discussed in detail in studies by Chu, Misinde et al., (2010), Chu,
Mahlangeni et al., (2010) and Ziegler et al., (2003). Other factors such as sex and
occupation have not been found to be significant although the number of deaths is
disproportional in these subgroups (Makombe, Harries and al, 2008; Chu, Misinde
et al., 2010).
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Table 3.1: Examples of risk factors for mortality in HIV patients with KS.
Risk factors Description
AIDS HIV patients with KS progress to AIDS increasing
their risk of death (Chu, Mahlangeni et al., 2010)
Advanced KS stage the risk of mortality is increased with KS stage
(Chu, Misinde et al., 2010)
Poor adherence patients with irregular uptake of treatment (HAART
and chemotherapy) have increased risk of mortality
(Ngarina et al., 2013)
Low CD4 counts high mortality in patients with low CD4 counts
(Johansson, Robberstad and Norheim, 2010)
Age older patients tend to have higher mortality risk
(Belayneh, Giday and Lemma, 2015)
3.3 HIV and TB Epidemiology
Tuberculosis is common in people with impaired immunity such as HIV positive
persons, diabetic, malnourished and tobacco smokers and is one of very the in-
fectious bacterial diseases. The disease is spread through air when an infected
person coughs, speaks or sings. It is one of the most common opportunistic infec-
tions in persons living with HIV. The recent TB fact sheet by the World Health
Organisation indicates that people who are HIV positive are 20 to 30 times more
27
likely to develop active TB (World Health Organization, 2016). For HIV positive
patients, being diagnosed with TB is a sign of progression to AIDS (CDC, 2016).
The World Health Organisation reports that TB is a leading killer of HIV patients,
with one in every three deaths among HIV patients was due to TB (World Health
Organization, 2016).
The global TB treatment success rates range from 30 to 83% but it is much lower
in HIV cohorts. HIV positive positive persons receiving ART have reduced risk
of developing TB as several studies have reported the protective effective of ART
on opportunistic illness, with a reduction in risk of death ranging from 70 - 90
% (Belayneh, Giday and Lemma, 2015; Vijay et al., 2011; Collins et al., 2010;
Johansson, Robberstad and Norheim, 2010).
In an effort to combat TB occurrence, several campaigns have been initiated all
aiming at eliminating the TB disease. These campaigns include adoption of uni-
versal ART provision, WHO End TB strategy which targets 35% reduction in
TB cases by 2020 and the UN zero campaigns targeting TB, AIDS, Malaria and
poverty among others. In Malawi the TB treatment success rate is estimated at
89% which is higher than the WHO target of 85%. The main reason is for this suc-
cess is due to the increase in funding the country has received from international
grants such as the Global Fund (WHO, 2014a).
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3.4 Loss to follow-up in HIV cohorts
Like in other cohort studies, loss to follow-up (LTFU) is still a challenge in HIV
studies(Freeman, Semeere and Wenger, 2016). Being lost to follow-up is defined
as failing to attend scheduled clinic visits after a defined period of time. This
definition varies by country, but in Malawi patients are deemed lost to follow-up
if they do not show up after 120 days from a scheduled clinic visit date (Malawi
Ministry of Health, 2008; Chi et al., 2011). As a result, there is a growing interest
in addressing the impact of loss to follow-up data in estimation of survival in
HIV studies. Up to now the methods proposed to address the impact of loss to
follow-up (LTFU) on survival estimates have largely depended on the proportion
of deaths based on a sample of LTFU patients.
Without a clear picture of mortality in the LTFU patients, analyses ignoring this
phenomenon may underestimate survival and mortality rates in such cohorts be-
cause the deaths in LTFU patients are not included in the analysis. In absence
of active patient tracing, different approaches have been used to improve estim-
ation of mortality in HIV cohorts. These methods include; tracing a random
sample of LTFU patients (tracing method) and meta method (Yiannoutsos, An
et al., 2008; Egger et al., 2011; Henriques et al., 2012; Kiragga et al., 2013).
These proposed methods are have been largely developed by a South African re-
search initiative on International Epidemiological Databases to Evaluate AIDS
(IeDEA) (http://www.iedea-sa.org/). For the tracing approach, a random
sample of LTFU patients is usually selected and traced to ascertain their true
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outcomes and the final data for analysis is adjusted to reflect an estimate pro-
portion of deaths among LFTU patients. For the meta method, a meta-analysis
of LTFU studies is conducted and the resulting estimates of mortality in LTFU
patients is used in a developed formula to estimate mortality (see the formula at
http://www.iedea-sa.org/index.php?id=2785, accessed; 2016-02-20)
We compiled some of the studies that have been conducted using active tracing
of patients and the reported proportions of mortality among LTFU patients in
HIV cohorts varied across studies (see Table 3.2 below). It can be noted that
studies that traced between 13 and 45 % of LTFU patients reported proportion of
deaths ranging between 20% and 60% among traced LTFU patients. On the other
hand, studies that had traced at least 50% of lost patients, reported proportion
of deaths in this group ranging between 20 - 87%. These statistics point to the
fact that in some HIV cohorts, mortality is higher than others thereby limiting the
generalization of the tracing and meta method. We will use these figure later in
Chapter 5 to inform our approach of addressing this issue of LTFU in our analysis.
In Malawi despite a decline in HIV deaths, the national LTFU rates have consist-
ently remained around 2% since the start of ART programme in 2004, as shown
in Figure 3.4 (here, the LTFU rate is labelled as "‘Default rate"’).
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Table 3.2: Proportion of deaths among LTFU HIV patients
Figure 3.4: Quarterly rates of attrition from ART cohort as composed from
those who stop taking ART, patients loss to follow-up and those who die while
on ART treatment. This includes funding for different types of TB [Source:
(Malawi Minstry of Health, 2016)]
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General statistical review of survival
analysis methods
Summary
In this chapter, we provide a general review of statistical methods for analysing
time-to-event data. The main focus in this chapter is on methods for analysing
right censored time to event data in which not all individuals experience the event
of interest by the end of the study. We also review and discuss some of the
extensions of standard survival models such as; flexible parametric survival models,
competing risks model and multistate models and spatial methods for survival
data and their application to disease epidemiology. Inferential approaches are also
discussed for each model and efforts are made to link these methods to future
studies in the next three chapters.
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4.1 Introduction to survival analysis
Survival analysis techniques are used to analyse time to event data. These methods
have been extensively used in many application fields such as engineering sciences,
social science, medicine and epidemiology. For example, in medicine, survival
methods are used in clinical trials and epidemiological studies. For instance, sur-
vival analysis is used for analysing time to death, time to cancer remission and
length of stay in hospital (Kleinbaum and Klein, 2012; Diva, Banerjee and Dey,
2007).
In many studies not all individuals necessarily experience the event of interest by
the end of study. In cohort studies, individuals may also be lost to follow-up during
the course of a study. For individuals that did not experience the event of interest
by the end of study, their observed times are referred to as right censored times.
An analysis based on the complete event times only (by omitting the incomplete
times) will more often over estimate the parameters of interest (see Figure 5.2 on
page 104). Any analysis tool to be applied to such types of data ought therefore
to account the fact that complete time was not observed for some individuals.
Regression models that take into account this problem are popularly known as
survival or duration models.
In analysing survival data, interest often focusses on modelling the instantaneous
risk of experiencing the event or the estimated time before an individual experi-
ences the event of interest. As a result, the main functions used in survival models
are the hazard function and survival function. These functions are formally defined
40
and discussed in detail in subsection 4.1.3 and subsection 4.1.4 below. A detailed
tutorial on survival analysis can be found in many textbooks such as Ibrahim,
Chen and Sinha, (2010), Kleinbaum and Klein, (2012), Kalbfleisch and Prentice,
(2002) and Hosmer and Lemeshow, (1999), and Cox, (1972).
4.1.1 Right Censoring
In studies in which not all individuals experience the event of interest, the invest-
igators only have knowledge about the survival time up to a certain point but
not the complete true observed time. In many cases, incomplete time is observed
when either
• the individual does not experience the event by the end the study or
• the individual is lost to follow-up or
• the individual voluntarily withdraws from the study (the reason could be on
health ground).
When the event time for an individual in the study has not been observed, then
such times are referred to as censored times. In this thesis, we consider random cen-
soring which is a common assumption in many application fields such as medicine
and epidemiology. Random censoring means that survival times are independent
of the underlying censoring mechanism (Kleinbaum and Klein, 2012). There are
three types of censoring; right-censoring, left-censoring and interval censoring.
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Observed times are said to be left-censored if the event of interest has already
occurred before date of enrolment. Interval censoring is when the event time is
known only to have happened in an interval.
However, in practice most survival data are right-censored (Kleinbaum and Klein,
2012, p. 7). Data are right-censored when an individual has not been observed to
experience an event of interest by the end of study. This means that the event of
interest in known to have happened after some time t but the exact time is not
known. Henceforth, we will assume that the data of interest are right-censored.
In most studies, the study period is determined in advance (fixed or Type I censor-
ing ), and in this case the number of events is random. In some studies, however,
the number of events is determined in advance (random or Type II censoring)
meaning the study period is random, with the study ending when the required
number events has been observed.
Table 4.1 shows the general design of data for a simple right-censored survival
analysis. As we will notice from section 4.3, this design may change depending on
the complexity of the problem under study.
Table 4.1: Data preparation for a simple right-censored survival analysis
ID# age sex times status
1 18 F 119 1 ← event
2 40 F 75 0 ← censored
3 22 M 30 1
4 38 F 19 0
5 30 M 101 1
6 20 F 80 1
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4.1.2 Density and Distribution Functions
The probability density function f(t) for a random variable T , denoting survival
time, is defined as;
f(t) = lim
∆t→0
P (t < T ≤ t+ ∆t)
∆t
(4.1)
where ∆t represents a small change in t and t ≥ 0. And the cumulative distribution
function of T is




where f(t) is given as above. The distribution F (t) gives the probability that the
survival time does not exceed some given value t (Collett, 2014, pp. 11).
4.1.3 Survival function
The survival function, denoted as S(t) is related to the distribution function of t
as follows;
S(t) = P (T > t) = 1− F (t) (4.3)
The S(t) function gives the probability of an individual surviving beyond time t
(Cox, 1972).
The survival function can be estimated by both non-parametric and paramet-
ric methods. Some parametric methods are described in detail under subsec-
tion 4.2.2. For non-parametric estimators, the two most popular methods used
are the Kaplan-Meier (K-M) and the life table estimators. The only difference
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between these two non-parametric estimators is that the life table method is a
grouped analogue of K-M method and is usually used for larger samples of data
or population-level data. Again these methods are well described in main text
books on survival analysis (Ibrahim, Chen and Sinha, 2010; Kleinbaum and Klein,
2012; Kalbfleisch and Prentice, 2002; Hosmer and Lemeshow, 1999; Cox, 1972).
However, in this thesis we concentrate on the use of Kaplan-Meier estimator of the
survival function developed by Kaplan and Meier, (1958) because it is the most







where nj and dj are the number of individuals at risk and the number of deaths
respectively in the time interval (tk, tk+1), with k = 1, 2, 3, . . . r events occurring
at times t1 ≤ t < t2 ≤ · · · tr. Survival curves based on the K-M estimator in
Equation 4.4 are popularly referred to as Kaplan-Meier (K-M) curves, named
after the authors. The K-M estimator has the following assumptions (Kaplan and
Meier, 1958);
• that censoring is not related to the prognosis of patients.
• the survival probability is the same for patients recruited early and late in
the study.
• that events actually occurred at the reported event times.
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In survival studies, we are often interested in measuring the effect of covariates on
the time of occurrence of an event. In this case, the use of the K-M estimator is
limited only to inclusion of one categorical covariate or factor in the model. To
compare the K-M curves amongst different groups we can use the log-rank test.




dij − eij (4.5)
where dij is the number of deaths in group i at time j, and eij = nijdj/nj is the
expected number of individuals who die at time tj in groug i (Collett, 2014).
The statistic for comparing survival between two groups is
WL = UL/
√




where VL is the variance and WL ∼ χ21.
4.1.4 Hazard Function
The hazard function denoted as h(t) is a function that measures the probability of
failure in an infinitesimally small time period (t, t+ ∆t), given that the individual




P (t < T ≤ t+ ∆t|T > t)
∆t
}
, t ≥ 0 (4.7)
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where T is as defined above. The hazard, survival and the density functions are
mutually related. The density function f(t) is just the product of the hazard
function and the survival function i.e. f(t) = h(t) × S(t). From the relationship
of f(t) and S(t) in Equation 4.3, this means that the hazard function can also be
expressed as;
h(t) = f(t)/S(t) = − ∂
∂t
logS(t) (4.8)
4.2 Models for Survival Data
In many cases especially in medical and epidemiological studies, there is interest
in adjusting for the effects of covariates on the risk under study. In order to do
this, regression models are used. These models fall under two main frameworks:
proportional hazards (PH) models and accelerated failure time (AFT) models. We
review these two modelling frameworks in the sequel. However, our review here
is limited to time-constant covariates, but extensions for handling time-varying
covariates are available in standard survival textbooks and software.
For the rest of this review we will use the following notation for simplicity. Let n
be the number of individuals and p be the number of covariates for each individual.
Also, let X be a n× p design matrix and β be a p× 1 vector of covariate effects to
be estimated from the data.
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4.2.1 Proportional Hazards Model
Proportional Hazards (PH) models are regression models in which the hazards are
modelled using the covariates and possibly random effects. The main assumption
of PH models is that the hazard ratios between individuals in two different groups
are proportional over time. In addition, they also assume that the covariates
included in the model have a multiplicative effect on the hazard ratios (Kleinbaum
and Klein, 2012). If the hazard ratio is greater than one, the exposure effect lowers
the survival rate (increases risk of an event occurring) and vice versa.
A proportional hazards model can either be semi-parametric or parametric. We
discuss these different types of models in turn under subsubsection 4.2.1.1 and in
subsubsection 4.2.1.2.
4.2.1.1 Semi-Parametric PH Models
A semi-parametric model is a model that has both parametric and non-parametric
components. An example of a semi-parametric model is the widely applied Cox
PH regression model. The Cox PH model is a semi-parametric model because the
distribution of the baseline hazard function is left unspecified. The Cox PH model
is defined as
h(t) = h0(t) exp (Xβ) (4.9)
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where h0(t) is the baseline hazard (distribution-free). The cumulative baseline













= exp {−H(t)} , (4.11)
where H(t) is called the cumulative hazard function. This relation makes easy
to generate one function from the other. For instance, if the survival function is
available, one can obtain the cumulative hazard function by taking the natural
logarithm of the survival function i.e. H(t) = − logS(t) from which h(t) follows
(Collett, 2014).
The parameters β can be estimated from the data (ti, δi, X) (time, censoring in-
dicator, covariate) for i = 1, 2, . . . , n individuals by maximizing the logarithm of









where δi is an indicator of whether ti is a right-censored time or not, R(ti) is the
set of individuals at risk of experiencing the event at time ti and Xi is the vector
of covariates for individual i. This likelihood assumes that there are no ties in
event times. However, if ties exist in the data, then the modified partial likelihood
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introduced by Breslow, (1975) or by Efron, (1977) can be used to estimate the









k∈Di Xk, at distinct time i and di is the number of deaths at time t.











where Di is a set of individuals that died at time i and all other terms as defined
above.
4.2.1.2 Parametric PH Models
As noted above, a functional form for the baseline hazard h0(t) is not specified in
the Cox PH model. However, it is also possible to specify a form for h0(t). When
the form of the hazard function is specified and depends on some parameters, the
resultant models are called parametric.
Parametric modelling has some advantages over the Cox PH modelling. Among
others, parametric models have better prediction and extrapolation, better per-
formance in modelling time-dependent effects and often produce reliable and con-
sistent estimates under asymptotic results (Nardi and Schemper, 2003; Efron,
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1977). The main caveat with parametric models is that they put strong assump-
tions on the distribution of the baseline hazard function. Due to uncertainty of
misspecification of the baseline hazard distribution, many analysts opt for Cox
PH over parametric model because the distribution of baseline hazards is left un-
specified. However, the use of cubic splines in flexible parametric modelling of
log of the cumulative hazard function provide similar estimates to the Cox PH
and is increasingly being applied in medicine (see page 53 on discussion of flexible
modelling).
In this section we limit our discussion to the case when the form of the baseline
hazard function is derived either from the Exponential , Weibull, or Gompertz
distribution. We also consider:
i) Exponential PH model
The Exponential distribution is a one parameter (rate) distribution that assumes
that the rate is constant over time. So the hazard function is written as;
h0(t) = λ
where λ is the rate parameter. The resultant Exponential PH model is
h(t) = λ exp(Xβ) (4.15)
Also the survival function in this case is S(t) = exp {− exp(Xβ)λt} (see Equa-
tion 4.11), and the density function of T becomes f(t) = λ exp(Xβ) exp {− exp(Xβ)λt}.
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{λ exp (Xβ)}δi exp {− exp(Xβ)λt} (4.16)
ii) Weibull PH model
The Weibull distribution yields a more flexible baseline hazard than the Expo-
nential in the sense that it has two parameters, a scale and shape parameter and
includes the Exponential as a special case. The shape parameter controls the shape
of the hazard function allowing it to either decrease or increase monotonically over




h(t) = λαtα−1 exp (Xβ) (4.17)
where λ is the scale parameter and α is the shape parameter, both λ,α > 0.
If α = 1, then Equation 4.17 becomes an Exponential model (special case of
Weibull model) and λ is interpreted as a rate parameter. If α > 1, then the
hazards increase over time and if α < 1, the hazards decrease over time. The
Weibull survival function is S(t) = exp {− exp(Xβ)λtα}) and the density function
for T is f(t) = λαtα−1 exp (Xβ) exp {− exp(Xβ)λtα}). The likelihood function is
expressed as





}δi exp {− exp(Xβ)λtα} (4.18)
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iii) Gompertz PH model
The Gompertz model is also a two-parameter model with the hazard and survival
functions defined as follows;
h0(t) = λ exp(γt)
S(t) = exp
{−λγ−1(exp (γt)}
where λ and γ are unknown parameters to be estimated from the data. The
Gompertz PH model is
h(t) = λ exp(γt) exp (Xβ) (4.19)
A positive value of γ means increasing hazard rates with time, a negative value
means a decreasing hazard rate and if γ is zero, then the model reduces to an
exponential model. The β are obtained by maximising the log-likelihood;
L(β, γ, λ) =
n∏
i=1
{λ exp(γt) exp(Xβ)}δi exp{− exp(Xβ)λγ−1 exp(γt)} (4.20)
iv) Flexible PH Model
This is one of the flexible parametric models proposed by Royston and Parmar,
(2002). Royston and Parmar, (2002) proposed a flexible method for estimating
the baseline hazard function h0(t). They proposed to model the log of cumulative
hazard function using a natural cubic spline constrained to be linear beyond the
maximum survival time. Cubic splines are basically piecewise polynomials passing
through a set of control points, also known as knots. The flexible PH model is
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formulated as follows;
logH(t) = s(log(t); γ) +Xβ (4.21)
where H(t) is the cumulative hazard function, s(.) is natural cubic spline with γ
as spline coefficients and s(.) is defined as
s(x; γ) = γ0 + γ1x+ γ2v1(x) + . . .+ γm+1vm(x), with
vj(x) = (x− kj)3+ − λj(x− kmin)3+ − (1− λj)(x− kmax)3+
where vj(x) is the jth basis function, k1 < . . . km being the internal knots, and λj
is a jth location parameter defined as λj = (kmax − kj)/(kmax − kmin)
It is usually optimal to choose the internal knots around more dense regions to
minimise variance. As such, knots around the median or quantiles are preferred,
suffice to say that the placement of knots does not critically affect the goodness
of fit of the model (Hinchliffe and Lambert, 2013).
iv) Flexible Proportional Odds Model
Similar to Equation 4.21, the flexible parametric proportional odds model is for-
mulated as
log(S(t)−1 − 1) = s(log(t); γ) +Xβ (4.22)
where S(t) is the survival function, s(.) is natural cubic spline with γ as spline coef-
ficients, all other parameters defined as in Equation 4.21. A detailed description
of these flexible models can be found in Royston and Parmar, (2002).
53
4.2.2 Accelerated Failure Time Models
The AFT models describes the direct relationship between failure time and co-
variates. While in Cox PH model the key assumption is that the hazards are
proportional, in AFT models the key assumption is the accelerated failure time.
An acceleration factor is a measure of association in AFT models just as hazards
ratio in Cox PH models. This factor describes the stretching out or contraction of
survival functions when comparing one group to another for any fixed value of the
S(t). An acceleration factor of greater than one indicate that the covariate effect
is beneficial (or stretches out survival time) and vice versa. The frequently used
distribution families in AFT modelling are; Exponential, Weibull, Log-logistic,
Log-normal and Gamma distribution(Kleinbaum and Klein, 2012). The Expo-
nential and Weibull models are special cases of parametric survival models that
satisfy both PH and AFT assumptions. The advantage of parametric PH models
over Cox PH models is that they are consistent with theoretical survival function
S(t) (Kleinbaum and Klein, 2012).
The AFT models put individuals with different covariates on different time scales.
Also, the AFT models assume that the log of failure time T, log T , is in a linear
relationship with a mean µ, the covariates (and their parameters) and an error
term W , where W takes a particular distribution. In other words, AFT models
are additive on log scale but multiplicative with respect to T.
log T = µ+Xβ + σW
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where σ is a scaling parameter. The type of model to be fitted depend on the
choice of the distribution for the errors W . As already mentioned in preced-
ing paragraphs, the available distribution for survival models in analysis software
are Exponential, Weibull, Gompertz, generalized Gamma, Log-normal and Log-
logistic.
In practice, AFT models are rarely used in application analyses, with PH models
more popular in medicine and epidemiology. However, AFT models offer a good
alternative to PH models in that they can be used when the PH assumption is
violated. The PH assumption may be violated in the instances when the treatment
under study tends to delay the onset of the event as opposed to increasing or
reducing occurrence of the event (Patel, Kay and Rowel, 2006).
In the next sections, we briefly summarize the behaviour of the hazard and survival
functions for each of these distributions.
In AFT framework and using Section 4.2.2, the parametric models have the sur-
vival function in the form of S(t) = S0 {t/ exp(Xβ)}, where S0 is the baseline sur-
vivor function defined as, S0(t) = P {exp(µ+ σW ≥ t)} (Collett, 2014, pp. 207).
4.2.2.1 Weibull Model
The AFT form of the Weibull model is parametrised in terms of survival time
(Kleinbaum and Klein, 2012, pp. 208). We have discussed that the Weibull PH
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model is
h(t) = λαtα−1 exp(Xβ) (4.23)
S(t) = exp {−λtα exp(Xβ)} (4.24)
The parameters are obtained by maximising the log-likelihood function;
L(β, α, λ) =
∏
[λαtα−1 exp(Xβ)]δi exp {− exp(Xβ)λtα} (4.25)
The limitation of the Weibull model is that it is a monotonic function of time, can
either increase or decrease.
4.2.2.2 Log-logistic Model









where µ and σ are as defined in subsection 4.2.2 and are estimated from the data.
The model can be used in situations where the hazard is thought to increase for
a short time and decrease overtime, such as in studies on risk of death in patients
after a heart transplant. If the proportional odds assumption holds for the data,
then the Log-logistic model can also be fitted as a survival odds model; S(t)
1−S(t)
(Kleinbaum and Klein, 2012).
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4.2.2.3 Log normal Model
The log normal and log logistic models tend to be similar since the logistic and
normal distribution are similar. These models are parametrised only as AFT.
In both models, the natural logarithm follows a normal and logistic distribution
respectively. These models are usually suitable for scenarios where the hazard rates
are non monotonic, specifically increasing in the first instance and then decreasing.
The survival function for the log normal model is






where Φ(z) is a normal cumulative distribution function, µ and σ are estimated
from the data (Collett, 2014)
4.2.2.4 Generalized Gamma Model
Finally, we consider a generalized gamma model which is also parametrised as an
AFT model only and offers more flexibility in modelling hazard functions. The
survival function is given by
S(t) = 1− Γ(µt)θ(ρ)
where Γ(µt)θ(ρ)0 = 1Γ(ρ)
∫ (λt)θ
µρ−1 exp(−µ)du. The flexibility of the hazard func-
tion of the generalized gamma distribution is that it has the Gamma, Weibull,
Exponential and Log normal models as special cases. If both ρ and θ are equal to
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1, then it becomes exponential model, if ρ = 1 it becomes Weibull, and reduces to
log normal if ρ→∞ (Collett, 2014).
4.3 Extensions to Standard Survival Models
The modelling techniques discussed so far can be considered as standard. How-
ever, extensions to these models are available which are aimed at modelling more
complex datasets. Here, we present and discuss frailty models, spatial models and
multistate models (which include the competing risk models).
4.3.1 Frailty Models
In survival modelling, sometimes interest lies in modelling heterogeneity at the
individual or at a group level not captured by the available covariates. To accom-
plish this, all of the survival models discussed in the preceding paragraphs can
be extended to incorporate a term that specifically measures heterogeneity, pop-
ularly referred to as a frailty term (Collett, 2014; Therneau and Grambsch, 2000;
Wienke, 2011). For example, the Equation 4.9 can be extended to incorporate a
frailty term Z to become
h(t) = Zh0(t) exp(Xβ) (4.28)
Here, Z has a known distribution form and is a surrogate for unobservable het-
erogeneity, say, amongst individual patients or clusters: Z can be thought of as a
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multiplicative random effect. Mathematically, Z is defined as Z iid∼ f(.;σ) where f
is a positive-valued probability density function of given form (e.g log-normal or





{zih0(t) exp(Xβ)}δi exp {−ziH0(ti) exp(Xβ)} (4.29)
where δi is the censoring indicator, β and σ are parameter estimates for covariate
effect and the heterogeneity component respectively, and H0(ti) is the cumulative
baseline hazard function. Larger values of this variance indicate greater hetero-
geneity among the sample units. The Gamma and the Log-normal distributions
are the popular choices for the distribution of Z.





where its variance σ is indirectly calculated as V ar(z) = λ2k. The interest is in
the value of this variance











where σ is the variance, and again this is reported in the fitted models.
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4.3.2 Spatial Survival Modelling
Spatial survival models are another extension of the standard survival models.
These models are an extension of frailty models in which the frailties are allowed
to be spatially correlated and this correlation depends on the distance apart in
space or depends on the spatial neighbourhood effect. In these models, the assump-
tion of independence in the residuals is relaxed. In the context of epidemiology,
spatial methods have extensively been used to study disease pattern and identify-
ing the source of a particular problem (Adebayo and Fahrmeir, 2005; Henderson,
Shimakura and Gorst, 2002; Li and Ryan, 2002; Banerjee and Dey, 2005). Spatial
methods have a particular appeal in epidemiology as they can help understand
underlying environmental factors influencing disease occurrence or progression.
Fitting such models can help in planning and allocation of resources to tackle the
disease. With survival analysis being popular in epidemiology and health research,
spatial survival analysis have become popular with the growing methodological
work (including computation methods) in this area in the past two decades.
One of the main reasons to conduct a spatial survival analysis is to identify regions
in space in which the risk of experiencing the event is unusually large. Other
factors being equal, we might expect individuals closer in space to have similar
environmental exposures compared with individuals far apart.
In subsection 4.3.1, we discussed frailty models as an extension of the Cox PH
model. A similar approach is used in spatial survival models to include the spatial
frailties. These spatial frailties describe the spatial variation in survival or hazards
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of death. The general formulation of the proportional hazards spatial frailty model
denoted by re-writing Equation 4.28 as,
h(t;x) = h0(t) exp {Xβ + S(x)} , x ∈ R2 (4.32)
where βs as defined above, S(x) is the value of a continuous stationary Gaussian
process (SGP) at x in space. Values of S(x) are more correlated between points
that come close compared to those that are far away. Different choices of S(x) are
available. For example, Henderson, Shimakura and Gorst, (2002) used a slightly
different parameterisation and a gamma random field. It is also possible to have
assume models that assume discrete spatial variation:
h(t, s) = h0(t) exp {Xβ + Si} (4.33)
where Si are defined on discrete regions and possibly have a conditional autore-
gressive correlation structure.
Our focus in this thesis is on spatial proportion hazards (PH) models defined in
Equation 4.32 and these models have been discussed by Henderson, Shimakura and
Gorst, (2002), Li and Ryan, (2002), and Banerjee and Carlin, (2003). Methodology
work on other modelling frameworks is also available in the literature: Banerjee
and Carlin, (2004) on spatial proportional odds models; Zhang and Lawson, (2011)
on spatial AFT models; Banerjee, Wall and Carlin, (2003). Also, some work
has been done on spatial multistate modelling by Nathoo and Dean, (2008) and
Brezger, Kneib and Lang, (2005).
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Due to complexity of spatial survival models, the Bayesian approaches to modelling
are common than the Frequentist approach. Taylor and Rowlingson, (2014) is an
example of recent methodological work aimed at improving the computation time
of spatial PH models and the authors provide a concise review of other available
computation approaches. In Chapter 6, we employ the computation approaches
as proposed by Taylor and Rowlingson, (2014). Their methods are implemented
an R-package spatsurv.
4.3.2.1 Covariance Functions
The list of available covariance functions used for this purpose among others in-
clude; Gaussian, Spherical, Wave, Power law and the Matern family and details
about these functions can be found in textbooks such as Diggle and Ribeiro, (2007,
p. 54-56) and Banerjee, Carlin and Alan E, (2004, pp. 32-35).
However, in many applications due to its flexibility, the Matern family functions
are favoured in model selection process (Banerjee, Carlin and Alan E, 2004; Hende-
rson, Shimakura and Gorst, 2002). The Matern family has an Exponential as a
special case.
Here, we present a summary of some of popularly used correlation functions due




ρ(µ) = exp(−µ/φ), φ > 0 (4.34)
where µ = ‖x− x′‖ is the distance between two arbitrary points x, x′ ∈ R2,
and φ is the spatial decay parameter with dimensions of distance.
2. Powered exponential (Diggle, Tawn and Moyeed, 1998):
ρ(µ) = exp[−(µ/φ)κ], φ > 0 (4.35)
where κ (also called the order) is a shape parameter determining how smooth
the underlying S(x) is, and φ is as defined above.
3. Matern function (Matern, 1986):
ρ(µ) = [2κ−1Γ(κ)]−1(µ/φ)κKκ(µ/φ), κ, φ > 0 (4.36)
in which κ and φ are as defined above, andKκ(.) is a modified Bessel function
of order κ. The Exponential function is a special case of the Matern function,
with κ = 0.5.
The correct choice for the underlying spatial correlation function is important
because it informs extent to and manner in which the correlation decays in space
for the disease. Misspecification of this function may lead to incorrectly specifying
how spread disease is in space and the closeness of the spatial units.
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4.3.3 Competing risk and Multi-state Modelling
The methods presented so far assumed standard time-to-event data in which only
one event (all-cause death) is of interest and all other events are censored. However,
in medical research there are situations in which we may wish to model failure from
a number of possible causes. We call these causes competing risks. For example, if
our interest is to study time until death due to breast cancer, then if some women
die from stroke, this will impede the occurrence of death due to breast cancer. In
this case, we regard stroke as a competing cause of death.
It should be noted that all competing events have the same initial state (being
alive and free of breast-cancer as in our example). Sometimes, interest is in estim-
ating transitions into intermediate states/events, for instance from being diseased
to disease-free (healing/recovery) or to relapse. In this case, we can use multistate
models which are a generalization of the competing risks models. In these mod-
els, subjects are usually assumed to belong to one of a finite number of states,
including death or censored. The rest of this section is devoted to reviewing the
mathematical theory and their assumptions of the competing risk and multistate
models.
We hasten to mention to the reader that although there are extensions of multistate
models to include individual frailties and spatial frailties are available, we restrict
our review in this section to the non-spatial multistate and competing risk models.
For models with frailties, see some of the methodological work by Alvaro-Meca et
al., (2012) and Nathoo and Dean, (2008) and Brezger, Kneib and Lang, (2005).
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4.3.3.1 Competing Risk Modelling
The data set up in competing risk framework is different from the standard time-
to-event data with one cause of death. In competing risk data, in addition to
censored times (0) and cause of interest(1), other competing causes are assigned
values 2, 3 · · · instead of being censored to indicate they are also outcomes of
interest. Table 4.2 shows how data are commonly set up before analysing them.
In this example, individuals with IDs 1 and 5 had the same event 1, the individuals
3 experienced the event 2 while individuals 2 and 4 did not experience any event
by the end of the study and were censored (0).
Table 4.2: Data preparation for competing risk modelling
ID# age sex times status
1 18 F 119 1
2 40 F 75 0
3 22 M 30 2
4 38 F 19 0
5 30 M 101 1
R1 R2 Rn. . .
Event
Figure 4.1: Competing risks Ri. The direction of arrows denotes "‘competing
to"’ the Event of interest.
The all-cause hazard rate was defined in Equation 4.7. Under the competing risk
framework, the instantaneous risks of dying from cause j (cause-specific hazard),
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with t and ∆t as defined above (Andersen, Per Kragh and Keiding, 2006; Collett,
2014, pp. 405-21).
The overall survival function is defined as the probability of an individual surviving















The survival function Sj(t) = exp {−Hj(t)}, with Hj(t) as the cumulative hazard
for cause j does not have the same interpretation as S(t) in Equation 4.38 as
m > 1.
The assumption for Sj(t) is that an individual will survive one cause only. But in
practice, Sj(t) is not observable since survival is defined as surviving all causes,
not just one cause (Collett, 2014). Because of its awkward interpretation, Sj(t) is
rarely reported in the survival analyses.
Under the assumption of independent censoring, the density and partial likelihood
functions for a specific cause j follow from Equation 4.8 and Equation 4.12, and
are expressed as;












In order to fit the regression models for competing risk data, separate cause-
specific models are fitted by treating all other causes as censored. For instance, a
Cox regression for the cause-specific hazard model is a modification of Equation 4.9
and is written as;
hj(t) = h0j(t) exp(Xβj) (4.41)
where the baseline hazard is now cause-specific baseline hazard and the covariate
coefficients βj are for a cause j. These models can be used to determine association
between covariates and the specific cause j.
4.3.3.2 Cumulative incidence function
The survivor function is a useful summary for the standard survival data with
no competing risks. However, in the presence of the competing risks, the cause-
specific cumulative incidence function (also called the subdistribution function)
is used as a summary tool for these types of data (Beyersmann, Allignol and
Schumacher, 2012; Collett, 2014, pp. 405-21). A cumulative incidence function is
the probability of an individual dying before time t from cause j in the presence
of all other competing risks. It is expressed as;
Fj(t) = P(T < t,C = j), for j = 1, 2 . . . . . .m (4.42)
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Following the expression of fj(t) in Equation 4.39, the cause-specific cumulative
incidence Fj(t) is just the integrated function and can be estimated as a product










is the Nelson-Aalen estimator of the hazard function for the jth cause, δij
is an event indicator for cause j, ni is the number of individuals just before time
t that are alive and uncensored and Sˆ is the K-M estimate of the overall survival
function ignoring different competing causes. This is because Equation 4.43 uses
information on death times for all causes. Suffice to say that in time-to-event
data where m = 1, it is possible to obtain the cumulative incidence function from
the hazard function (pp. 247-66 Kalbfleisch and Prentice, 2002; Collett, 2014,
pp. 405-21).
4.3.3.3 Fine and Gray Model
In order to obtain an interpretable cause-specific cumulative incidence function,
Fine and Gray, (1999) proposed a modified cause-specific hazard (Equation 4.37)
to include individuals that died from a cause other than cause j (as still event-
free). The modified cause-specific is called the subdistribution function and is the









Using this hazard function, it is now possible to obtain an interpretable corres-
ponding cause-specific cumulative incidence function. This can be modelled either
using a Cox regression or parametric models. In a Cox regression, the partial









in which the product is taken over rj individuals who died from cause j at ordered
times t(1), t(2), . . . . . . , t(rj), Xh is a vector of covariates for individuals who died
at time t(h), h = 1, 2, . . . . . . , tj and βj is as defined above. The risk set R(t(h))
contains individuals who have not yet died by time t(h).
The formulation of the Fine and Gray hazard model is similar to Equation 4.41 but
the main differences are in the calculation of the risk set and how the product in the
likelihood function is calculated (Collett, 2014, pp. 405-21). Also, the cumulative
incidence function can be estimated as





where Hˆij(t) is an estimate of the cumulative subdistribution hazard function
estimated as
λij(t;Xi) = λ0j(t) exp(Xiβj)
Researchers are often faced with a decision to choose between the use of Cox PH
for a cause-specific hazard and a Fine & Gray model. There three main issues
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that ought to be considered. First, The estimates from cause-specific hazard func-
tion do not have an informative interpretation because they rely heavily on the
assumption that censoring is independent from competing events (Fine and Gray,
1999). Secondly, because of the issue of possible dependent censoring, the use of
cause-specific K-M estimate would be difficult to interpret as it ignores the issue of
dependent censoring among competing events, which is very difficult to verify. As
such, by assuming the overall function (see Equation (4.43), the CIF bypasses this
dilemma. Lastly, although the cause-specific hazard ratios and subdistribution
hazard ratios provide an informative summary of covariate effects, the proportion-
ality assumption cannot be satisfied at the same time for both models (Fine and
Gray, 1999).
The subdistribution function is analogous to Cox PH model. However, in subdis-
tribution function, the CIF is used as the hazard function and its interpretation
can be tricky to non-statisticians. Due to awkwardness in interpretation of the
subdistribution function, cause-specific cumulative incidence function (CIF) are
rather popular in analysis of competing risks data (Zhang and Fine, 2008).
4.3.3.4 Multistate Modelling
In the competing risk modelling framework, times of occurrence to competing
events from the initial state is the main concern. However, sometimes the times of
occurrence between non-fatal states other than initial state or death are of interest
and competing risk models cannot be used in this case. This is where multistate
models come in.
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Multistate models are used to analyse event history data collected over a period
of time and all events occurring for the individuals are recorded. Before analysing
data using the multistate models, it ought to be prepared in the right format.
The format of the data depends on whether the sequence or the order in which
the occurrence of states matter. For example, if the order of visits to the states
matters, then the data is put in a counting process format. Table 4.3 is an example
of data in the counting process format.
Table 4.3: Data preparation for Multistate modelling
ID# baseAge sex timein timeout state
1 23 F 0 200 0
1 23 F 200 247 0
1 23 F 247 283 2
2 34 M 0 121 0
3 30 M 0 197 1
3 30 M 197 233 0
4 17 F 0 75 0
4 17 F 75 177 0
4 17 F 177 190 0
Healthy (0) Sick (1)
Dead (2)
Figure 4.2: The illness-death model
For example, the individual with ID number 1 died after 283 days in state 2 and
the individual 4 remained in the initial state 0 by the end of the study.
Figure 4.2 is a popular illness-death model in multistate modelling. The individual
starts in initial state of being healthy and can move (transition) to other states
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either being sick or die. Depending on the type of the disease, it is also possible
to move back from being sick to being healthy again (recovery). But once an
individual is in ′dead′state , no further transitions are possible. States ′healthy′
and ′sick′ are called as transient states whereas state dead is called an absorbing
state.
A comprehensive review of methods for multistate models can be found in text-
books such as Collett, (2014), Klein et al., (2013) and Beyersmann, Allignol and
Schumacher, (2012), and Cox and Miller, (1965). In this overview, only Mark-
vov processes are discussed. We start by giving some definitions and introducing
notation to be used in the sequel.
A stochastic process (SP)X is a collection of random variables (rvs) {X(t) : t ∈ T }
with T being some index set 0, 1, 2, 3, . . .. Let S be the state space (the set of
possible values ) of a stochastic process of X(t), with S = {1, . . . , p}. Let pik(0) =
Prob(X(0) = k) k ∈ S be the initial distribution.
A stochastic process is a Markov process if P [X(t) = j|H−] = P [X(t) = j|X(t1) =
i1], for t > t1 > t2 > . . . and H− = {X(t1) = i1, X(t2) = i2, . . .} is the history of
the process. This means that the current state does not depend on the whole
history H− of the the process but just on the immediate previous state X(ti−1).
This assumption is often criticised as too simplistic especially in medical research
in which patient’s medical history play an important role in predicting patient’s
prognosis. Nevertheless, all the transition functions in this thesis will assume the
Markov property. Details of statistical methods for non-Markovian processes and
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hidden-Markovian processes can be found in the referenced textbooks.
The derivation of functions in multistate models is similar to the way the hazard
and the survival function are derived except that in the multistate modelling the
emphasis is on obtaining the dynamics of transitions from one state to another.
The transition probability of state j to k (j → k) is
Pjk(s, t) = Prob(X(t) = k|X(s) = j), j, k ∈ S (4.47)
The transition probabilities can be summarized in a matrix called transition prob-
ability matrix. In our example, the probability matrix at time t is






where p11 and p22 are probabilities of remaining in state 1 and 2 respectively,
p12 is the probability of moving from state 1 to state 2, p13 is the probability of
moving from state 1 to state 3, p21 is the probability of moving from state 2 back
to state 1, p23 is the probability of moving from state 2 to state 3. State 3 is an
absorbing state so transitions out of this state are not possible, therefore there is
100% chance (p33 = 1) of remaining in this state at any time t. Also note that the
sum of each row must equal to 1 (law of total probability).
The transition intensity is the transition rate describing the rate at which a Markov










The transition intensity kernel (matrix) for the multistate models contains non-
zero elements for all possible transitions, and zero otherwise. As in the transition
probability matrix, the transitions are read from left to right. For example, in







where q11 and q22 is intensities of remaining in healthy state and in sickness state
respectively, q12 is the transition health → sick, q13 is the transition health →
death state, q21 is the recovery process sick → health, q23 is the transition sick
→ death. The last row of Q has all entries zeros because transitions out of this
state are not possible once an individual has entered the death state (absorbing
state). The row sum of the entries in the matrix Q are zero and the diagonal
entries are defined as the negative sum of off-diagonal entries in the same row, i.e.
q11 = −(q12 + q13) and q22 = −(q21 + q23).
The likelihood is formulated as follows. Let T ijk be the ith individual’s time of




jk(t) be counting process





jk(t) be the number of individuals at risk in state j at time t−,
j, k ∈ S. Then the likelihood function is (pp. 181-82 Hougaard, 2000; Aalen,
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where covariates information is contained in qijk(.) and qijk(.) may well depend on
whole history Hit of the process.
Table 4.4 provide a summary of other common functions of interest in multistate
modelling.
Table 4.4: Common expressions in Multistate modelling
Name Expression
State Probability pij(t) = Prob(X(t) = k)
=
∑
j∈S pij(0)Pjk(0, t), j, k ∈ S




jk(t), j 6= k
direct j → k transitions where N ijk(t) = #direct transitions
in interval [0,t] j → k in [0,t] for i





4.4 Model Diagnostics and Selection
In this section we provide a summary review of general methods for assessing fit-
ness of the survival model to the data at hand. For proportional hazard models,
we discuss how the assumption of proportionality is assessed. Several other model
diagnostics methods including graphical diagnostic plots based on deviance and
martingale residuals and a statistical test using Schoenfeld residuals are well doc-
umented in survival textbooks such as Collett, (2014), Therneau and Grambsch,
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(2000) and Hosmer and Lemeshow, (1999), and Kleinbaum and Klein, (2012). We
also look at available methods for comparing and choosing a best model from a
set of competitive models.
4.4.1 Testing the PH Assumption
It is important to check the proportionality assumption in PH models. The as-
sumption is checked for every variable included in the model. To check this as-
sumption, usually graphical plots and Schoenfeld residual test are used.
The model-based graphical plots used for this purpose are; plots of complementary
log-log survival curves against survival time, and plot of the observed K-M estim-
ates Sˆ(t) and the expected survival estimates S(t; θˆ) with a covariate included.
The scaled Schoenfeld residuals are calculated for each covariate in the model. This
is different from other types of residuals which are just a single value (Therneau
and Grambsch, 2000). The assumptions for this test is that Schoenfeld residuals
for each covariate are independent of each other. The test assesses if the residuals
are correlated to some function of time g(t). Different forms of g(t) are available
such as K-M estimator, ranks and log(t) (Therneau and Grambsch, 2000, pp. 127-
152).
The Schoenfeld residuals are defined as;
r∗i = r var(βˆ) rji (4.50)
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where r is number of events, var(βˆ) is the variance-covariance matrix of the








, xji is the value for jth covariate for ith individual in the study,
and l is number of individual at risk at time ti.
If the PH assumption is violated by a model (or indeed for a particular covariate
in the model), then some of the options available are to consider fitting a stratified
Cox PH model or a parametric model.
4.4.2 Residual Analysis
As mentioned in preceding paragraphs, the parametric models assigns a distribu-
tion for the survival function (and consequently the hazard function). In analyzing
whether this assumed distribution best describes the data at hand, we opt to use
two residuals; the modified Cox-Snell and Deviance residuals. Firstly, we define
the general Cox-Snell residuals (Collett, 2014) as;
ri = − log[Sˆ(ti)] (4.51)
where Sˆ(ti) is the survivor function of the ith individual at time ti , i=1,.....,n
individuals. The modified Cox-Snell residuals
rcsi =

ri if T ≤ C
ri + 0.693 if T > C
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where T is the survival time, C is the censoring time, i ranges from 1 to n indi-
viduals.
The modified Cox-Snell residuals (rcs) have a property that if the model fits the
data well, then these residuals follow the standard exponential distribution with
mean one (Collett, 2014, p. 233). However, for T > C, the median(rather than the
mean) is chosen for the unit exponential survival function for the excess survival
time: t(50) = log 2 = 0.693 (Collett, 2014, p. 233) as defined in equation for rcsi
above. The plot of rcsi against the cumulative hazard of the residuals should
closely follow the x = y line if the model fits the data well.
Secondly, Deviance residuals are defined as;
Di = sign[Mi]
{−2[Mi + δi ln(δi −Mi)]1/2} (4.52)
whereMi = δi−ri are Martingale residuals, δi ∈ (0, 1) and ri = Hˆ0(ti) exp(
∑
Xβ),
i = 1, ......, n and Hˆ0 is a Breslow estimator of the baseline hazard. Using both
residuals, if the assumed distribution fits the data well, then the plot should show
a linear trend with intercept zero (i.e a line of y=x).
4.4.3 Model Selection
The estimation of parameters in survival analysis is accomplished by maximizing
either the partial likelihood, the profile likelihood, marginal likelihood or the full
likelihood functions or through Bayesian estimation. The proportional hazards
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model developed by Cox, (1972) and its variants described earlier on make use
of the partial likelihood function. The process of selecting a parsimonious model
makes use of these likelihood quantities.
There are several ways of choosing the best fit model. Informally, the likelihood
values can be compared and the best model is chosen as the one that maximizes
the likelihood. Semi-parametric and parametric models can not be compared to
each other using the likelihood statistic because these two models use different
forms of likelihood functions in estimating the model parameters. However, the
more formal ways of comparing models are through the use of (i) likelihood ra-
tio test (LRT) for nested models, (ii) Alkaike Information Criterion (AIC), (iii)
Bayesian Information Criterion (BIC), and (iv) Deviance Information Criterion
(DIC). The goal of these measures is to find the parsimonious model from a set
of possible models by penalizing any additional parameters added to the model.
These methods are described in many standard survival texts such as Hosmer and
Lemeshow, (1999) and Ando, (2010) and in a recent review by Gelman, Hwang
and Vehtari, (2014). Here, we only present their definition and we will mainly use
LRT, AIC and DIC (for Bayesian models) for model selection because they are
widely.
The LRT is a measure of how the log-likelihood values for two models being com-
pared deviate from each other. It is calculated as;
LRT = −2(logLS − logLC) (4.53)
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where logLS is the log-likelihood value of the simpler model and logLC is the log-
likelihood value for the complex model(model with additional parameters). The
LRT can also be thought as a difference of deviances from two models (deviance
= −2(logL). In our study we will use partial log-likelihood instead of full likelihood
because models to compared are semi-parametric. The test of difference between
the simper model and complex model is approximated by assuming that the LRT
is a Chi-Square statistic;
LRT ∼ χ2dfC−dfS
where dfC and dfS is the number of degrees of freedom from the complex and the
simpler model respectively.
The AIC values are calculated as follows ;
AIC = −2 log(L) + 2(p) (4.54)
where L is the likelihood and p is the number of parameters estimated in the
model. The best model for the data tend to minimize the AIC value (Gelman,
Hwang and Vehtari, 2014).
The BIC is similar to AIC only that BIC more heavily penalizes additional para-
meters in the model by log(n), n is the sample size of the data. Its formula is
BIC = −2 log(L) + p log(n) (4.55)
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where n is the number of uncensored observations (events). The model with a
lower BIC values is the one that is chosen a best fit model.
Both AIC and BIC have an advantage that they can be easy computed and are
widely understood in the conventional literature. However, the disadvantage for
these criteria is that they work better in linear models and survival data with large
sample sizes but not for censored data with small sample size (Hurvich and Tsai,
1986). To address this problem in censored data, some methodological work has
been done including the work of Hurvich and Tsai, (1986), Faraggi and Simon,
(1998) and Volinsky and Raftery, (2000) and Liang and Zou, (2008).
The DIC value from which a generalization of hierarchical modelling of the AIC
is calculated as (Gelman, Carlin et al., 2010, p. 182);
DIC = D(θ¯) + 2pD (4.56)
where D(θˆ) = −2 log(p(y|θˆ))+C is the deviance, (C is a constant that cancels out
when comparing the models), pD = D¯−D(θ¯) is the effective number of parameters,
θ¯ = E[θ] is the posterior mean and D¯ = E[D(θ)] is the posterior mean deviance.
Again, like AIC and BIC, the model with the lowest DIC value is selected among
a set competitive models.
A relatively new widely applicable information criterion (WAIC) was proposed by
Watanabe, (2010). The WAIC is defined as;




i=1 E log ppost(y¯i) is the expected point-wise predictive density and
pWAIC is the effective number of parameters calculated same as pD.
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Part II
Modelling survival in HIV cohorts
89
Chapter 5
Quantifying mortality risk and
survival in HIV patients diagnosed
with KS during treatment initiation
Summary
In this analysis, we look at estimating survival in our HIV cohort. The main focus
is on a subgroup of patients who are clinically diagnosed with Kaposi’s sarcoma
(HIV/KS) at the time of starting a lifelong HIV treatment (ART). With com-
promised immunity, this group of HIV patients is reported to have poor diagnosis
compared to the general HIV population. However, within-group differences in
prognosis are rarely reported for this ART group. Our aim is to understand more
about the survival in this group and how it differs with patient covariates. To do
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this, we consider both semi-parametric and parametric models. We conclude with
assessing how the problem of loss to follow-up (LTFU) could affect the estimation
of survival by conducting the sensitivity analysis on the approximate bound for the
proportion of deaths among LTFU patients. Using this approximate bound, our
model diagnostics and selection indicate that (i) a random effects Cox Model with
Log-Gaussian frailties and (ii) a flexible parametric proportional hazards model,
describe the risk of mortality in the HIV/KS patients well. This subgroup ana-
lysis can be used to inform targeted patient management treatment strategies,
rather than the ’blanket-method’ of treating all patients in the same way, and
thus can provide the basis for formulating a more efficient triage system for care
and treatment of patients.
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5.1 Introduction
Malawi, like many other sub-Saharan countries, is one of the developing nations
with a poorly resourced public health system. The country is characterized by high
infant mortality and high mortality in 15-49 age group (Malawi NSO, 2008). It also
has a heavy disease burden ranging from Human Immunodeficiency Virus (HIV),
malaria, tuberculosis (TB) and an increasing trend of non-communicable disease
cases such as cancer, cardiovascular diseases, respiratory disease and diabetes.
(World Health Organization, 2008). A 2014 Country Report by the World Health
Organization estimates that there are up to 55,000 new HIV infections per year
in Malawi, with high national HIV prevalence among women (13%) than men
(8%). Non-communicable disease co-morbidities such as cancer are common in
HIV population, particularly Kaposi’s sarcoma, breast cancer and cervical cancer
(Gbabe et al., 2014; Msyamboza et al., 2012; Makombe, Harries and al, 2008).
In 2004, in the face of a growing HIV epidemic, the Malawi Ministry of Health
with the help of development partners, introduced free HIV treatment and care ser-
vices to all individuals diagnosed with the HIV virus (Malawi Ministry of Health,
2003). Consequently, HIV care and treatment services were expanded to include
HIV testing and counselling services, services aimed at prevention of HIV trans-
mission from mother to child during pregnancy and breastfeeding, provision of
tuberculosis (TB) and antiretroviral therapy (ART) treatment. The purpose of
HIV treatment is to help boost the immunity system of HIV-positive patients, and
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if taken correctly, it can prolong one’s time to death due to Acquired Immunodefi-
ciency Syndrome (AIDS). This has resulted in a significant decrease in the number
of deaths in general HIV population (Malawi Minstry of Health, 2014b).
In Malawi, previous studies by Mwinjiwa et al., (2013), Msyamboza et al., (2012)
and Makombe, Harries and al, (2008) have reported on the incidence of Kaposi’s
sarcoma (KS) and on the differences in treatment outcomes among patients with
KS. However, studies highlighting the survival prognosis from sub-group analysis
of HIV patients such as patients with both HIV and KS (HIV/KS) are lacking. In
this chapter, we attempt to fill this gap by studying the within-group differences
in survival of HIV/KS patients in Zomba, Malawi. We argue that such analyses
are necessary to help clinicians and public health specialist in their efforts to triage
patients based on their prognosis. The Zomba district has one of the highest HIV
prevalences in Malawi, estimated at 16% in 2010 (Malawi NSO, 2008). As of
2008, the life expectancy in the district was higher in women (51 years) compared
to males (47 years). This life expectancy is lower than what was reported in
Europe and Asia around same period of time (Adetunji and Bos, 2006). High
HIV mortality and high disease morbidity are the main factors for such low life
expectancy in SSA region.
Also, we address the issue of loss to follow-up (LTFU). Recently, there has been a
growing interest in addressing the impact of loss to follow-up data in the estimation
of survival in HIV cohorts (Freeman, Semeere, Wenger et al., 2015; Kiragga et al.,
2013; Henriques et al., 2012). The methods proposed to address the impact of
LTFU on survival estimates have largely depended on the number of deaths in
93
a sample of LTFU patients (Yiannoutsos, Johnson et al., 2012; Yiannoutsos, An
et al., 2008). Others have proposed treating LTFU as a competing event to the
occurrence of death (Graham et al., 2013). In the current analysis, we consider the
use of a sensitivity analysis by comparing the overall survival to cohort data that is
treated as an approximate upper bound of the survival curve. With this approach,
it is also possible to get an approximate lower bound for the proportion of LTFU
patients that are actually deaths. We apply this novel approach by retrospectively
analysing routinely collected HIV data. In the presence of high loss to follow-up,
our aim is to improve the estimation of survival in KS patients and further improve
our understanding of KS epidemiology in HIV population.
5.2 Objectives
In this chapter, we address the first two objectives of this thesis work as listed in
section 2.2. The two objectives are;
1. Understand the relationship between individual risk factors for mortality
amongst HIV/KS patients.
2. Provide an approximate lower bound on the proportion of patients recorded
as lost to follow-up that are really deaths.
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5.3 Data Description
We consider cohort data from HIV patients that were additionally diagnosed with
Kaposi’s sarcoma at the time of treatment initiation. The data are taken from
an HIV clinic at Zomba Central Hospital (ZCH), in the eastern region of Malawi.
The main outcome was all-cause death. However, we also fitted models with being
lost to follow-up as a competing outcome to the occurrence of death.
During the study period (2004 -2011), all persons in the district who tested HIV
positive at HIV testing centres were referred for an ART initiation eligibility assess-
ment either to the HIV clinic at Zomba Central Hospital or referred to other peri-
pheral HIV clinics. The ART eligibility assessment was based the World Health
Organisation (WHO) HIV clinical staging and using CD4 count measurements
(Malawi Ministry of Health, 2003). HIV positive persons were started on ART
immediately if they were categorized to be in WHO stage 4 or they were in Stage
3 with TB episodes. Also, if CD4 count was used as an assessment criterion,
then patients were started on ART if their CD4 count was less than 250 cells/µL
(Malawi Ministry of Health, 2003). The CD4 threshold changed over time: from
2004-2006: 200; 2006-2011: 250; 2011-2014: 350; from 2014 onwards: 500. Over-
all, the majority of patients in this cohort were started on ART largely based on
WHO clinical staging criteria. The reason for this is being that the laboratory dia-












Developed KS after starting ART
ART refills
Figure 5.1: Treatment initiation and follow up for HIV and HIV/KS patients
at Zomba HIV Clinic. The starting point is after patients are deemed eligible
for treatment.
In addition to their HIV treatment, HIV patients diagnosed with Kaposi’s sar-
coma (HIV/KS) were also given chemotherapy to treat KS unless the extent,
location, and symptomatology were not severe. Figure 5.1 is a flowchart showing
how patients were enrolled at HIV and HIV/KS clinic for follow-up and clinical
management.
The data comprise approximately 14, 884 adult HIV-positive patients that were
enrolled in HIV clinic care in Zomba from 2004 to 2011. Three percent (615)
of these adult HIV patients were diagnosed with Kaposi’s Sarcoma (skin tumour)
during ART eligibility screening stage (Malawi Ministry of Health, 2011). Baseline
and follow-up demographic and clinical information including the following were
collected using a standardized national ART clinic form; age, sex, address (village
name and traditional authority), treatment start date, occupation, TB history,
KS status, outcome, outcome date. We also obtained geo-coordinates data from
Malawi National Statistical Office and matched the coordinates to the patients’
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address by matching the names of the locations in both data sets. We calculated
the Euclidean distance (the straight-line distance) from each patients’ village or
reported residency location to the HIV clinic at ZCH. The locations of patients
were represented at the village level.
||(x, y)− (ai, bi)|| =
√
(x− ai)2 + (y − bi)2 (5.1)
where ||.|| denotes distance, (x, y) are the coordinates of the clinic and (ai, bi)
are coordinates associated with patient i, with i from 1 to n individuals. Geo-
coordinates for special features in a village were used. These features included
church, market place, school, dam, hospital, military, and police.
The issue of accessibility to the HIV clinic makes the Euclidean distance interesting
as a predictor of survival. However, the disadvantage is that this is measured as a
straight-line distance which in many cases is not reflective of how patients travel
to the clinic, hence underestimating the travel distance by patients. Distance was
categorised into two groups: ≤ 8 km and >8 km, with the category based on
radius of the catchment area for the clinic (based on the unpublished interviews
with the clinicians in Zomba).
Table 5.1 is a summary of definitions for all the covariates considered in the study.
In order to come up with a lower bound of proportion of deaths in LTFU as
proposed in Section 5.6, a reference dataset with complete outcome data was
needed. Unfortunately, such complete datasets are rare in Africa as the issue
of LTFU is a one of major challenges in cohort studies, mainly due to lack of
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Table 5.1: List of Covariates as defined in section 2.6
Variable Categories
Age (yrs) Continuous
Sex 1= Male, 2= Female
ART period 1= 2004-2007, 2= 2008-2011
TB status 1= TB(current/past), 0= No TB
Occupation 1= Employed (includes teachers & health care workers),
2= Self-employed(includes business persons & farmers),
3= Student, 4= Other(occupation not specified)
Distance (Km) 1= ≤8 Km, 2= >8 Km
KS status 1= With KS, 0= NO KS
Outcome 1= dead, 2= active follow-up, 3= lost to follow up
Times Continuous
national vital registration systems. As such, we obtained permission to extract
KS data from the SEER database of the National Cancer Institute, United States,
was obtained from http://seer.cancer.gov/. These data date back from 1973
to 2010. We restricted the period and age to time between 2004 and 2010 and
maximum age of 68 years respectively in order to match the age range of the
Malawi data. The following variables were selected;
• Age at diagnosis. It is recorded as AGE_DX in the database.
• Status. In the database, it is STAT_REC and the categories were 1 for "Alive"
and 4 for "Dead".
• Time. This is the time of follow-up in months and is recorded as SRV_TIME_MON
in the SEER database.
The total number of patients included in the SEER data were 2,019 and the ages
ranged from 19 to 68. The median follow-up time was 28 months and maximum
follow-up time was curtailed at 80 months in order to match with our data.
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5.3.1 Inclusion and Exclusion Criteria
We included data for all adult HIV/KS patients and data for non-KS HIV patients
for comparison. We excluded patients aged below 14 years because KS in children
is not a big problem and its diagnosis is not well developed as in adults (Bruin
and Stefan, 2013). We also excluded patients referred from neighbouring districts
because our study is limited to Zomba district. In addition, patients with missing
date of initiation or sex were excluded. Consequently, we excluded 9% (n=56) and
leaving 559 HIV/KS patients in the final analysis.
5.4 Survival Modelling
This section contains details of the analysis methods and models fitted the right-
censored data used in this analysis. We first present the semi-parametric models;
the standard Cox PH model and the two Cox frailty models. The last subsection
describes the AFT models considered in this analysis.
5.4.1 Semi-parametric Models
We started by conducting a descriptive analysis of covariates included in the ana-
lysis. We also plotted K-M curves based on Equation 4.4 and used the log-rank
test (see Equation 4.5) to compare survival amongst different groups of patients.
In order to assess risk factors of mortality, we fitted different proportional hazards
regression models with the aim of choosing the best-fit model.
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The following are the variants of the semi-parametric proportional hazards (PH)
models used in this analysis (see Equation 4.9 and Equation 4.28 for definitions);
• Standard Cox PH as in Equation 4.9
• Cox/Gamma frailty model, where Z in Equation 4.28 has a gamma distri-
bution (see Equation 4.30)
• Cox/Log-Gaussian frailty model, where Z takes a log-Gaussian distribution
(see Equation 4.31)
We compared results from these three semi-parametric PH models and the best-
fit model was selected based on the model with the minimum value of the partial
likelihood value (PLik) since these models do not use a full likelihood function.
5.4.2 Parametric models
In addition, we fitted and compared results of six parametric models; four acceler-
ated failure time (AFT) models and a flexible proportion hazards model (FPH) and
a flexible proportion odds model (FPO). The two latter models were based on Roy-
ston & Parmar spline model (Royston and Parmar, 2002). The AFT models take
the form as defined in subsection 4.2.2 and we considered: Weibull, Log-Normal
(LogN), Log-logistic (LogLog) and the Gamma models. The flexible models for-
mulated as defined in Equation 4.21 and Equation 4.22. The best fit model from
a set of parametric models fitted was selected using Alkaike Information Criteria
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(AIC) as defined in chapter 4 in Equation 4.54. The best model for the data
minimizes the AIC value.
All the analyses were conducted in R-Software using the survival and flexsurv
packages. We reported the corresponding 95% confidence intervals (95% CI) for
each estimated βˆ.
5.5 Descriptive Analysis
In this section, we provide a detailed descriptive analysis of the data by presenting
the overall survival among patients and a detailed description of each covariate to
be included in the survival modelling.
5.5.1 Overall Survival
A total of 105 all-cause deaths were recorded among 559 HIV/KS patients rep-
resenting a seven-year death rate of 19% (Table 5.2). The death rate among HIV
patients without KS at baseline was 7.8%. The majority of all patients were aged
between 30 and 45 years and 48% of all recorded deaths were also seen in this
age group. For all patients, the age ranged from 15 to 68 years, with on average
male patients being older than females (Male: 36.3, Female: 32.7, not shown in
Table 5.2).
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Table 5.2: Baseline demographic, clinical characteristics and outcomes of HIV/KS patients.
Covariate Total Patients Patients alive LTFU Patients No. of Deaths Median Event time†
n(%total) n(%total) n(%total) n(%total) (25%,75% quantiles)
Total 559 (100) 231(41.3a) 223(39.9b) 105(18.8c) 5.1(2.0, 11.8)
Age (yrs) 34*(28, 42)
15-29 178(31.8) 63(27.3) 81(36.3) 34(32.4) 3.8(1.8, 10.05)
30-44 303(54.2) 137(59.3) 116(52.0) 50(47.6) 5.9(2.4, 10.8)
45+ 78(14.0) 31(13.4) 26(11.7) 21(20.0) 6.4(1.9, 15.4)
Sex
Female 252(45.1) 111(48.1) 92(41.3) 49(46.7) 4.9(1.7, 12.9)
Male 307(54.9) 120(51.9) 131(58.7) 56(53.3) 5.8(2.3, 10.6)
ART Period
2004-2007 259(46.3) 80(34.6) 110(49.3) 69(65.7) 6.2(2.3, 14.8)
2008-2011 300(53.7) 151(65.4) 113(50.7) 36(34.3) 4.2(1.9, 6.8)
Distance 7.4*(3.7, 14.6)
≤8 kms 288(51.5) 125(54.1) 114(51.1) 49(46.7) 5.5(2.9, 10.3)
>8 kms 271(48.5) 106(45.9) 109(48.9) 56(53.3) 5.0(1.9, 13.3)
TB Status
No TB 528(94.5) 219(94.8) 213(95.5) 96(91.4) 5.3(1.9, 12.9)
With TB 31(5.5) 12(5.2) 10(4.5) 9(8.6) 4.4(1.9, 6.7)
Occupation
Student 10 (1.8) 5(2.2) 3(1.3) 2(1.9) 9.4(6.6, 12.3)
Employed 38 (6.8) 12(5.2) 17(7.6) 9(8.6) 5.1(3.9, 7.2)
Self-Employed 371(66.4) 157(68.0) 149(66.8) 65(61.9)
Other 140(25.0) 57(24.7) 54(24.2) 29(27.6) 4.4(1.9, 10.9)
*median age and distance, †Time in months
a, b, c these are row percentages
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Half of the 105 deaths occurred within five months after starting ART. Younger
patients (age < 30 years) had shorter crude median time to death (3.8 months)
compared to other age groups. A total of 223 (39.9%) patients were categorised
as a loss to follow-up (Table 5.2). A larger proportion of these LTFU patients was
recorded among patients who were either middle-aged (30-44), had no TB or were
self-employed.
In Table 5.2, we also note that nearly half of the patients (46%) in our cohort
entered into treatment programme between 2004 and 2007. The percentage of
deaths was higher in patients who started treatment in the earlier period – 65%
of deaths were in those entering treatment 2004-2007. Contrastingly, the crude
median time to death was greater (but not significantly so) among patients who
entered into treatment 2004-2007.
We also compared two different empirical cumulative distributions (ECDF) and
survival functions (see Equation 4.1) between the HIV/KS patients and the 14,325
non-KS HIV patients. At a glance, it can be seen in Figure 5.2 (a) that HIV/KS
tend to have a lower ECDF than HIV patients when we consider event times only.
However, if we include the censored times, the difference is no longer obvious as
shown in Figure 5.2 (b), although arguably HIV/KS still have relatively lower
ECDF. However, these graphs highlight how the use of the ECDF may not be
the proper distribution to explain the differences in survival because it does not
account for censoring. In section 5.4, we have outlined appropriate analysis meth-
ods that handle the influence of censored times including the use of survival and
hazard functions.
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Figure 5.2: Comparison of empirical distribution for HIV/KS (blue) and non-
KS patients (black). Plot (a) is a plot for event times only while plot (b) includes
both event times and censored times.
Using the K-M estimator given in Equation 4.4, we compared the estimated the
crude K-M survival curves between HIV and HIV/KS patients. The survival
curves are presented in Figure 5.3. Among the non-KS patients, the survival is
higher compared to HIV/KS patients. There seems to be a rapid deterioration of
prognosis amongst HIV/KS patients compared with non-KS patients. However,
the overall survival probability in both groups remained high, approximately above
70% although the uncertainty (95% CI) in the survival increased with increasing
follow-up time.
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Figure 5.3: Survival curves (95% CI - dotted lines) based on K-M estimates.
Higher survival can be noticed in HIV group than in HIV/KS patients.
5.5.2 Prevalence of KS at ART initiation
Overall, the percentage of patients starting ART with KS decreased over time
as shown in Figure 5.4. The highest prevalence was recorded in 2005 when 70
(11% out of 615) patients had KS at the time of starting ART. It can be noted
that thereafter the annual prevalence fell steadily to about 2% by 2011. This
decline could be due to the expansion of HIV treatment services in the district
since Kaposi’s sarcoma is associated with advanced disease progression in HIV
populations.
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Figure 5.4: Prevalence of Kaposi’s sarcoma during initiation of a lifelong HIV
treatment (ART) over a 7 –year period. The dotted lines are the 95% CI, with
the significant decrease in prevalence diminishing by year 2008.
5.5.3 Age
The ages for the HIV/KS patients ranged from 15 to 68 years, with a median
age of approximately 35 years. Amongst the 105 deaths, half of the patients
were aged 34 years or below. The plot in Figure 5.5 highlights the fact that the
difference in median age between patients that died and patients with censored
times is coincidental as the confidence intervals for mean age overlap for these two
outcomes. Table 5.2 shows that three-quarters (75%) of patients that died were
aged below 45 years. This is the same age group 15-49 that is considered to be
sexually active and the majority of patients in HIV care are from this age group,
as shown in the density plot on the left panel of Figure 5.6. Age is an important
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Figure 5.5: Mean age (with 95% confidence interval) of patients that experi-
enced the event (labelled 1 on x-axis) and those with censored times (labelled 0
on x-axis). Note the overlapping confidence intervals.
factor in predicting survival because of the ageing effects, that is, the older one
becomes, the more frail they become.
5.5.4 Sex
There was a total of 252 females and 308 male HIV/KS patients. Among the 252
(45%) females, 49 (19% of all females) died and their crude median event time was
4.9 months with 25% and 75% quantile range of approximately 2 and 13 months
respectively Table 5.2. On the other hand, males tended to have longer crude
median event time compared to females (5.8 vs 4.9). In addition, 60(20%) of 308
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Figure 5.6: The plot on the left shows age distribution of HIV/KS patients and
the plot on the right is a comparison of mean age of male and female HIV/KS
patients. On averege, male patient seems to be older than females.
males died and half of them died within 5.8 months after starting HIV treatment.
On average, male patients were older than females, as shown in the right panel of
Figure 5.6 and the left panel of Figure 5.7.
To compare the number of observed and expected deaths in males and females,
we used the log-rank statistic, which is approximately a Chi-Square statistic with




dij − eij (5.2)
where dij is the number of deaths in group i at time j, and eij = nijdj/nj is
the expected number of individuals who die at time tj in groug i (Collett, 2014,
p. 233).
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The statistic for comparing survival between two groups is
WL = UL/
√




where VL is the variance and WL ∼ χ21. Table 5.3 provides summary results from
the log-rank tests for different covariates. At 5% significance level, the results for
comparing number of deaths among male and female patients indicate that non-
significant differences in observed and expected number of deaths in both males
and females (p = 0.949), although more deaths were observed in male patients
than expected. This observation is emphasized by visual output using Figure 5.8
which is a plot of survival curves male and female patients. We also note there is
a steep decline in survival probability in both sexes during the early days of ART
treatment.
Table 5.3: Using Log-rank test to compare the observed and expected number
of deaths by sex, Treatment Period, TB history and Occupation.
Covariate #patients #observed deaths #Expected deaths p-value
Sex
Females 252 49 49.3 0.949
Males 307 56 55.7
Period
2004-2007 259 69 54.2 0.003
2008-2011 300 36 50.8
TB Status
No TB 528 96 100.4 0.0547
TB 31 9 4.86
Occupation
Employed 38 9 7.62 0.76
Self-Employed 371 65 70.07
Student 10 2 1.52
Other 140 29 25.79
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Figure 5.7: Density distribu-
tion of age grouped by sex
Figure 5.8: Survival curves
for males and females
5.5.5 Period of starting HIV Treatment
In 2008, the Ministry of Health in Malawi revised the HIV treatment guidelines
to improve the way patients were managed (Malawi Ministry of Health, 2008).
Following the provision and expansion of HIV services, one of the questions of
interest for clinicians and public health specialists, would be to find out if patients’
prognosis has improved as treatment and routine clinical management and care
of the HIV infected patients continues to improve over time. In this regard, we
were interested in comparing the statistics and survival between the periods 2004
- 2007 and 2008 - 2011.
From Table 5.2, over half of HIV/KS patients started treatment between 2008
and 2011. Among the 105 patients that died, over 60% had started treatment
between 2004 and 2007, of which half of them died during the first six months on
treatment. Interestingly, among the 36 patients that died during the 2008 - 2011
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period, half of them died during the first four months after starting HIV treatment,
two months faster compared to those who started treatment before 2008. As seen
from Table 5.3, log-rank tests results indicate a significant increase in the number
of expected deaths amongst those that started treatment before 2008 (p-value
=0.003). This difference in survival was more pronounced just after one year, as
shown in Figure 5.9. Table 5.3 provides summary results from the log-rank tests
for different covariates. At 5% significance level, the results for comparing the
number of deaths among male and female patients indicate that non-significant
differences in observed and expected number of deaths in both males and females
(p = 0.949), although more deaths were observed in male patients than expected.
This observation is emphasized by visual output using Figure 5.8 which is a plot of
survival curves male and female patients. The curves cross each other suggesting
a non-significant difference in survival. We also note there is a steep decline in
survival probability in both sexes during the early days of ART treatment.
5.5.6 Distance to HIV clinic
At the time of this study, the HIV clinic at Zomba Hospital was the only clinic in
the district that provided clinical care to patients diagnosed with both HIV and
KS. As a result, all HIV/KS patients were required to seek and access treatment
services at Zomba HIV clinic.
We computed the Euclidean distance from patient’s village-level point to Zomba
HIV clinic using Equation 5.1. Most urban settlements around the Zomba town
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Figure 5.9: Survival curves for patients that started in 2004 - 2007 period and
2008 - 2011 period. Higher survival is noticed amongst those that started in
latter period.
lie within an 8 kilometre-radius. Hence, we categorized the distance into two
groups; within 8 km and over 8 km. Our main interest was to assess whether this
covariate relates to patient outcomes considering that in most low-income countries
patients travel long distances to access health services. However, using PubMed
and Google Scholar engines, we did not find any literature relating distance to
clinic and survival outcomes. Nevertheless, we hypothesized that distance could
influence attendance to clinical appointments, with more patients living far from
the clinic being prone to missing appointments. This could lead to poor treatment
adherence and increase the risk of death.
The distances travelled by patients to the clinic ranged from <1 km to 31.4 km. In
Table 5.2, it is seen that approximately 53% of patients that died were coming from
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Figure 5.10: Survival curves for HIV/KS patients by distance to the clinic.
The plots cross each at least at three separate occasions.
a distance of 8 km or more. The overall median distance for all HIV/KS patients
was 7.4 km. Despite the differences seen in the survival curves in Figure 5.10, the
log-rank test provided a non-significant p-value of 0.38, indicating no difference
between the observed and expected number of deaths both distance categories.
Like other factor variables, at this point we did worry about the proportion of
deaths amongst LTFUs by distance and just treated all LTFUs as censored.
5.5.7 TB Status
Among the HIV/KS patients, there were only 31 (9%) patients with TB, of which 9
(29%) died during the study period. Mortality was lower amongst patients without
TB, about 18%. Furthermore, patients with TB had a shorter crude median time
113
Figure 5.11: Survival curves for patients with and without TB. Having TB is
associated with a lower survival.
to death, shorter by one month compared to the non-TB patients as shown in
Table 5.2.
A log-rank test in Table 5.3 also indicated that the number of observed deaths
amongst the TB group was marginally insignificant at 5% level (p-value = 0.0547).
Figure 5.11 shows the K-M survival plots by TB history, and higher survival is
observed in TB free patient group.
5.5.8 Occupation
The majority (66%) of HIV/KS patients were self-employed, of which 65 (18%)
died. Half of self-employed patients died within the first 6 months of starting
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treatment. There were 38 teachers and health care workers (categorized as em-
ployed) with HIV and KS and approximately 24% died during the study period.
More deaths than expected were observed among patients that were either em-
ployed, were students or those categorised as "Other" (Table 5.3). Despite this
observation, the differences were not statistically significant at 5% (p-value= 0.76).
Figure 5.12: Proportion of times the Zomba curve was below California curve.
The blue dotted lines are the 95% lower and upper bounds of the proportion
satisfying Sˆ(80in Malawi) ≤ Sˆ(80in US).
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5.6 Accounting for loss to follow-up and determin-
ing a lower bound for the proportion of LTFUs
that are deaths
In the Zomba KS dataset, 223 (39.9%) patients were lost to follow up meaning
that their vital status was not ascertained during the study period. Since some of
the LTFUs may be deaths, we used a novel way of understanding and accounting
for potential deaths among the patients who were lost to follow-up. Other stud-
ies in sub-Saharan Africa have also reported high loss to follow-up and many of
these studies have reported that in fact many of these LTFUs may be deaths (see
Section 3.4).
We began by assuming that all LTFUs were censored observations. However, when
we compared the resulting survival curve to that of US population (described in
Section 2.6), we found that the Malawi cohort was doing much better. This
was surprising since we would expect survival in the Malawi cohort to be worse
compared to the US cohort, so we consider the US data as providing a sort of the
"‘upper bound"’ for the survival curve. However, we do not know the proportion
of LTFUs that are really deaths in our cohort.
Suppose we have a candidate proportion (c_p) of deaths among LTFUs. For
any c_p, we can randomly change the 223 × c_p patient’s status to death and
the remainder be censored. Using this modified data, we would get estimates of
βˆ1 from the model. Repeating this process with a different 223 × c_p patient’s
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statuses modified, we would get another βˆ2. Repeating this, say k times, we get;
βˆ1, βˆ2, . . . , . . . , βˆk
and we can combine these to get an overall βˆ for this given c_p.
For each c_p and simulated dataset, we compared the 80 month survival to that
from the US cohort. The time point of 80 months was chosen as an example
based on the maximum time point when the K-M estimate become constant in
the Malawi cohort. We found an approximate lower bound for c_p as the minimum
value of c_p such that the 80 month survival in all simulated datasets was below
that of the US cohort.
In summary, our Comparison approach of identifying an approximate lower bound
for mortality rate among LTFUs was conducted in 6 main steps;
Step 1: We created a list of candidate proportions (c_ps) of deaths amongst LTFU
patients from 0 to 1 increasing by 0.01 units. As a result 101 c_ps were
used.
Step 2: For each selected c_p, we generated 100 different datasets in which 223×
c_p of the LTFUs follow-up times were changed to event-time otherwise
they were censored. This means the number of deaths increased gradually
with increasing proportion (c_p).
Step 3: A Cox model was fit using this updated dataset.
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Step 4: We also created a 100 x 101 matrix whose entries took the value of 1 if the
survival probability Sˆ(80) based on the K-M curve at 80 months (S(t=80))
for Zomba cohort was less than the survival probability for California
cohort i.e. the matrix entries were defined by an indicator function as;




Step 5: We computed the proportion of times the K-M estimate (at month 80) for
Zomba patients was less than California patients.
Step 6: We plotted the candidate proportion against the proportion calculated in
Step 5. The cut-off value of c_p is the value of c_p corresponding to the
point when the mean acceptance first records a 100% acceptance. This is
our lower bound for c_p.
Using this selected value, we conducted sensitivity analyses for the two final selec-
ted models (semi-parametric and parametric). We sampled 1000 times with c_p%
of patients assigned as ’deaths’ during each sampling. This is equivalent to fitting
1000 models and saving the estimated β for each covariate in a matrix, with cov-
ariates as rows and estimates as columns (p × 1000). The final βˆ were estimated
as E(βˆ) = E[E(βˆ|Y )] and the variance of βˆ using the law of total variance defined
as
Var(βˆ) = Var {E(β|Y )}︸ ︷︷ ︸
Var(β)




where Y denotes the random sample data. Using E(βˆ) and V ar(βˆ) we were able
to construct the confidence intervals.
We compared the crude survival estimates of our HIV/KS cohort data to the KS
cohort from USA, California described in Section 2.6. We followed the steps as
described above. The USA dataset was used because it had complete and updated
patient outcomes, of which it difficult to find datasets of such quality in Africa
which have high rates of loss to follow-up (Freeman, Semeere, Wenger et al., 2015).
The main limitation of using these USA data is that these come from two different
healthy setting with the USA data expected have more healthier population than
the Malawi data. However, using these data gives us an approximate upper bound
on survival on which we can compare with our data.
Figure 5.12 shows the value of the candidate proportion (c_p) against the pro-
portion of datasets for which the simulated Sˆ(80in Malawi) ≤ Sˆ(80in US). In
order to help make the survival curves from the USA data and the Malawi data
comparable, we ensured that the following were the same: same age range of 15 -
68; same study period, 2004 - 2010; and same maximum follow-up time of months.
We truncated the follow-up period at 80 months and also restricted age to less
than 69 years to ensure comparable Sˆ from the two cohort data.
The comparison results showed that a minimum of 34% of deaths should be as-
sumed among LTFU patients (Figure 5.12). Any proportion > 34% resulted in the
Zomba curve to be consistently below the California curve as measured at month
80.
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Figure 5.13: Top Left panel : Comparing survival plots of Malawi and US
data based on the initial data. Top Right panel : The Malawi curve has been
adjusted after accounting for 34% mortality in the loss to follow-up patients
using California data as an upper bound for the survival curve. Bottom plot :
Comparing survival plots of Malawi and US data assuming a worst case scenario
(all LTFUs as deaths) in Malawi data.
Figure 5.13 (right panel) shows the "‘best scenario"’ K - M survival plot assuming
34% of deaths in LTFU patients. The estimated survival probability dropped to
0.47 (0.38 - 0.59) by 80 months of follow-up compared to 0.73 (0.68 - 0.78) in
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the unadjusted estimates (left panel). With c_p = 34%, the median survival was
estimated at 73.9 months (approximately 5 years).
5.7 Results from Semi-parametric and Parametric
Models
In this section we present results from all competitive models. We also include
results of correcting for LTFU using 34% as a minimum proportion of deaths
among patients that were lost to follow-up. We end by presenting adjusted model
results and the sensitivity analysis plots for the semi-parametric model.
5.7.1 Risk factors of loss to follow-up
After adjusting for TB status, treatment period, distance to the clinic and occupa-
tion, we found that male patients (HR: 1.39, 95%CI: 1.04 - 1.86) were significantly
associated with being lost but older patients were less likely to be lost from the
cohort (see Table 5.4). This analysis could have been done using a multivariate
logistic model as well since in this case we are not concerned with censoring. How-
ever, we opted for a time-to-vent analysis approach so that we make the results
comparable to the results from the risks of mortality from the survival models.
Moreover, when we fitted the logistic model for the censored data, we noted that
the direction of interpretation of estimates did not differ from the ones we obtained
from the Cox models reported here.
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5.7.2 Risk factors of mortality and survival
Table 5.5 provides a summary of results from different Cox models. The age
was fitted as a continuous variable because the scatter plot smoothing of K-M
estimates against patient age did not suggesting groups or clusters. The standard
Cox model and extended Cox model with Gamma frailties gave similar estimates
of the hazard ratios. All the models indicate that time of starting treatment and
TB history are statistically significant factors for quantifying risk of death in these
data. In particularly, patients starting HIV treatment between 2008 and 2011 had
almost 50% lower risk than those starting before 2008 (HR 0.53, CI: 0.35 - 0.81).
In addition, high mortality risk was observed in patients who had TB or had TB
episode in last two years prior to starting HIV, treatment. They were twice more
likely to die than patients without TB (HR: 2.21, CI: 1.05 - 4.25). The 95% CI
also suggest that the patients with TB could be four times higher in risk compared
to their counterparts.
Baseline age, distance to the clinic, sex and occupation were not significant in
the model. However, older patients tended to have increased risk, 1% higher than
younger patients. Men also seemed to have a lower risk of dying than females (HR:
0.95). Furthermore, patients living near the HIV/KS Clinic tended to be 8% lower
in risk of dying than those living more than 8 km away from the clinic. Lastly, the
self - employed patients tended to have lower mortality risk than the employed,
but students tended to have a higher risk (5.8% higher) than the employed.
The Weibull, Log-Normal, Log-logistic and generalised Gamma models were fitted
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in AFT parametrization. This means that, instead of getting estimates of HR, or
OR, we get time ratios (TR). Time ratios are also called accelerated factor. In this
scale, we interpret the results in terms of survival. A value more than one indicates
that survival rate is prolonged (accumulated), and vice-versa. The flexible PH
estimates the cumulative HR, whereas flexible PO estimates cumulative OR of
survival. Results from all AFT models lead to the same conclusion as Cox models.
For instance, patients, starting treatment in 2008 - 2011 period had survival times
twice longer than those that started in the 2004-2007 period (as shown in Table 5.6.
Likewise, survival times for patients with TB in this cohort were shortened by a
factor of 0.30, compared to those without TB.
Table 5.7 shows that the two models have similar estimates. The only difference
is in the interpretation. For the flexible PH, the estimates are cumulative hazard
ratios while for the flexible PO the estimates are interpreted as odds of survival.
The results are quite similar to those reported in Table 5.5.
5.7.3 Describing patient heterogeneity
We also included two more complex models as an extension of the standard Cox
PH model to model patient-level heterogeneity. The advantage of these two models
is that they capture some information on unobserved individual-level heterogen-
eity that is otherwise not capture by the Cox model. Having this result informs
the analyst the amount of variation in heterogeneity (frailty) among patients that
is not explained by variables included in the model. Table 5.5 shows that the
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extended Cox PH model with log-Gaussian frailties explains the data well. The
inclusion of frailties to measure individual-level heterogeneity in the model sig-
nificantly improved the model fit (partial likelihood ratio test: p-value < 0.001).
The variance of the frailty value of 0.34 indicates the presence of heterogeneity not
explained by the model with all covariates. We conducted a sensitivity analysis
Table 5.4: Hazard ratios for loss to follow-up using a Cox/log-Gaussian frailty
model based on c_p = 34%
Variable Adjusted HR (95%CI) p-value
Age (years)
15-29 Reference
30-44 0.62(0.43 - 0.89) 0.010
45+ 0.62(0.36 - 1.07) NS
Sex
Female Reference
Male 1.38(0.96 - 1.97) NS
Initiation period
2004-2007 Reference
2008-2011 1.69(1.19 - 2.41) 0.004
TB status
No TB Reference
With TB 1.05(0.51 - 2.16) NS
Distance
>8 km Reference
Within 8 km 0.79( 0.56 - 1.10) NS
Occupation
Employed Reference
Student 0.44(0.05 - 3.48) NS
Self-Employed 1.09(0.57 - 2.07) NS
Other 0.88(0.45 - 1.77) NS
on the choice of knots k for both flexible models reported in Table 5.7. In a flexible
PH model, we varied the knots from 3 to 5 using the flexsurv package in R. For
instance, with k = 5 and df = 15, the HR for TB was 2.11 (1.05 - 4.24) which
is similar to the result when k = 3 (df = 13) as reported in Table 5.7. All other
covariate effects were similar to 2 decimal places in both PH and PO model. The
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Table 5.5: Hazard ratios (95% CI) for death from Cox PH Models with all
LTFUs treated as censored
Covariate Cox Cox/Gausian Cox/Gamma
Age 1.01(0.976-1.03) 1.01(0.99-1.03) 1.01(0.976-1.03)
Sex
Females Reference
Males 0.95(0.63-1.45) 0.96(0.62-1.47) 0.95(0.63-1.45)
ART Period
2004-2007 Reference
2008-2011 0.53(0.35-0.81) 0.53(0.34-0.81) 0.53(0.35-0.81)
TB Status
No TB Reference
With TB 2.12(1.06-4.26) 2.21(1.05-4.65) 2.12(1.06-4.26)
Distance
> 8 km Reference
≤8 km 0.92(0.62-1.37) 0.92(0.61-1.39) 0.92(0.62-1.37)
Occupation
Employed Reference
Self-employed 0.88(0.43-1.80) 0.88(0.41-1.86) 0.88(0.43-1.80)
Student 1.55(0.32-7.60) 1.48(0.28-7.81) 1.55(0.32-7.60)
Other 1.01(0.47-2.14) 1.01(0.46-2.22) 1.01(0.47-2.14)
Frailty term(p-value) 0.34(0.37) 5e-05(0.75)
choice of the number of knots does not significantly change the size of estimates
and direction of interpretation (Hinchliffe and Lambert, 2013).
5.7.4 Adjusting for Loss to follow-up and Results from Sens-
itivity Analysis
In this section, we look at how the mean HRs vary with changing datasets using
the selected c_p = 34%. The value of 34% was identified as an approximate lower
bound for the mortality among LTFUs but other studies on mortality in LTFUs
reported mortality rates ranging from 20 - 83 % (see Table 3.2). We only report
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Table 5.6: Time ratios (95% CI) for Parametric Models with all LTFUs treated
as censored
Covariate Weibull LogN LogLog Gamma
Age 0.98(0.95-1.02) 0.99(0.95-1.03) 0.98 1.01(0.98-1.03)
Sex
Females Reference
Males 1.11(0.54-2.26) 1.08(0.53-2.21) 1.07 1.11(0.66-1.88)
ART Period
2004-2007 Reference
2008-2011 2.13(1.01-4.49) 2.19(1.07-4.48) 2.31 1.58(0.91-2.76)
Distance
> 8 kms Reference
≤8 kms 1.13(0.58-2.21) 1.12(0.56-2.22) 1.12 1.13(0.65-2.00)
TB History
No TB Reference
With TB 0.30(0.09-1.01 0.31(0.08-1.18 3.91 0.89(0.28-2.81)
Occupation
Employed Reference
Self-employed 1.02(0.35-4.13) 1.08(0.29-3.96) 1.19 0.50(0.21-1.67)
Student 0.33(0.21-5.04) 0.61(0.03-11.08 0.45 2.61(0.32-21.68)
Other 0.94(0.29-3.43) 0.90(0.23-3.57) 0.95 0.63(0.21-1.92)
results for the selected Cox/log-Gaussian model. A similar methodology can be
used for parametric models.
In Table 5.8, we note that estimates of covariate effects are similar for model 2 and
Model 2 in the majority of covariates. when comparing all the three models, the
direction of interpretation was different in three covariates; male gender, student
and "‘other"’ occupations.
Figure 5.14 shows mean HRs plotted against the proportion of deaths in LTFU
for each covariate in the Cox/log-Gaussian model. The mean HRs are based on
the 1000 times re-sampled data without replacement for each proportion of deaths
(0-100%) in LTFU patients. Again, we note that ART period and TB status are
significant for certain ranges of the number of deaths in LTFU patients. Also,
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Table 5.7: Estimates from Flexible Parametric Proportion Hazards (Hazards
Ratio) and Proportional Odds (Odds Ratio) Model with all LTFUs treated as
censored









> 8 kms Reference
≤8 kms 0.92(0.62-1.37) 0.92(0.59-1.44)
TB History
No TB Reference






the ranges of HRs and their 95% CIs are not very much different from the ones
reported in the model results.
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Table 5.8: Adjusted HR estimates from the Cox/Log-Gaussian Model after
accounting for 34% of mortality among LTFU patients.
Covariate Model 1 Model 2 Model 3
Age (years) 1.01(0.99, 1.03) 1.01(0.98, 1.03) 1.00(0.99, 1.02)
Sex
Female Reference
Male 1.02(0.69, 1.50) 0.97(0.63, 1.49) 0.99(0.70, 1.39)
ART Period
2004-2007 Reference
2008-2011 0.54(0.36, 0.82) 0.52(0.34, 0.81) 0.70(0.50, 0.99)
TB status
No TB Reference Reference
With TB 1.97(0.95, 3.92) 2.19(1.04, 4.60) 1.45(0.73, 1.38)
Distance to ZCH
>8 km Reference
Within 8 km 0.84(0.57, 1.25) 0.93(0.62, 1.42) 0.99(0.72, 1 .38)
Occupation
Employed Reference
Student 1.08(0.22, 5.23) 1.45(0.28, 7.66) 0.92(0.18, 1.52)
Self-Employed 0.78(0.38, 1.61) 0.88(0.41, 1.87) 0.94(0.51, 1.72)
Other 0.96(0.44, 2.07) 1.02(0.46, 2.26) 1.03(0.55, 1.95)
Frailty variance 0.34(p<0.001) 0.37(p <0.001)
Model 1 = Each covariate fitted separately in the model
Model 2 = Results based on the model with all covariates included and 0%
deaths assumed among LTFUs
Model 3 = Results from a model with c_p = 34%
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Figure 5.14: Sensitivity analysis plots for exponentiated mean β based on 1000 permutations of the data.
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5.8 Model Diagnostics and Selection
It is good practice to select models that fit the data well amongst a set of com-
petitive models. In this section, we present results from assessing PH assump-
tions, model selection and residual diagnostics. For comparison purposes, models
were fitted on the data with no deaths assumed among LTFUs. However, the
c_p = 34% was applied to the selected Cox model (semi-parametric) and para-
metric model.
5.8.1 Checking the Proportional Hazards Assumption
The results from the Schoenfeld residual test for both individual covariates and
the global test indicate non-violation of the PH assumption. Therefore, our data
support the use of the proportional hazard assumption. Table 5.9 gives a summary
of the PH test. If ρ > 0, then the linear trend is increasing, decreasing otherwise.
5.8.2 Comparing Cox Models
In Table 5.10, we have reported both the partial log-likelihood values and p-value
from likelihood ratio test (LRT). The LRT shows a significant improvement in
model fit from Cox PH model to Cox/log-Gaussian frailty model (p < 0.001),
hence the Cox/log-Gaussian frailty model is the one that maximises the partial log-
likelihood function (-PlogLik = 1155.43). This suggests the presence of unobserved
individual heterogeneity among the patients.
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Figure 5.15 shows three diagnostic plots based on Cox-Snell residuals against cu-
mulative hazard estimates. As expected, the plot for Cox and Cox/Gamma are
quite similar. However, residuals plot from a Cox/Log-Gaussian model indicates
relatively higher residuals suggesting great variability in survival estimates. The
great variability in the residuals is due to the presence of frailties which were found
to be significant in Cox/log-Gaussian model.
Table 5.9: Test statistics for linear trend using the Schoenfeld residuals in a
standard Cox PH model.
Covariate rho chisq p
Age 0.14 2.34 0.13
Sex -Male 0.06 0.39 0.53
ART period-2008-2011 -0.09 0.77 0.38
TB -with TB -0.01 0.01 0.92
Distance -0.01 0.02 0.89
Occupat-Other 0.04 0.18 0.67
Occupat-Self-Employed 0.03 0.07 0.79
Occupat-Student 0.14 2.02 0.16
GLOBAL 5.29 0.73
Table 5.10: Comparing Cox models using the partial likelihood (LogLik) val-
ues.
Model -2LogLik partial LRT test




Figure 5.15: Diagnostic plots from Cox models using the Cox-Snell residuals.
5.8.3 Comparing Parametric Models
Table 5.11 presents AIC and BIC values based on Equation 4.54 and Equation 4.55.
The AIC selects the Flexible Proportional Hazard (FPH) model and the BIC se-
lects the generalised Gamma model. Figure 5.17 and Figure 5.16 show cumulative
hazard function and survival function estimated from the Cox/Log-Gaussian and
the parametric models. Both the FPH and the FPO follow the Cox/Gaussian func-
tion more closely than other models. This is one of the reasons flexible models
have found their place in survival analysis literature and are increasingly becom-
ing popular because of their ability to flexibility model the hazard and survival
function.
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Table 5.11: Selecting a best fit model using AIC and BIC values
Statistic Weibull LogN LogLog Gamma FPH FPO
AIC 1886.47 1868.35 1879.91 1845.99 1839.57 1840.16
BIC 1925.41 1907.23 1918.84 1889.25 1891.49 1892.07
Figure 5.16: Survival functions from parametric model and a K-M plot from
Cox/Log-Gaussian model.
5.9 Discussion and Conclusions
This is the first (at least to our knowledge) subgroup analysis of focusing on
quantifying survival HIV patients diagnosed with KS at a time of starting HIV
treatment. This is because other studies on KS patients such as Ziegler et al.,
(2003), Makombe, Harries and al, (2008), and Chu, Mahlangeni et al., (2010), only
compared the risk in KS and no-KS patients. In addition, studies conducted by Wu
et al., (2014) and Nelson et al., (2013) looked at incidences of KS in HIV population
and also treatment options and outcomes available for HIV/KS patients. None
of the studies extended the analysis to HIV/KS patients only. In general, the
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Figure 5.17: Cumulative Hazards functions from parametric models and
Cox/Log-Gaussian model.
survival in this patient group was high, though lower than HIV patients without
KS. There were 105 (18%) deaths, 219 (39%) patients were either lost to follow-up
or transferred to another clinic and 235 (42%) were still alive by the end of the
study. In a cross-sectional (retrospective) studies by Mwinjiwa et al., (2013) and
Makombe, Harries and al, (2008) it was also reported that higher proportion of
patients at the time of the end of the study were still in the cohort and close to 20%
were either transferred or lost to follow -up. These statistics are also similar to
the ones routinely reported in national HIV progress reports (Malawi Ministry of
Health, 2011). These results continue to highlight the importance of establishing
social services in HIV programmes to deal with this high defaulter rates.
Adjusting for other covariates in the model, the results showed that patients’
age was not statistically significant in influencing the survival in this patients’
group. However, the estimate of the hazard ratio suggests a slightly higher risk
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of death in older patients. Other researchers such as Chu, Misinde et al., (2010)
and Chu, Mahlangeni et al., (2010) fitted age as a categorical variable and none
of the age groups were reported to be statistically significant, although the risk
of death tended to increase across age groups. However, these results should keep
reminding policymakers to be prepared for the ageing HIV population. Moreover,
in the general population, older people are at more risk of dying since they tend
to have a weaker immunity.
The period in which patients started treatment was found to be a significant factor
influencing mortality. Adjusting for age, sex, TB history, occupation and distance,
there was a significant reduction in the risk of dying for patients that started
HAART between 2008 - 2011 period. (HR:0.53, CI:0.35 - 0.81). With the progress
of provision of HAART, there has been increased awareness of starting HIV treat-
ment in good time. The Ministry of Health (MOH) decreased and decentralised
HIV services to rural health centres, making HIV programs easier. Furthermore,
the MOH revised the HIV treatment guidelines for three times between 2004 -
2011 (Malawi Ministry of Health, 2008; Malawi Ministry of Health, 2011). These
revisions are a sign of commitment by MOH to improve management of HIV pa-
tients including those with KS. No wonder, patients who started HIV treatment
had a better prognosis, as they were likely to have started treatment early. Jo-
hansson, Robberstad and Norheim, (2010) reports early starting of HIV treatment
associated with high survival.
Another covariate found to be significant is TB history, as shown in Table 5.7.
Patients who had TB or had suffered from TB in the past two years had risk of
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dying twice higher than the patients TB history. The results from the retrospective
review by Makombe, Harries, Yu et al., (2007) showed high mortality in HIV-TB
co-infected groups. With an addition of KS burden/patients with HIV,TB and
KS are likely to be more at risk of death. Changes have been made in treatment
guidelines to immediately initiate HAART for HIV patients with TB co-infection
(Malawi Ministry of Health, 2011). HIV patients in these data had also access
to a dedicated TB/HIV clinic within the Zomba hospital. These results support
the need to continue increase TB prevention treatment and care in the general
population. Normally, people with a compromised immune system have a higher
risk of TB.
The results for the relationship of sex and survival showed that sex is not a sig-
nificant factor of mortality. However, male patients appeared to have a greater
risk of dying than females (though not significant ). In the general HIV and KS
population, the number of males with KS is always higher than males (Mosam,
Carol and al, 2008; Mwinjiwa et al., 2013). This could be explained by the poor
health-seeking behaviour amongst the general male population.
The baseline occupation status for HIV/KS patients was also not associated with
mortality. However, the risk of dying was elevated in students, 48% higher than
the employed, group, which included the teachers, security staff, and health care
workers. The self-employed patients tended to have a reduced risk 12% lower
than the employed. Our results mirror those in a case-control study by Ziegler
et al., (2003) in Uganda in which they evaluated the association of having KS
and occupation categorized as farmers and others . No significant differences were
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noted in both case and controls. Despite the challenges, many organisations are
introducing HIV workplace Policies to help their employees have early access to
HAART and combat stigma and discrimination (Soko, Umar and Lakudzala, 2012;
Bakuwa, 2010).
The calculation of the Euclidean distance to the Zomba hospital is one of the
strengths of this study. However, it is unclear to what extent the Euclidean dis-
tance correlates with travel time and costs for travel to the hospital. Distance to
the HIV/KS clinic was not associated with KS mortality in our study. We did
not find other literature from the region on the relationship of distance to the
clinic and KS mortality. The lack of association with survival may thus simply
reflect a poor correlation between Euclidean distance and the difficulties patients
experience travelling to the hospital (Rachlis et al., 2013).
The results from model selection showed that the Cox/Log-Gaussian frailty model
and flexible Proportional Hazards models are adequate for explaining the risk
in HIV/KS patients (refer to Table 5.5 and Table 5.7. Moreover, the Cox/Log-
Gaussian model suggests the presence of unobserved heterogeneity in this patient
group, looking at the value of variance for the frailty term in the model. As
such, models fitted to these data ought to account for this heterogeneity. In
particular, the flexible parametric proportional hazards model provide a very stable
and flexible functional form for the cumulative hazards (Figure 5.17). As shown in
Figure 5.17 and Table 5.7 the hazard functions and the HR estimates are similar
for these two models.
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From the sensitivity analysis, we can only estimate a lower bound of the propor-
tion of deaths amongst LTFU. These results highlight the need for ascertaining
the vital status (either through active tracing or other means) of all patients in
survival analysis in order to obtain reliable estimates of survival and covariate ef-
fects. However, where ascertainment of vital status was not possible, our method
provides a better alternative way of identifying mortality bounds amongst loss to
follow-up. The majority of countries in the sub-Saharan country do not have a ro-
bust vital registration system to record vital statistics (such as deaths, births) for
their citizens (Singogo et al., 2013). For countries with vital registration systems,
the systems are weak and data on vital statistics are not easily accessible.
The issue of correcting estimates for loss to follow-up (LTFU) in HIV cohorts has
been discussed and explored by colleagues from the International epidemiological
Databases to Evaluate AIDS (IeDEA) network and elsewhere (Freeman, Semeere,
Wenger et al., 2015; Kiragga et al., 2013; Henriques et al., 2012). However, the
methods proposed for analysing these data are limited to HIV programmes with
capacity for (some sort of) active tracing of LTFU patients which we did not
have. However, these proposed methods assume high mortality as a reason for
the loss to follow-up. As is in this study, where there is high survival rate in
HIV cohort, it is relatively reasonable to assume low mortality as well in LTFU
group as demonstrated by our comparison method and the sensitivity analyses.
The results from our simulation methods were not very much different from the
standard model in which vital status was not ascertained in LTFU patients. The
only notable difference in the estimates was the smaller standard errors in the
138
model with c_p = 34% deaths among LTFUs (not reported here).
This study has some limitations. One of the limitations is that we used routinely-
collected information from clinic registers, master cards and an electronic monit-
oring system. This may have affected data quality to some degree, but the data
generated from the national standardized monitoring and evaluation tools in the
Malawi HIV programme have been found to be of good standard. This is because
these data are audited every quarter by program experts from Ministry of Health
headquarters. Any data quality issues are resolved on-site (Malawi Minstry of
Health, 2014b). Secondly, we used data from 2004 to 2011 and the results may
not reflect the current prognosis in the cohort.
In conclusion, it is important to identify potential factors that may influence pa-
tient’s survival. In this study, we have seen that the subgroup analysis can be
used to inform targeted patient management and treatment strategies. This can
be achieved by formulating a more efficient triage system for care within a partic-
ular group of patients. For example, despite the fact that HIV/KS patients would
likely be prioritized compared to non-KS HIV patients, there is still need to triage
patients within the HIV/KS patients during ART initiation. This sub-triaging can
also help monitor the high-risk patients over time. For instance, our results show
HIV/KS patients with additional TB burden have poor prognosis compare to those
without TB. In addition, patients with longer follow-up time, in particular, would
need attention during care. There is also a need to strengthen tracing efforts for
LTFU patients and bring them back to care. Future operational studies are needed
to study geographical differences in KS epidemiology and treatment outcomes and
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to describe the impacts of the ever-changing HIV treatment guidelines in line with
one of the 2030 sustainable development goals of eliminating HIV/AIDS by 2030.
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Estimating spatial variation in
survival in HIV patients.
Summary
In this analysis, we examine geographical variations in survival in a sample of 1,931
HIV patients enrolled in ART program in Zomba district. Our motivation for this
analysis comes from the fact that in resource-limited settings such as our study
setting, there are enormous challenges in providing and accessing essential health
services. With only a few specialised HIV clinics available, most patients are forced
to travel long distances to access HIV treatment. Therefore, we are interested in
studying how the risk of death varies in space. We use spatial survival models
which are just extensions of the proportional hazards model to include the spatial
frailties. Our model selection criteria indicate that a Weibull spatial survival model
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with an exponential spatial covariance structure adequately describe the variation
in survival in our data. More importantly, we produce risk maps highlight the
areas with lower and high risk. We note that there is noticeable local geographical
variation in terms of hazards of death, with the risk of death being elevated in
the northern and southern parts of the district. Highlighting the areas that are
likely to have poor survival outcomes and mapping the risk of mortality can help
policymakers identifying priority areas during resource allocation process.
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6.1 Introduction
Despite recent progress in reducing HIV/AIDS morbidity and mortality as a res-
ult of expansions of HIV-related activities in Africa, over 70% global AIDS-related
deaths occur in Africa especially sub-Saharan Africa (World Health Organisation,
2016). Reports from Africa have also highlighted the in-country required variab-
ility in the HIV morbidity and mortality.
To study geographical variations of a particular disease, spatial methods are in-
creasingly being applied. The spatial analysis methods have a long history in
studying disease epidemiology and geographical variations. The spatial epidemi-
ology has been extensively used in the modelling and prediction of the incidences
of diseases such as HIV/AIDS, malaria, cancer, and Schistosomiasis, especially
in sub-Saharan Africa region. For example, in Malawi, spatial analysis tools have
been used in the modelling prevalences and incidences of pneumonia, malnutrition,
malaria, and perinatal mortality (Kazembe and Kamndaya, 2016; Banda et al.,
2016; Cuadros and Abu-Raddad, 2014; Kazembe, Muula et al., 2007; Kazembe,
Kleinschmidt et al., 2006). All these studies highlighted the vital roles which the
spatial epidemiology plays in increasing our understanding of the diseases as well
as in the planning of resources to tackle these diseases.
Although considerable spatial epidemiology studies have been largely devoted to
study HIV incidence and prevalence, rather less attention has been paid to study
spatial variations in survival in HIV populations. Considering that HIV patients
have compromised immunity, their survival is severely reduced especially if not on
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ART treatment. Hence, studying geographical patterns in survival would help to
plan and allocate resources to areas with likely to have poor treatment outcomes.
Though HIV prevalence is high in urban areas, but the survival in this area is
expected to be better compared to the rural areas because the urban areas usually
have better access to health and social services. Therefore, we apply the spatial
survival analysis methods to examine geographical variations in survival among
ART patients in a rural district in Malawi, Africa.
6.2 Objectives
In this study, we address the third objective as listed in section 2.2; Adjusting
for individual-level covariate data, investigate the geographic variation in survival
prognoses in the Zomba district. In particular, are geographical determinants part
of the unexplained observed variation in the hazards of death?
Our overall anticipation is that this study will add to our understanding of the
epidemiology of Kaposi’s sarcoma among HIV patients in Zomba, Malawi and
whether the survival outcomes are characterized by the geographical distribution.
6.3 Data description
The data used in this study is from 1,931 HIV patients who started routine HIV
treatment between 2004 and 2011 in Zomba district, Malawi. We randomly se-
lected 1,500 patients (controls) from a cohort of 14,300 adult HIV patients from
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Zomba HIV clinic. This cohort was selected using database IDs and efforts were
made to have complete data for these patients. As such, a filed visit to Malawi
was organised during summer in 2015 and recruited two research assistants to help
in this exercise. These data were added to 559 HIV patients with KS (cases) at
baseline. Although the total number of patients was 2059, 128 patients did not
have complete data on sex, age and date of starting ART, all of which were re-
quired for in this analysis. Therefore, the final dataset that was used had 1931
patients. In both datasets, baseline data were used in the analysis.
During the period under consideration, all Kaposi’s sarcoma (KS) patients in the
district were centrally clinically managed at Zomba Central Hospital (ZCH), one
of the two referral tertiary hospitals in the southern region of Malawi. Other HIV
patients without KS were clinically managed either at this central hospital or at
decentralized HIV clinics in the district. More complicated cases from decentral-
ized clinics were referred to Zomba HIV clinic.
The following patient covariate information was available: age, date of registration,
sex, tuberculosis history (TB within past two years), KS status and follow-up time.
To get the geographical coordinates, we matched the names of the villages where
patients came from to the names of landmark locations identified by the National
Statistics office (NSO), Malawi. These locations included residences for traditional
leaders, markets, hospitals, military camps, schools, churches, and mosques. We




The model fitted in this chapter is of the form as in Equation (4.32) defined on
page 61. We use the model that has the baseline hazard function from Weibull
distribution. Other complex model exists but are more computation intensive and
the Weibull distribution also offers a flexible distribution (increase or decrease)
and is popularly used in medical studies.
Our aim is to model possible residual spatial variation in survival after account-
ing for patient-specific prognostic factors and unobserved individual frailties. For
convenience sake, we repeat this model here;
h(t; ξ, x) = h0(t) exp {Xβ + S(x)} , x ∈ R2 (6.1)
where ξ = (β, α, λ, τ 2, σ2, φ) is a vector of the model parameters, α and λ are shape
and scale parameters for the baseline hazard function from the Weibull distribu-
tion, β andX as defined above, and S(x) is a value of spatial continuous stationary
Gaussian latent field measured at location of survival time i with σ2 and φ being
the marginal variance of the Gaussian field and spatial decay parameter the cov-
ariance functions. In this study, we consider the Exponential covariance function
and Matern function as defined in Section 4.3.2.1 on page 62 and a baseline hazard
from Weibull distribution. The choice of this baseline hazard function was largely
based on the limited availability of other options in the R package spatsurv that
we used for spatial survival data. At the time of this time, only Exponential and
Weibull were available options for the baseline hazard but we opted for the Weibull
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distribution because it is more flexible compared to the Exponential function.
Fixing the baseline hazard function (Weibull distribution), we fitted eight (8)
variants of Equation (6.1) and selected the model that fits the data well. Here is
a list of all the models considered;
Model 1: Exponential model with spatial frailties only. The parameters estimated
in this model are; β, α, λ, φ, σ2. Using an exponential covariance func-
tion, this model estimates spatial variance (σ2) in survival estimates.
It also estimates covariate effects (β), the spatial decay parameter and
parameters from the baseline hazard function (α, λ). This model is same
as Matern with k = 0.5.
Model 2: Exponential model with both Individual-level and spatial frailties. The
parameters estimated in this model are; β, α, λ, τ 2, σ2, φ. In addition
to parameter estimates in Model 1, this model provides one additional
estimates: the variance τ 2 which describes the heterogeneity in patients.
Model 3: Matern (κ = 1) model with spatial frailties only. The parameters estim-
ated in this model are; β, α, λ, φ, σ2. This model is similar to Model 1,
with the only difference being the covariance function.
Model 4: Matern (κ = 1) model with Individual-level and spatial frailties. The
parameters estimated in this model are; β, α, λ, τ 2, σ2, φ. This model is
similar to Model 2, with the only difference being the covariance func-
tion.
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Model 5: Matern (κ = 1.5) model with spatial frailties only. The parameters
estimated in this model are; β, α, λ, φ, σ2. This model is similar to Model
3, with the only difference being an increase in smoothing parameter
k = 1.5 specified in the covariance function.
Model 6: Matern (κ = 1.5) model with Individual-level and spatial frailties. The
parameters estimated in this model are; β, α, λ, τ 2, σ2, φ. This model is
similar to Model 4, with the only difference being an increase in smooth-
ing parameter k = 1.5 specified in the covariance function.
Model 7: Matern (κ = 2) model with spatial frailties only. The parameters estim-
ated in this model are; β, α, λ, φ, σ2. This model is similar to Model 3
and Model 5, with the only difference being an increase in smoothing
parameter k = 2 specified in the covariance function.
Model 8: Matern (κ = 2) model with Individual-level and spatial frailties. The
parameters estimated in this model are; β, α, λ, τ 2, σ2, φ. This model
is similar to Model 4 and Model 6, with the only difference being an
increase in smoothing parameter k = 2 specified in the covariance func-
tion.
The resulting integrals from the likelihood functions of these models are very
complex, necessitating the use of Bayesian approaches. To complete the Bayesian
framework, we specify the independent Gaussian (IG) priors for the parameters
to be estimated in the model. Since the parameters in the baseline function and
those in the correlation function are always positive, the specified priors are given
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on the natural logarithm scale. The priors for the parameters are specified as
follows;
 βi ∼ N(µ = 0, sd = 10)
 log(αi) ∼ N(µ = 0, sd = 10)
 log(λi) ∼ N(µ = 0, sd = 10)
 log(σi) ∼ N(µ = 0, sd = 0.5)
 log(τi) ∼ N(µ = 0, sd = 0.5)
 log(φi) ∼ N(µ = 8, sd = 0.25).
The prior for the spatial decay parameter was not vague in order to reduce the
computation time. When we used vague priors for this parameter, it took long
twice as much time as when it was not vague. Specifying a prior close to the true
value of φ (used variogram) significantly decreased computation time by almost
half when using high end computing (HEC) and by four fold when using a 64
bit/4GB RAM laptop. On HEC, each model took an average of 2 days to complete
the run and about 6 days on a laptop (using non-vague parameters).
Ideally in a Bayesian analysis we would select model priors to be diffuse, and we
have attempted to do this here, with the exception of the parameter φ, which is
typically poorly identified by the data in spatial applications, our prior for log(φ)
lends support to spatial dependence between values of φ 1 and 7 kilometres. For
diffuse priors; log(σi) and log(τi) has a support between 0 and 7; for βi, log(αi)
and log(λi) the support is between 0 and 8e+15.
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6.4.1 Model Diagnostics and Comparison
All the analyses were done in R software using spatsurv package(Taylor, Davies
et al., 2015). The autocorrelation plots and log-posterior plots were used to check
evidence of reasonable mixing of chains and convergence of chains respectively.
These diagnostics plots were done using mcmcplots package in R.
The DIC is frequently reported in Bayesian models. However, the review of dif-
ferent criteria of comparing competitive Bayesian models by Gelman, Hwang and
Vehtari, (2014) recommended the use of WAIC in selecting a best fit model. The
WAIC is preferred to DIC because it is based on the posterior density unlike the
DIC which is based on the posterior point estimate such as mean or median.
6.5 Descriptive Analysis
A total of 1931 HIV patients comprising of 560 patients diagnosed with Kaposi’s
sarcoma during treatment initiation and 1371 HIV patients without KS. There
were a total of 238 deaths recorded, 105 among KS patients and 133 in HIV
patients without KS.
Figure 6.1 shows parts of the district with low and higher number of patients who
attended the HIV clinic. We created quadrant over the map and counted the
number of patients falling inside each quadrant. This gives a rough estimate of
how patients are distributed in the district. In our data, we observe that many
patients attending the clinic tend to be those living in the centre of the town near
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where the clinic is. This could be explained by the high population density around
this area as the clinic is inside Zomba city.
Figure 6.1: Quadrant counts showing areas with high number of HIV patients
in Zomba. The counts were calculated by counting the number of patients in
each quadrant created over the map.
However, the lake on the right side of the district has so many small islands
and most can not be seen with the current map resolution. As such, subsequent
(probability) maps in this chapter must be interpreted with caution especially for
areas seen to be on the lake. Figure 6.2 shows a google maps snapshot of the
islands on the northern part of the lake.
6.5.1 Mapping deaths, active follow-up and lost to follow-up
In total, there were 238 deaths and 605 patients in active follow-up at the end
of the study. About 64% of patients with censored times were patients that were
categorised as lost to follow-up. One possible reason for this high attrition rate
could be due to poor documentation especially in cases where patients have been
transferred to other HIV clinics.
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Figure 6.2: Map of Lake Chilwa showing different small islands, with the
majority of larger islands in the northern end. Also, some tiny islands also exist
in the southern end of the lake
One of the interesting descriptive result would be to visualise how the patients that
experienced the event (death) and LTFUs are distributed on the map. To do this,
we used the smoothed Kernel intensity estimates to compare the patient counts
for those who died versus those who were lost to follow-up, and the deaths versus
those who were still in active clinic follow-up at the end of the study. We are inter-
ested in the exceedance probabilities Prob {intensitydeath − intensitya > 0} where
a ∈(active follow-up:alive, LTFU ). We plotted these probabilities to identify areas
with high probabilities of finding more deaths.
The plot on the left panel in Figure 6.3 (Death vs Alive) is an exceedance probabil-
ity map showing how events (deaths) and active follow-up patients are distributed
in Zomba. We plotted the difference in their the kernel estimate of point process
intensities ( deaths - alive), so that the colour corresponding to high probability
values on the scale bar indicate the areas likely to have more counts of deaths
(more yellow-red), and low probability values indicating areas likely have similar
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intensity estimates for the two events being compared (more blue). From this
map, it can be seen that more deaths were likely to be observed around Lake
Chirwa (refer to Figure 2.1), the eastern direction of the map. Similarly on the
right panel of Figure 6.3 (Death vs LTFU), the exceedance probability map is for
the differences between the process intensity estimates for death events and loss
to follow-up. Compared to observed LTFUs, we also note that in addition to the
eastern region of the district, more deaths were also likely to be observed on the
south- west and northern part of the district. These latter two areas coincide with
the locations of two of the earliest HIV clinics in the Zomba district. On both
maps, we see some areas in the lake with high probability of having more counts
of deaths. This is because there some islands in the middle of the lake. Since
we used smoothed mapping, even other points on the lake had an estimate but
had zero probability of having death counts. This is one of the limitations for
these maps because we did not have polygons for these islands so that they can
be isolated.
159
Figure 6.3: Left panel : The Zomba map showing areas with high probability
of having more number of deaths compared to those in active clinic follow-up:
using the difference in the kernel estimate of point process intensities for death
events and alive patients. The colour corresponding to high probability values
on the scale bar show areas with larger intensity estimates for the death. Right
panel : The map on the right density differences of death events vs lost to follow-
up (LTFU). Likewise, the colour corresponding to high probability values on
the scale bar correspond to the areas with more deaths events compared to the
LTFU.
The issue of LTFU is considered for reference when fitting the models in Sec-
tion 6.6.3 and the maps for these are included in Figure 6.9. We used two propor-
tions of deaths among LTFU: 34% and 60%.
6.5.2 Distribution of patients by ART period
In the study in Chapter 5, we found that the date of starting ART was significantly
associated with the risk of death as well as being lost to follow-up, with patients
who started in the later period having significantly lower hazards of deaths. We
would like to explore if the distribution of patients between the two ART periods
differ.
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A total of 644 (33.4%) started HIV treatment (ART) between 2004 and 2007, and
1287 between 2008 and 2011. We used the kernel estimation to estimate point
process intensities in order to compare the distribution of patients in these two
ART periods. We also used exceedance probabilities as described above, but the
difference in intensities was between estimates for patients who started ART in
2004-2007 period and those in 2008-2011 period. We were interested in areas of
the district with this difference > 0, to indicate more patients who started in
2004-2007 observed.
Figure 6.4: Map showing exceedance probabilities, with colours corresponding
to higher values of probabilities showing areas that are likely to have more
patients who started ART in the 2004-2007 period, otherwise no difference (more
blue).
Figure 6.4 is an exceedance probability map and the colour corresponding to higher
values of probabilities show areas likely to have more observed patients who started
ART in the 2004-2007 period. The parts of the district with more blue colour (i.e.
lower probabilities) indicates the point process intensities for the two periods are
likely to be similar. From this map, it is suggested that the western, south-
west, north-west and north-eastern parts (more red colour) of the map were likely
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to have earlier ART initiations (2004-2007) compared to initiations in the later
period (2008-2011). Again, some areas in islands on the lake did also have higher
probability having earlier initiations.
6.5.3 Mapping TB Episodes and KS Diagnosis
In the analysis in the Chapter 5, we also found that TB status was an important
predictor or mortality. Therefore, we wanted to identify areas that observed more
TB episodes. In addition, we also plotted the KS cases on the map.
A total of 301 (15.6% of 1931 patients) were either diagnosed with TB or were on
TB treatment at the recruitment time. The plot on the left panel of Figure 6.5
is an exceedance probability map obtained by calculating the probabilities that
the difference between intensity estimates of having TB and no TB (TB vs no
TB). Similarly, the colour corresponding to the greater probability values on the
scale bar represent areas on the map likely to have more TB episodes observed
compared to TB-free episodes. It can be seen that there were more TB episodes
on the eastern and north-eastern parts of the district.
Among the 1931 patients, a total of 560 were diagnosed with Kaposi’s sarcoma
during routine initiation of ART in Zomba during the study period. We also
used the differences in the intensity estimates to check areas with more KS cases
compared to non-KS cases. Similar to other maps, the KS cases seemed to be likely
to be observed in the western, north-western and eastern parts of the district as
shown in the right panel of Figure 6.5.
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Figure 6.5: Left panel : The map of Zomba showing exceedance probabilities of
the difference in intensity estimates between patients with TB and those without
TB episodes (TB - no TB) being greater than zero. The greater probability
values on the scale bar correspond to the areas with more TB episodes (more
red colour). Right panel : An exceedance probability map showing areas where
more KS cases were recorded: more red colour corresponding to areas likely to
have more KS cases.
6.6 Spatial Survival Model Results
This section contains results from different competitive models considered in this
analysis. We start by presenting model comparison results based on the WAIC
and DIC values. Then we present the results from the MCMC diagnostics for the
chosen model. Lastly, we end the current section by presenting the exceedance
probability maps in order to provide an intuitive interpretation of the areas with
high hazard rates by using example cut-off points.
6.6.1 Model Comparison
We compared eight (8) competitive spatial survival models, all with a Weibull
baseline hazard function. We chose the best fitting model to the data using the
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WAIC value as presented in the Table 6.1 below. The final model was chosen
using WAIC values. We preferred WAIC to DIC because the WAIC uses the whole
posterior density while the DIC uses a point estimate of the posterior distribution.
The limitation of using the point estimates is that sometimes they do not provide
a good summary of the distribution. In our case, the newly introduced WAIC
addresses this limitation.
Table 6.1: Comparing Weibull spatial survival models with different covariance
functions.
Model PD DIC WAIC
Model 1 Exponential: Spatial* -25.22 4500.82 4564.38
Model 2 Exponential: Individual-level + Spatial† -8 4512.11 4580.78
Model 3 Matern (κ = 1): Spatial -26.55 4498.59 4564.66
Model 4 Matern (κ = 1): Individual-level + Spatial -10.94 4516.58 4583.24
Model 5 Matern (κ = 1.5): Spatial -19.82 4511.71 4583.58
Model 6 Matern (κ = 1.5): Individual-level + spatial -8.97 4525.15 4583.53
Model 7 Matern (κ = 2): Spatial -25.89 4518.98 4584.41
Model 8 Matern (κ = 2): Individual-level + spatial -8.03 4521.17 4582.63
*Spatial= Spatial frailties
†Individual-level + Spatial = Individual-level + Spatial frailties
After comparing the WAIC values, a Weibull spatial model with an exponential
correlation function was found to fit these data well. However, a Weibull spatial
model with a Matern κ = 1 had a similar WAIC value to the exponential model
(4564.66 vs 4564.38). To our understanding, this difference in the WAIC values
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is very minimal such that these two models should give comparable parameter
estimates. Lastly, we note that in all the models, the inclusion of the Individual-
level frailties was not beneficial to the overall model fitness using both DIC and
WAIC values.
6.6.2 MCMC Diagnostics
We give details of the MCMC diagnostics for the Weibull Spatial frailty model
with the exponential covariance function. We run 2,000,000 iterations with burn-
in of 100,000 and thinning every 1000th sample. The computation time varied
on personal computers and high end computing (HEC). On a desktop it took an
average of five days to complete a model while on HEC it took an average of two
days for the same models.
We conducted diagnostic checks for reasonable mixing and convergence of the
chains. In Figure 6.6, a lag-1 autocorrelation plot (first plot from left) of posterior
MCMC samples shows independence of in the samples drawn (autocorrelation
clustered around zero). The log-posterior density plot in Figure 6.6 (second plot
from left) indicates the chain has found a mode and remained around it for the
duration of the run. This is evidence that the chain has left the transitory stage.
The last two plots in Figure 6.6 are the density plots for the prior and posterior
distributions for the parameters of the correlation function. When we fit a Bayesian
model, we input a prior density for our parameters of interest and the data modify
the prior through the likelihood to arrive at the posterior. We can therefore
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compare plots of the prior and posterior to get an idea of the information content
in the data. When the data are well able to identify a parameter in our model,
we expect the prior and the posterior to look very different, however if the prior
and posterior look similar, then the data do not provide much information on the
parameter. These plots indicate that there is some information added from the
data to the prior for the spatial variance parameter (σ) but not in the case of the
distance parameter, φ, a common phenomenon in spatial analyses. For the spatial
variance parameter σ, there is a small shift to the right in the posterior density.
All trace plots for fixed and random effects parameter indicate reasonable mixing in
the chains as shown in Figure 6.7 and also shown in Figure 6.8. The MCMC chains
for the parameters of the baseline hazard function (Weibull, α, λ) and spatial
correlation function (φ, σ2) are shown in Figure 6.7 while chains for fixed effects
are shown in Figure 6.8.
The diagnostic plots for the other models considered in this analysis looked similar.
Figure 6.6: The first two plots on the left are plots for convergence,indicating
close-to-zero correlation between samples. The last two plots are overlay plots
of posterior density over prior density show how information from data improve
the prior knowledge
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Figure 6.7: Trace and autocorrelation plots for the chains of parameters for
the baseline hazard and for the spatial correlation function.
Figure 6.8: Trace and autocorrelation plots of the chain for the fixed effects βs
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6.6.3 Estimates of model parameters
Table 6.2 shows summary posterior estimates of the fixed and random effects from
the Weibull spatial survival model with an exponential correlation function. From
this table, only sex, ART period and (not) diagnosed of KS were significantly as-
sociated with risk of death. Male HIV patients were 50% more at greater risk of
dying than female patients (HR: 1.509, 95% HPD: 1.149 - 1.961). Low mortal-
ity risk was observed in patients who started HIV treatment from 2008 onwards
(HR: 0.558, 95% HPD: 0.421 - 0.740). Low mortality was also observed in HIV
patients who were not diagnosed with KS, with approximately 60% reduction in
risk (HR: 0.398, 95%HPD: 0.306 - 0.527). No statistically significant associations
were observed among patients with different ages and whether patients had TB or
not.
The estimate of the spatial variance indicate evidence of unobserved spatial het-
erogeneity in the survival in the district (see Figure 6.9).
Table 6.2: Posterior summaries of fixed and random Effects from Weibull
spatial model.
Covariate 50% 2.5% 97.5%
Age β1 1.000 0.984 1.015
Sex Ref:Females
Males β2 1.509 1.149 1.961
ART Period Ref: 2004 - 2007
2008-2011 β3 0.558 0.421 0.740
TB Diagnosis Ref: No TB
With TB β4 1.218 0.851 1.737
KS status Ref: With KS
No KS β5 0.398 0.306 0.527
Spatial variance σ2 0.428 0.226 0.689
Correlatio scale φ 2858.184 1784.839 4517.591
Weibull shape α 0.52310 0.46623 0.5836
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6.6.4 Exceedance Probability Maps
Probability maps are maps that are generated by plotting the probability of a
certain phenomenon happening. In our case, we are interested in generating maps
that can be used to show areas with high probability of having low survival es-
timates (or high hazards for deaths). For this purpose, exceedance probabilities
are commonly used. An exceedance probability is defined as probability that the
hazard rates ( as in our case) exceed a certain threshold value. The choice of
a threshold value is largely based on the expert advice or clinical relevance of
the cut-off value. Arguably, the use of the probability maps in spatial epidemi-
ology provides an intuitive interpretation of how the risk is spatially distributed.
Secondly, when calculating the exceedance probabilities, the mean prediction and
standard errors are taken into account, thereby simplifying the burden of compar-
ing two different maps: one for mean prediction and another for standard error.
The quantity exp(S) which is the hazard rates (HR) is a post-estimate of Equa-
tion (6.1). However, we plotted the exceedance probabilities P[exp(S) > c] for a
particular spatial location, with c taking the following values; 1.3 and 1.5. In our
case, the choice of reference value was arbitrary but clinically interpretable. We
also tried other cut-off values such as 2 (twice the hazard rates) and 2.5 but the
maps for these values were very faint.
To account for the issue of lost to follow-up (LTFU) in cohort studies, fitted three
different variants of the final spatial model: i) the model assuming 0% mortality
rate among LTFU patients, ii) a model assuming 34% mortality among LTFU
169
patients, and iii) a model assuming 60% mortality among LTFU patients. Due to
the complexity of spatial models and the associated high computation cost, we did
not perform sensitivity analysis for the assumed choices of 34% and 60% mortality
rates. As such, we did not report covariate effects from the spatial model for these
models but instead produced exceedance probability maps based on these model
results.
We plotted three different maps, each having a different representation of propor-
tion of mortality among the LTFU patients. In Figure 6.9, the maps in the first
row were produced with all LTFU patients censored (0% deaths among LTFU pa-
tients). The middle row of Figure 6.9 were produced after assuming 60% mortality
among LTFU patients. The last row was produced using the minimum value 34%
mortality among LTFU, the value which was identified in the comparison method
for identifying an acceptable lower bound of death rate among LTFU patients as
reported in Chapter 5 under Section 5.6. Unlike in Chapter 5, we did not conduct
sensitivity analysis of spatial model because of the high computation cost involved
in fitting these models.
In Figure 6.9, the first two rows of the plots show similar areas where probability is
likely to exceed 1.3 and 1.5 (with a lake on the eastern side). These plots indicate
the northern and southern parts of the district having a higher probability of the
hazard rates exceeding 1.3 and 1.5. However, the choropleth maps on the bottom
row highlight different areas to the other plots on the first and second rows. The
plots on the bottom row indicate that the areas around the city centre of the
district are the ones that likely to have the highest probabilities of exceeding the
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reference HR values. A possible explanation for this difference could be due to
sampling bias in deaths among LTFU since this area is densely populated.
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Figure 6.9: Maps showing probability of hazard ratios of death using two cut-
off values; 1.3 and 1.5. Top row: P0[exp(Y ) > 1.3] (left) and P0[exp(Y ) > 1.5]
(right) indicate the areas on the map with the probability of HR exceeding the
two cut-off values when mortality amongst the LTFU patients is ignored. Middle
row: P34[exp(Y ) > 1.3] (left) and P34[exp(Y ) > 1.5] (right) indicate the areas
on the map with the probability of HR exceeding the two cut-off values when the
proportion of deaths amongst the LTFU patients is assumed to be 34%. Bottom
row: P60[exp(Y ) > 1.3] (left) and P60[exp(Y ) > 1.5] (right) indicate the areas
on the map with the probability of HR exceeding the two cut-off values when
the proportion of deaths amongst the LTFU patients is assumed to be 60%.
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6.7 Discussion
Overall, we noted that the majority of patients on the HIV treatment were living
around Zomba Central Hospital (see Figure 6.1). When comparing the distribu-
tion of patients by ART outcomes (deaths, active follow-up and lost to follow-up
(LTFU)), we noted that more deaths than the number of patients in active clinic
follow-up were observed around the eastern part of the district. Comparing the
number of observed deaths to the number of LTFU patients, we noted again that
there were more deaths observed in the northern outskirts and eastern parts of the
district. In the northern part of the district, there is an HIV clinic that started
providing ART in 2004 and this could explain the observed mortality due to age-
ing cohort. In eastern part, there is a lake and many fishing and other economic
activities happen in the area and that could increase the risk of HIV/AIDS and
mortality in this area.
When mapping TB episodes and KS using intensity maps, we noted that the
majority of TB episodes observed in the district were likely to be observed in
the western, eastern and north-eastern part of the district. We did not have
an immediate explanation for this observation but around these areas of the map,
there are two important features: the lake where many economic activities happen;
and on the western part of the district, there is an HIV clinic which is one of the
earliest clinics in the district.
In calculating the exceedance probabilities in Section 6.5.1, Section 6.5.2, and
Section 6.5.3, we made an assumption that the standard errors for "‘cases"’ and
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"‘controls"’ are independent. This is an assumption of convenience and will not
be always true in practise, and so these exceedance probabilities are likely to be
conservative.
When comparing results in Chapter 5, the effect of TB status and age at recruit-
ment on mortality changed in a spatial survival model. The ART initiation age
tended to be associated with mortality while TB was not significant. This change
could be due to the addition of the spatial dimension to the model.
Model comparison showed that models with spatial frailties were out-performing
model that included both patient-level frailties and spatial frailties. The use of
grids was to reduce the computation time of fitting the models and does not
affect model choice. Two competitive models were found: an Exponential model
and Matern 1 (kappa=1) model both with spatial frailties only. The final model
results and hazards prediction was based on Exponential model. Similar results
can be obtained using a Matern 1 model. There was good mixing of chains and a
reasonable convergence was reached.
Adjusting for age, TB status and spatial location, the following variables were
significant in the model; sex, ART period and KS status. Male patients were
at a greater risk of dying. The hazards of death were so higher in males than
in females. These result in consistent with common knowledge about low health
seeking behaviour in men compared to females. A multinational study in resource
limited setting also found that female had low risk of death compared to males
across all age groups (O’Brien et al., 2016).
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Patients who started ART from 2008 to 2011 had significant reduction in hazards
of death. This result can be explained by better service provision and better scale-
up of HIV treatment programs over time. With the new efforts to start all HIV
patients on treatment immediately, it will be interesting to see how results will
compare spatially.
The exceedance probability maps show that HIV patients living in the north-
ern and southern ends of the district tend to have lower survival. This result is
also consistent with (sensitivity analysis) results obtained after adjusting for 60%
deaths among loss to follow-up patients. However, after accounting for deaths
amongst LTFU patients, the exceedance probability increased considerably from a
maximum of 0.6 to 0.8 and 0.4 to 0.6 for HR >1.3 and HR > 1.5 respectively (20%
increase in both cases). Patients living closer to the town have better prognosis
than those leaving far away. We are not able to explain the poor survival observed
in areas far north and south of the district because there are two relatively big
HIV clinics around those areas. However, possible explanations could be that early
ART initiations were from these regions and also the type of quality of care and
treatment services provided in these regions. These geographical variations should
not be ignored but should inform routine HIV programme and form a basis for
further operational research to better understand these differences.
One of the limitations of this study is that there was high loss to follow-up which
can impair estimation of survival in this cohort. However, our sensitivity analysis
results support the general finding of existence geographical variations in survival
in Zomba district. Also, we used data that is routinely collected as part of program
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activities and quality of data has been a great issue in such study settings but the
data were generated from the nationally standardized monitoring and evaluation
tools used in the Malawi HIV programme and have been found to be of good
standard.
In conclusion, this study highlights the geographical variations in survival in KS
epidemiology and HIV treatment outcomes often not reported in most sub-Saharan
Africa HIV programmes. We found significant geographical variation in survival
among different sexes, ART period and KS status. The relative hazards of death
increase in males, almost halved in patients who started ART during 2008 -2011
period, and a three-fold decrease in relative hazards in patients not diagnosed with
KS. Overall variation in survival in the district should not be ignored in routine
HIV programming. Similar analyses at regional and nation-level to study KS
epidemiology and other types of cancer in HIV programmes could inform current
efforts to improve HIV programming in resource-limited settings.
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Multistate Markov modelling in TB
Epidemiology
Abstract
Multistate models in survival analysis are used for analysing data in which patients
experience different intermediate states (events) before experiencing the event of
interest. In this final case study, we consider the time to different states in which
TB patients in HIV cohorts go through (TB free, TB infection, cured, relapse
and death). A time-homogeneous Markov model is applied to a sample of 1483
patients randomly selected from an HIV cohort of approximately 20,000 patients.
The total follow-up period was 120 months (10 years) and approximately 12.6% of
total patients had at least one TB episode during the follow-up period. Mortality
in these patients was around 9%, with most of patients that died being patients
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that were diagnosed with TB after they had already started ART. The main
transitions observed in this cohort were; remaining TB free, no-TB directly to
death, TB infection to cured, no-TB then TB then cured, no-TB then TB then
died, in that order. Patients that had finished TB treatment and were not cleared
of TB at the end of TB treatment were more likely to restart TB treatment again
(not cured). Mortality was three times higher in patients who got TB after starting
ART than in patients who started ART while on TB treatment. Among patients
with no TB at baseline, male patients were at significantly greater risk of dying
than female patients. Also, patients that started ART from 2008 had significantly
lower risk of TB infection if they did not have TB at the time of starting ART.
Our study presents different transition quantities between the states of interest
that can be easily be understood by clinicians and public health specialists. More
importantly, the results provide clear pathways taken by HIV patients as they
move from one TB state to another, an aspect mostly often not reported in TB
analyses. More importantly, the clinical implications of these findings suggest
that patients that had a non-conclusive TB treatment result could be restarted
on TB treatment rather than wait for further confirmation results. Also, from
public health interest, these findings suggest the protective effect of ART on TB
episodes with patients that start TB after scale-up of ART having less likelihood
of experiencing a TB episode.
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7.1 Introduction
In Chapter 5 and Chapter 6, we modelled the time to an event happening, namely
death. In addition, in Chapter 5 we considered; i) death as an outcome, ii) death
as a competing risk to occurrence of lost to follow-up event i.e. dying before being
lost to follow-up and lost to follow-up before death being recorded or observed. In
both cases, one of the assumptions was that all patients had the same origin status
(also called initial state). In Chapter 6, only the death outcome was considered
but an extension was made to study how the hazard of death varied geographically.
However in some diseases, patients go through multiple states before experiencing
a terminal state (such as death). To get a better understanding of the disease
progression, it is therefore important to model this process.
In this chapter, we consider an example of epidemiological study in which patients
visit four (4) states; TB free, TB infected/Receiving TB treatment, TB treatment
completed and death. These states are based on nationally standardised definition
of TB treatment outcomes in Malawi. In particular, unlike having a single unique
transition record per patient (alive → dead or to another competing event), we
consider all transitions between states. The methods used to analyse these kinds
of data are generally mathematical modelling of infectious diseases and 2) the
multistate models, also known as event history modelling.
In general mathematical modelling of infectious diseases uses a set of differential
equations. For these equations the following must be established or specified: the
number of individuals who are susceptible to the disease; the number of individuals
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exposed to the disease; the number of individuals infected by the disease and
; the number of individuals that recovered or died from the disease. All the
parameters that govern the infection process ought to be specified too. Such
parameters include; the infection rate, recovery rate, and the basic reproduction
number of the disease. The modelling process becomes complex when modelling
co-infections such as HIV and TB co-infection. Available literature on modelling
the dynamics of HIV/TB co-infections have been done at cellular level, hence
requiring immunological measurements such as T cells, CD4 cell count, CD8+ cell
counts and viral load (Dodd et al., 2014; Shah and Gupta, 2014; Wang, Yang
and Zhang, 2013; Castillo-Chavez and Song, 2004; Blower et al., 1995). These
measurements indicate the level of compromise of an individual’s immunity with
TB and HIV co-infection. Since we did not have all these measurements, we did
not consider mathematical modelling, and this is one of the limitations of these
data.
In our our literature review, we did not find any studies on TB treatment outcome
that used multistate models. This lack of literature in public domain is echoed
in an overview by Beyersmann, Wolkewitz et al., (2011). However, multistate
models have been used to study disease progression and efficacy of TB diagnostics
and treatment regimen with studies from Malawi, South Africa, Zambia and Kenya
(Keiser et al., 2011; Bwayo et al., 1995; Heymann, 1993). In other studies, Markov
multistate models were used in economic evaluations of preventive therapy regimes
of TB aimed at preventing the spread of tuberculosis (Mandalakas et al., 2013;
Bell, Rose and Sacks, 1999; Bachmann, 2006).
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7.2 Objective
We use these multistate models to study the epidemiology of TB in HIV cohorts.
Specifically, the purpose of this chapter is to address the last objective: Using
multistate survival models, investigate the different infection pathways for indi-
viduals with both TB and HIV as listed under section 2.2 on page 7. In particular,
the goals of this analysis are to; i) model the probability of transitioning between
each pair of states and ii) assess the effects of covariate on these transition prob-
abilities. The overall motivation of this analysis is that a better understanding of
the complex epidemiology of HIV and TB co-infection could be vital in provid-
ing insights into care and treatment practices in HIV programmes. A detailed
description of methods used in multistate modelling have been described under
subsection 4.3.3 from page 64.
7.3 Recap: HIV and TB co-infection
Tuberculosis is one of the most common opportunistic infections in persons liv-
ing with HIV. The disease takes advantage of the compromised immunity the
HIV patients have and being diagnosed with TB is a sign of progression to AIDS
(CDC, 2016). TB examination is either through sputum smear examination (very
common) or chest X-ray examination. Once diagnosed with TB, in addition to
HIV treatment drugs (ART) patients are started on first line TB drugs for a min-
imum of six months. The most common drugs are isoniazid (INH) and rifampicin
(RMP). Sometimes HIV patients develop a more complex form of TB known as
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Multi-drug-resistant tuberculosis (MDR-TB). MDR-TB patients are treated for a
longer period of time- usually a minimum of eight months (Malawi Ministry of
Health, 2011). The possible outcomes of the TB treatments are cured, relapse,
complete (TB outcome not yet confirmed), death or loss to follow-up. In low-
income countries with high burden of HIV disease, research in TB epidemiology is
becoming increasingly useful in informing the integration of HIV and TB services
especially in sub-Saharan Africa. Some of the studies reporting efforts on the HIV
and TB integration services include studies by Sculier, Getahun and Lienhardt,
(2011), Zachariah et al., (2011) and Howard and El-Sadr, (2010) and Churchyard
et al., (2007).
7.4 Data Description
The data used in this analysis were collected from 1, 500 HIV patients randomly
selected (without replacement) from an HIV cohort with approximately 20, 000
patients on HIV treatment in Zomba district in Malawi. The selection of the
random sample was restricted to only patients who started the lifelong HIV treat-
ment antiretroviral therapy (ART) between 2004 and September 2011. The size
of the sample was constrained by resources and time. After obtaining permission
from the hospital officials, we organised and collected patients records for patients
that started ART during the study period. With the help of five research assist-
ants, we retrospectively reviewed paper records containing clinic visits for all 1,
500 selected patients and entered the data in an electronic database. Here, TB
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is defined in general as having a TB diagnosis regardless whether it is a simple
TB or MDR-TB. This is because the MDR-TB testing was not available for the
majority of the study period. In addition, all the data from sputum smear and
chest X-ray examinations are included. After data cleaning, only 1483 patients
were eventually used in the final analysis, because the other 17 patients did not
have complete information on important variables (sex, date of birth and date of
starting HIV treatment). In total, there were more than 35, 000 clinic visits made
by the 1483 sampled patients in the study period.
7.5 Multistate modelling
We identified four possible TB states (status) through which HIV patients go
through. These states are;
 TB free. This is a state when patients do not have TB or have been cured
after TB diagnosis and have successfully completed TB treatment as per
national treatment guidelines. Patients in this state could be misdiagnosed
as TB free and this in turn would overestimate the number of patients of
cured of TB.
 Receiving TB treatment. This is a state for all patients diagnosed with TB
and are receiving TB treatment in addition to their routine ART treatment.
There are two scenarios for an HIV patient to be on TB treatment; Firstly,
all HIV patients screened for TB at baseline and subsequent follow-up clinic
visits. If diagnosed and confirmed with TB, they are started on TB treatment
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in additional of their usual ART drugs. Secondly, the other entry point is
the TB clinic. All patients in TB clinic are routinely offered HIV testing
and counselling services as part their continuum care package. Therefore, at
the time of starting HIV ART (HIV treatment) some patients might already
have started TB treatment.
 TB treatment completed. The patients in this is state are patients that
have completed TB treatment but their TB status or outcome is not yet
confirmed. For some patients, this was taking up to three months to have
TB status results. The possible final outcomes from this state are; 1) patients
confirmed cured of TB (go to state 1 ) , 2) patients not cured are restarted
on TB treatment (go to state 2 ), and 3) other patients die while awaiting
ascertainment of TB status results (go to state 4 ).
 Death. The state for patients that died while on TB treatment or after
successful TB treatment or died without any TB episode. The limitation of
this categorisation is that such deaths are not attributed to TB/HIV as a
cause, its treated as all-cause mortality even though TB/HIV could be the
highly probable cause of death.
All possible transitions between these states are summarised in the flow diagram
in Figure 7.1.
The recruitment (baseline) time was defined as the time since starting the lifelong
antiretroviral therapy. We used a Counting Process (CP) format for our data. This
means that the time to a particular state is calculated from the recruitment time
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as opposed to resetting the clock to zero every time the patient leaves a particular
state (see an example given in Table 4.3). The reason for adopting this type of
time scale is because the order in which the states (events) occur is important in
our data. For example, while you can die without having any TB episode (1 →
4), it is impossible to be cured unless you first had TB and were on TB treatment.
So TB infection starts first before being cured of TB.
TB-FREE (1) ON TB TREATMENT(2)
TB TREATMENT COMPLETED(3)DEATH (4)
Figure 7.1: A model for TB events following initiation of HIV treatment(ART)
7.6 Model formulation and Parameter Estimation
Different approaches can be used to analyse multistate data in the counting process
approach. In the book by Beyersmann, Allignol and Schumacher, (2012), the
authors use a stratified Cox model to model transition hazards and probabilities.
However in the present analysis, a Markov model was used to model different
transition quantities of interest because the order in which events occurred is
important in our data. This order of occurrence of events is not captured by a
stratified Cox model. For instance, for patients to be in state 3, the must have
been on TB treatment first and also one can be cured of TB if they were first
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diagnosed of TB and put on treatment. The order of these possible transitions
is very important especially in estimating the probability of transition to a next
state i but not j.
In this study, we used a time-homogeneous Markov model. This assumption is
important as it simplifies the interpretation of different transition quantities. How-
ever, this is a strong assumption especially in TB epidemiology where the hazards
of TB infection could change over time and exposure due to change in public health
systems. Nevertheless, the motivation and availability of software for analysing
such data played a big role in choosing this model. This limitation is also reflected
through out in the discussion of results from these models.
To complete the formulation of a Markov model, a transition matrix specifying
all possible transitions must be defined. The diagonal elements are set to zero as




0 q12 0 q14
q21 0 q23 q24
q31 q32 0 q34
0 0 0 0

One of the goals of this analysis is to assess the effects of covariates on transition
quantities. To do this, we introduce a model for the hazard of transition between
each pair of states. We included covariates in our model in order to estimate the
effect on transitions between states. Equation 7.1 to Equation 7.7 give the series
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of all models for the transition hazards fitted in this study.
q12(t, x) = q
12
0 (t) exp(Xβ12) (7.1)
q14(t, x) = q
14
0 (t) exp(Xβ14) (7.2)
q21(t, x) = q
21
0 (t) exp(Xβ21) (7.3)
q23(t, x) = q
23
0 (t) exp(Xβ23) (7.4)
q24(t, x) = q
24
0 (t) exp(Xβ24) (7.5)
q32(t, x) = q
32
0 (t) exp(Xβ32) (7.6)
q34(t, x) = q
34
0 (t) exp(Xβ34) (7.7)
where q0(t) is the baseline transition hazard at time t and x is an individual
covariate value.
The estimation of the parameters β12, β14, β21, β23, β24, β32 and β34 is through max-
imum likelihood estimation using the likelihood function defined in Equation 4.49.
Detailed description of these methods is given under subsection 4.3.3.
The msm was the man package used in model fitting. The other two packages
developed by Beyersmann, Allignol and Schumacher, (2012) were also used in this
analysis as follows; mvna-multivariate Nelson-Aalen estimator of the cumulative
transition hazards for plotting cumulative transition hazards, and etm-Empirical




The total follow-up period was 11.23 years with a total of 35, 263 patient visits.
Among the 1, 483 HIV patients, a total of 130 (8.7%) patients died and a total
of 187 (12.6%) patients had at least one TB episode (generally called HIV/TB
co-infection). A total of 1194 patients did not have any TB episode during the
follow-up period (Table 7.2).
Among 130 patients that died, 102 (78.5%) did not experience any TB episode
during the follow-up period and a total of 28 (21.5%) of 130 patients that died
had at least one TB episode. This represents approximately 14.9% deaths among
the HIV/TB patients.
A total of 102 of 187 (54.5%) TB patients had TB at baseline, of which 8 (7.8%)
died. The remaining 85 of the 187 TB patients were diagnosed with TB after
starting ART, of which 20 (23.5%) died. Table 7.1 is a summary of all transitions
that happened in this sample.
The fewer numbers in state 3 is good from programme point of view since this
means more patients get post-treatment results in good time, no need to be in
state 3 awaiting their final TB result. However, in modelling this may lead to
great uncertainty due to large standard errors, hence wide confidence intervals.
From Table 7.1, there are no transitions from death (4) since it is an absorbing
state. Since patients cannot transition from state 4 (death), this is the only column
that has unique number of patients and the column total is therefore equal to the
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number of patients that died.
Table 7.1: Summary of state transitions. Transition numbers are as defined in
Figure 7.1
To
1 2 3 4
1 1325 87 0 104
From 2 139 0 33 22
3 7 5 0 4
There were a total of 20 unique transitions that patients passed through as sum-
marised in Table 7.2. For instance, among the 130 patients that died, 102 moved
directly from state 1 to state 4 (died without any TB episode during follow-up); 18
patients made the transition 1→ 2→ 4 (no TB at baseline and got TB and died
while on TB treatment); 4 patients made the transition 2→ 4 (had TB at baseline
and died while on TB treatment); 2 patients made the transition 2→ 3→ 4 (had
TB at baseline and died while awaiting ascertainment of TB status after TB treat-
ment), 2 patients made the transition 1 → 2 → 3 → 4 (no TB at baseline then
got TB and died while awaiting ascertainment of TB status after TB treatment);
and 2 patients made transitions 2 → 1 → 4 (had TB at baseline and got cured of
TB but later died).
A large number of patients had either one or two transitions only (Table 7.2).
Seven (7) patients experienced a relapse of TB, with 4 out 7 of them being cured;
the status of the other half was not ascertained by the time the study ended.
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Table 7.2: A list of transitions and number of patients in each combination of
transitions (1= TB free, 2= TB diagnosis and on TB treatment, 3=TB treatment
Completed/Awaiting confirmation of TB Status, 4=Dead)
Serial # Transitions Number of patients
1 1→ 1 1194
2 1 → 4 102
3 2 → 1 78
4 1 → 2 → 1 49
5 1 → 2 → 4 18
6 2 → 3 9
7 1 → 2 → 3 6
8 2 → 3 → 1 5
9 1 → 2→ 1 4
10 2 → 4 4
11 2 → 3 → 4 2
12 1 → 2 → 3 → 2 → 1 2
13 1 → 2 → 3 → 4 2
14 2 → 1 → 4 2
15 1 → 2→ 1→ 2→ 1 1
16 1 → 2 → 1 → 2 → 3 1
17 1 → 2 → 3 → 2 → 3 1
18 1 → 2 → 3 1
19 2 → 3 → 2 → 1 1
20 2 → 3 → 2 → 3 → 1 1
For patients with no TB at baseline, the median time to TB diagnosis was 10.5
months (95% CI: 6.7, 14.3). There was no noticeable difference in mean ages
between patients that had TB episodes and those without TB episode (Figure 7.2).
However, there was noticeable differences in mean age between female and male
patients, with male patients being older than females on average (Figure 7.3).
For patients that did not have TB at baseline, the probability of surviving a TB
diagnosis in the first five years (P {surviving TB in t≤ 5 yrs|no TB at baseline})
was estimated at 93% [95% CI: 91 - 95]. The time variable in this case is defined
as the time to TB diagnosis.
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Figure 7.2: Left: Density plot for patients with and without TB episode during
follow-up, with dotted lines representing the mean age in each group. Right:
Probability of surviving TB diagnosis for patients who started HIV treatment
without TB diagnosis at baseline.
Figure 7.3: Left: Density plot for patients’ age and sex (male/female). The
dotted lines are the mean ages at initiation of ART for each sex category.
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7.8 Model results and Prediction
We report the transition intensities, transition probabilities and transition hazards
(see pages 73 and 74 for definitions). These estimates were obtained using meth-
ods implement in msm R package. Comparable results for transition probabilities
and cumulative transition hazards1 were obtained using etm and mvna packages
respectively. All transition plots were done using etm and mvna. We discuss in
turn each of these quantities in the next three subsections.
7.8.1 Transition Intensities
The transition intensities describe the rates of transitions from one state i at time
t1 into another state j (possibly j = i) at time t2, t2 ≥ t1. The row transition
intensities in a transition matrix sum up to zero since the intensities of remaining
in the same state are defined as a negative summation of transition intensities
from this particular state to other states, qii = −
∑
j 6=i qij. Table 7.3 provides
a summary of the crude (no covariates included) and baseline covariate-adjusted
transition intensities with their corresponding 95% confidence intervals based on
the normal distribution. These baseline adjusted transition rates are obtained with
covariates set at their means. For intensity matrix that depends on a covariate,
see Table 7.6 on page 204. The transition rates are calculated per 120 months (10
years), the length of the follow-up.
1Cumulative transition hazards: the cumulative hazards of transitioning from one state to
another adjusting for patients’ covariates.
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Table 7.3: 10-Year Transition rates TR (95% CI) using a time-homogeneous
Markov Model(Adjusted for: initiation age, sex and ART period)
Transition Crude TR 95% CI Adjusted TR 95% CI
1 → 1 -0.00350 (-0.00405,-0.00303) -0.00318 (-0.00373,-0.00272)
1 → 2 0.001893 (0.00153,0.00234) 0.00172 (0.00137,0.00217)
1 → 4 0.001611 (0.00132,0.00197) 0.00146 (0.00117,0.00182)
2 → 1 0.192888 (0.16309,0.22813) 0.19622 (0.16515,0.23313)
2 → 2 -0.26647 (-0.30743,-0.23097) -0.25759 (-0.29996,-0.22120)
2 → 3 0.04547 (0.03194,0.06474) 0.03909 (0.02533,0.06034)
2 → 4 0.02811 (0.01772,0.04460) 0.02228 (0.01198,0.04142)
3 → 2 0.08772 (0.03679,0.20914) 0.07883 (0.02203,0.28213)
3 → 3 -0.15329 (-0.29306,-0.08018) -0.14840 (-0.37588,-0.05859)
3 → 4 0.06557 (0.02446,0.17578) 0.06957 (0.01813,0.26695)
The transition rate describes the rate of moving from one state to another. For
instance, there were 2 per 1000 HIV patients per 10 years who were infected of
TB and were put on TB treatment i.e they move from state 1 to state 2.
As seen in Table 7.3, there are no big differences in estimates obtained from un-
adjusted and adjusted model (adjusted for covariates).
The interest is on how transition from one state to another compare as well as
how different combination of transitions compare. From Table 7.3, it can be seen
that patients with no TB were 1.18 (95%CI: 0.85 - 1.64) times more likely to be
diagnosed with TB (q12) than die (q14).
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If patients were on TB treatment, the rates of moving to "cured state" were higher
than dying while on TB treatment or having the ascertainment of their TB status
prolonged after completing TB treatment. Patients were 5 (95% CI: 3 - 8) times
likely to be declared cured of TB (q21) than to remain without ascertainment of
their TB status (q23). Also if on TB treatment, patients were 9 (95% CI: 5 - 17)
times more likely to complete TB treatment and be cured of TB (q21) than die
while on TB treatment (q24). Once on TB treatment, patients were 69% more
likely to complete the treatment (q23) than die while on treatment (q24).
Patients who completed TB treatment and were awaiting ascertainment of their
TB status were 1.13 (95% CI: 0.17 - 7.17) more likely to restart TB treatment
(not cured, q32) than die (q34).
7.8.2 Transition Probability
The transition probability is the probability of occupying a given state j at time
t2 conditional on occupying state i at time t1, t2 ≥ t1. When the new state
occupied is an absorbing state, then the transition probability is equivalent to
an event probability. This is also analogous to cumulative incidence functions
discussed in the competing risk modelling (see subsubsection 4.3.3.1 for details on
the cumulative incidence function).
Since probabilities are defined for periods, the use of landmark time points to aid
interpretation of results is common practice in medical statistics. A landmark time
point is a time s that is chosen to mark a milestone of interest and can be used to
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check the progress of an outcome at different times. The landmark time approach
was first proposed by Anderson, Cain and Gelber, (1983). When calculating the
probability at a particular landmark time point, individuals are removed from the
data if they experience the transition of interest before this time (Anderson, Cain
and Gelber, 1983; Beyersmann, Allignol and Schumacher, 2012, p. 187). Two
comparisons between transitioning to TB diagnosis and to death are considered as
follows; P12(s, t) vs P14(s, t) and P14(s, t) vs P24(s, t) in Figure 7.4 and Figure 7.5
respectively. The estimated transition probabilities are based on Equation 4.47
on page 73. Let Y be a stochastic process for the TB states indexed by time on
ART with T= c(tmin, t1, . . . , tmax), for ti < ti+1. These transition probabilities are
defined as;
P12(s, t) = P (Yt = 2|Ys = 1)
P14(s, t) = P (Yt = 4|Ys = 1)
P24(s, t) = P (Yt = 4|Ys = 2)
In this analysis, three landmark time points were chosen at 6, 12, 18 and 24 months
after starting HIV treatment which are regarded as crucial time points for HIV
patients. The points were chosen based on the ART survival milestones reported
by the national HIV programme in Malawi (Malawi Minstry of Health, 2011).
In Figure 7.4, it can be noted that for each fixed s, we have P̂12(s, t) ≤ P̂14(s, t).
This difference is more pronounced with increasing period on ART for any fixed
landmark time point s. In general, P̂12(s, t) is decreasing over time while P̂14(s, t)
197
is increasing. Since TB diagnosis and on treatment (state 2) is a transient state,
some patients leave the state explaining the fluctuating behaviour of the prob-
abilities over time t for a fixed landmark time point s. Unlike patients on TB
treatment (state 2), patients who die (state 4 ) do not leave the state (absorbing)
hence the probabilities are bound to increase or be constant as time t increases for
a fixed landmark time point s. The width of the confidence bounds (dotted lines)
for P̂14(s, t) is increasing indicate growing uncertainty in the estimated probabilit-
ies. If patients were in TB free (state 1 ) after a long time on ART, the likelihood
of being diagnosed with TB decreases substantially although there are two spikes
between t=80 and t=100 with very wide confidence bounds. A possible explana-
tion for this observation could be due to the small number of TB cases during this
period causing wide and unstable confidence bounds.
Overall in Figure 7.5, the probability of dying while TB free (includes those cured
of TB) is consistently lower than dying while on TB treatment i.e. for each fixed
s, P̂14(s, t) ≤ P̂24(s, t). This difference is much smaller if patients did not have
TB in the first six months on ART but widens with increasing landmark time
point. Also note the increasing uncertainty of P̂24(s, t) with increasing values of
s. However, overall these results indicate if patients with longer follow-up time
are diagnosed with TB it is an indicator of worsening prognosis(as evidenced in
increasing probability of dying). Patients with longer follow-up time given that
they were TB free at s=18 and s=24 had a lower risk of death compared to the
risk in early follow-up time.
Table 7.4 shows the estimated 10-year transition probabilities for remaining in the
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same state and also transitioning to other states. The transition probabilities from
the same state sum up to 1. The crude probabilities are obtained from a model
without covariates and transition probabilities adjusted for age, sex and period of
starting ART are presented under the "Adjusted" column. The estimates from
both models lead to the same conclusions although 7 out of 12 times the adjusted
probabilities were slightly lower than the crude estimates.
From Table 7.4, we note a very high probability of remaining in state 1 using both
crude and adjusted results (Probability:0.9967, 95%CI: 0.9820-0.9971). Some of
the reasons for this high probability could be due to: fewer TB infections amongst
patients who started HIV treatment while TB free at baseline; low number of
TB relapses in patients that have successfully completed TB treatment and are
cured; and also it could be due to the long period used (10 years) could be long.
However, comparing transitions to other states, we note patients in state 1 (TB
free or cured of TB) had higher probability of being TB infected and put on TB
treatment than dying (Table 7.4).
Once on TB treatment (state 2), patients were more likely to complete the treat-
ment and be cured than dying while on TB treatment (0.169; 0.146-0.197). We
also note that patients on TB treatment had the lower probability of transitioning
to a death state was 3%, while transitioning to a state where they had to wait for
their final TB treatment result was 4%.
For patients awaiting ascertainment of TB status after completing TB treatment
(state 3 ), the probabilities of restarting TB treatment (not cured, going back to
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state 2 ) and probability of dying were both higher than being declared TB free
(cured, going to state 1 ). There was a 6% chance of dying if patients were in state
3. This result suggest restarting these patients on TB treatment would be a safer
option from a public health perspective.
Table 7.4: Estimates of 10-Year Transition Probabilities* (95% CI) using a
time-homogeneous Markov Model
Transition Crude Adjusted
1 → 1 0.99667(0.99620, 0.99710) 0.99698(0.99642, 0.99740)
1 → 2 0.00166(0.00133, 0.00203) 0.00152(0.00121, 0.00194)
1 → 3 0.00004(0.00003, 0.00006) 0.00003(0.00002, 0.00005)
1 → 4 0.00163(0.00133, 0.00201) 0.00147(0.00120, 0.00187)
2 → 1 0.16914(0.14550, 0.19650) 0.17279(0.14754, 0.20140)
2 → 2 0.76782(0.73700, 0.79210) 0.77429(0.74294, 0.80210)
2 → 3 0.03691(0.02571, 0.05230) 0.03195(0.02060, 0.04774)
2 → 4 0.02613(0.01752,0.04129) 0.02097(0.01255, 0.03705)
3 → 1 0.00736(0.00313, 0.01609) 0.00676(0.00187, 0.02002)
3 → 2 0.07120(0.02984, 0.15420) 0.06442(0.01769, 0.18320)
3 → 3 0.85953(0.72980, 0.92110) 0.86336(0.66850, 0.93750)
3 → 4 0.06191(0.02590, 0.16430) 0.06546(0.01894, 0.21780)
*P(0, t) for each pair of states, with t being the longest follow-up time.
Table 7.5 provides probabilities of the state being the immediate state to be visited,
−qij/qii state j to be visited immediately from state i. These probabilities are only
from all possible transitions from state i. For example, only two transitions are
possible from TB free status (state 1 ); transition to state 2 (TB infection/TB
treatment); transition to state 4 (dying while TB free). So we that TB infection
was likely to be the first state compared to death, with a ten-point difference in
probability (54% vs 46%). However, patients on TB treatment had a very higher
chance of being cured first before going to other states (72% vs 17% & 11%). Also,
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Figure 7.4: Probability of TB diagnosis (P12(s, t)) compared to transitioning
to a death state from a TB free state (P14(s, t)). Probabilities are plotted at
different landmark time points s since starting HIV treatment; 6 months (top
left), 12 months (top right), 18 months (bottom left), 24 months (bottom right)
we note that patients in state 3 were likely to transition to state 2 first (restarting
TB treatment) compared to moving to state 4 (death).
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Figure 7.5: Comparing transition probabilities of death without TB (P14(s, t))
versus death while on TB treatment (P24(s, t)). Probabilities are plotted at
different landmark time points s since starting HIV treatment; 6 months (top
left), 12 months (top right), 18 months (bottom left), 24 months (bottom right)
Table 7.5: 10-Year Probability of being the next immediate outcome to be
experienced
No TB TB TB Complete Death
No TB 0 0.54(0.47,0.61) 0 0.46(0.39,0.53)
TB 0.72(0.65,0.78) 0 0.17(0.12,0.23) 0.11(0.07,0.16)
TB Complete 0 0.57(0.28,0.83) 0 0.43(0.17,0.72)
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7.8.3 Transition Hazards Ratios
One of the important goals in survival analysis is to assess the effects of covariates
on the time to an event occurring. Like in the standard proportional hazards mod-
els, the transition hazards defined in Equation 7.1 to Equation 7.7 are assumed
to be proportional transition hazards models. This assumption eases the inter-
pretation of the estimated transition hazards. The likelihood function for these
models is defined as in Equation 4.49 with the transition intensity function defined
in terms of the corresponding transition probability.
Table 7.6 shows the estimated transition hazards ratios (THR) for age, sex and the
era in which the patients started ART (ART period). The hazards of remaining
in the same state are used as reference values (THR = 1). There were signific-
ant differences in the transition hazards of TB infection given they were TB free
(1→ 2), with patients who started ART after 2007 having a significantly reduced
risk of TB infection (THR: 0.524, 95% CI : 0.339, 0.810). Compared to female
patients, male patients had significantly higher hazards of death given they were
TB free 1→ 4 (THR: 2.274, 95% CI: 1.508, 3.428). For patients on TB treatment
(in state 2 ), there were no significant differences noted although a unit increased
in age and being a female patient had lowering effects on the hazards of being
cured of TB (2→ 1).
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Table 7.6: Estimates of 10-Year Transition Hazards Ratios (95% CI) using a
time-homogeneous Markov Model(Reference values: Female for Sex and 2004-
2007 for ART period)
Transition Initiation Age Sex: Male ART Period:2008-2011
1 → 2 1.014(0.992, 1.036) 1.303(0.825, 2.057) 0.524(0.339, 0.810)
1 → 4 0.981(0.960, 1.003) 2.274(1.508, 3.428) 0.692(0.459, 1.046)
2 → 1 0.998(0.982, 1.013) 0.858(0.599, 1.230) 1.248(0.853, 1.826)
2 → 3 1.009(0.975, 1.045) 1.677(0.774, 3.632) 0.866(0.379, 1.978)
2 → 4 1.037(0.994, 1.082) 1.600(0.580, 4.409) 0.461(0.171, 1.240)
3 → 2 1.016(0.949, 1.087) 0.967(0.150, 6.237) 1.126(0.109, 11.644)
3 → 4 0.975(0.888, 1.070) 0.297(0.038, 2.375) 0.163(0.016, 1.650)
In Figure 7.6, a comparison of cumulative hazards of death and TB diagnosis is
made for patients that are in the TB-free state. It can be noted that cumulative
transition hazards for death are higher (steep slope) than TB diagnosis in early
days on ART treatment but the opposite is true for later periods.
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Figure 7.6: Cumulative transition hazards of death without TB diagnosis (1→
4) compared to the hazards of TB diagnosis (1→ 2)
7.9 Model Assessment
It is important to assess if the fitted model suits the data well. In multistate mod-
els, two approaches are used: plotting the number of observed and expected counts
in each state and Pearson-type goodness of fit (which is analogous to Pearson χ2
test).
Suppose all patients start in state j and have a common initial time t. Then
the expected number of patients in state k at time t is n(t)P (t)j,k. Using this
definition, we compare and plot at one-year intervals the expected and observed
number of patients using the R-function prevalence.msm (Jackson, 2011). Here,
prevalence is defined as percentages of individuals in each state at a set of times.
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From Figure 7.7, it can be noted that the prevalence for the observed and expected
are similar for "‘TB Complete"’ and "‘ On TB treatment"’ states. However under
this model, the observed and expected are not predicted well for the "‘TB free"’
and "‘Dead"’ states. Less individual were observed than expected in the "‘TB
Free"’ state and more individuals were observed than expected in the "‘Death"’
state. This means that the model does not describe well these irregularly-observed
transition processes. From about 50 months (4 years), the model tend to overes-
timate the predicted number of patients who die. Also at around the same time,
the model tend to underestimate the number of patients who are TB free.
The possible reasons for this poor fit could be due to the following reasons. Firstly,
this could mean failure of the Markov assumption, meaning the transition intens-
ities may well depend on the time spent in previous states, the process history. To
address this, (Jackson, 2011) suggest the use of a Semi-Markov process model as
a possible solution but it is often difficult to account for the process history as the
process is only observed through series of snapshots. The other reason for poor
fit could be that the non-homogeneous time model is ideal for these data. To go
around this problem, one way is to consider modelling the transition intensities as
a piecewise-constant function of age.
The observed and expected number of patients in Pearson-type test are calculated
by (Jackson, 2011; Titman, 2009; Aguirre-Hernández and Farewell, 2002):
Ohlhrscg =
∑
I {S(ti,j+1) = s, S(tij) = r}
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P {S(ti,j+1) = s|S(tij) = r}
where r is the starting state, s is the finishing state, h is time between the start of
the process and the first observed pair, lh is the time interval between observations,
g is for diagnosing lack of fit and c is the impact of covariates summarised by qrr.
Here I(E) is the indicator function for an event E, the summation is over all
individuals and over the set of transitions in the groups defined by h, lh, c, g. The
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The results in Table 7.7 from the Pearson test (using pearson.msm in R, see
Jackson, (2011)) suggest there is a problem in the computation of the test. We
get;
Table 7.7: Model diagnostics using Pearson-type test
stat df.lower p.lower df.upper p.upper
468 NA NA 147 0
This means that the observed sample in some transition paths is not possible under
the null hypothesis. This is noted in Table 7.2 that there are very few individuals
in some transition paths (note: On TB treatment and TB complete are transient
states). In this case, this test may not useful, as a result we use the plots above
as a diagnostic tool.
7.10 Discussion and Conclusion
In medical and epidemiological studies, the odds ratios, relative risks and hazard
ratios are the quantities often reported and well understood by wider readership
in health field. However, in this study different quantities are modelled and their
relationship explained. The quantities reported in this analysis are the transition
intensities, transition probabilities and the transition hazard ratios. The overall
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aim was to provide an alternative interpretation of model results in order to aid a
better understanding of the epidemiology of diseases. In particular, in this study,
these methods were used to explain and better understand the TB epidemiology
in HIV cohorts.
We considered a multistate model as opposed to modelling as transition separately
because this accounts for the fact that patients can also visit other competitive
states. The results from the model better explains the transitions and their de-
pendencies as patients move from one state to another. Moreover, the probabilities
obtained from the models describe the random movements of patients providing
possible competitive pathways patients are likely to take.
There were three assumptions made for this analysis. Firstly, it was assumed that
the transitions we observed were unrelated to ART regimen and the latter was
unobserved. Secondly, it was assumed that TB treatment type was not responsible
for the transitions observed between the states. Lastly, our analysis focusses on
all-cause mortality because data on cause-specific were not captured in this HIV
cohort.
A larger proportion of TB patients were already on TB treatment at the time of
starting HIV treatment. This could be that these patients were already infected
with HIV and were just tested late for HIV since TB is an opportunistic illness
that takes advantage of worsening body immunity. The main clinical implication
of this result is to consider close monitoring of patients with HIV/TB co-infections.
The main transitions observed in this cohort were; remaining TB free, no TB to
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death, TB infection to cure, no TB then TB then cure, no TB then TB then died
in that order (Table 7.2). Mortality was three times higher in patients who got
TB after starting ART than in patients who started ART while on TB treatment.
Overall, mortality was low among TB patients (15%) compared to the rates repor-
ted from other studies in the tropics (Loveday et al., 2015; Velásquez et al., 2015;
Diendéré et al., 2015; Vijay et al., 2011; Collins et al., 2010; Makombe, Harries, Yu
et al., 2007). This result is consistent with current efforts that are being to made
in intensifying TB screening in HIV cohorts. Form public health perspective, HIV
programs should consider integrating more TB service in HIV cohorts rather than
HIV patients accessing TB services in standalone TB clinics.
Both unadjusted and adjusted models lead to same conclusions though inclusion
of patient covariates in adjusted models lowered the parameter estimates in the
majority of the cases (transition intensities, probabilities and transition hazards).
Patients in TB free status had a relatively higher probability of being diagnosed
with TB than dying TB free. However, the cumulative transition hazards were
higher for "TB free → death" transitions compared to the "TB free → TB infec-
tion" transitions during the early days on HIV treatment. Thereafter, the cumu-
lative hazards are similar and tend to level-off with time. Clinically, this implies
that the early period on ART is crucial and better practices for management HIV
patients during this period have been advocated elsewhere (Rabie et al., 2015;
Mosam, Uldrick et al., 2011; Vijay et al., 2011; Collins et al., 2010).
Once patients were on TB treatment, they were more likely to complete the treat-
ment than to die while on TB treatment. There was an eight fold chance of
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completing the TB treatment and be cured compared to patients dying while on
the TB treatment. This also observed in high treatment TB treatment success
rate of 76.5%. From clinical and public health perspective, this finding would
be pleasing to clinicians and public health specialists because the use of ART is
supposed to boost the immunity of HIV patients hence should have a spilling-
over protective effect on opportunistic illnesses such tuberculosis. Several studies
have reported the protective and beneficial effective of ART on opportunistic ill-
ness (Belayneh, Giday and Lemma, 2015; Vijay et al., 2011; Collins et al., 2010;
Johansson, Robberstad and Norheim, 2010).
The majority of TB patients who completed treatment had their TB status ascer-
tained soon after finishing TB treatment. However there were nine TB patients
who, despite finishing their TB treatment, their ascertainment results about TB
status after took longer than usual. For these patients, they were more likely to
restart TB treatment compared to declared cured or dying while waiting confirm-
ation results. The stock out of TB diagnostic test kits could be the main cause
of the delay of after-treatment confirmation tests. While there are continued ef-
forts in improving logistics in HIV and TB programming, countries in sub-Saharan
countries face so many logistics due to demands from disease burdens such as mal-
aria and cancer. These challenges if not addressed could erode the gains already
made in controlling TB in the general population.
There were only two transitions in which significant differences in patient covariates
were observed; transitions from TB free state to TB infection state and TB free
state to death (Table 7.6). Patients who were TB free and had started HIV
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treatment between 2008 and 2011 had significantly lower hazards of transitioning
to TB infection status compared to the hazards of directly transitioning to the
death state. Also TB free male patients were twice at risk of dying compared
to TB free women. In all other transitions, no significant differences were noted
neither by age, sex nor period of starting treatment. Gender differences in TB
outcomes as well ART outcomes have been reported in other studies in Africa
(Takarinda et al., 2015; Jarrin, Gestus and al, 2008).
The model assessment indicated that the homogeneous continuous time multistate
Markov model did not consistently fit the data well. The poor prediction seen in
t state 1 (TB free) and state 4 (death) could suggest a failure of the Markov
assumption or indeed the time homogeneous assumption used. To address this
prediction, one could consider modelling the transition intensities as a piecewise-
constant function of age. Also, one could consider relaxing the Markov assumption
and model the whole process history. Also, the Pearson-type test failed to be com-
puted because of the small number of observations in some transitions especially
transitions into "‘TB treatment complete"’ state. The limitation of this test was
also highlighted by Aguirre-Hernández and Farewell, (2002).
The issue of lost follow-up (LTFU) has been discussed in all previous chapters.
Unlike the first and second chapters, in this chapter the main focus was on the
diagnosis of TB. The data on TB patients used in this analysis was collected and
periodically updated at a district-level and was mostly complete with all outcomes
ascertained in the majority of patients. Nationally, the TB treatment default rate
(missing treatment) has fallen from 5% in 2006 to 2% in 2009 to 2010 period
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(Malawi Ministry of Health, 2011). In this sampled data, a low proportion of
loss to follow-up of approximately 10% was observed. We anticipate that even
after accounting for deaths in the 10% LTFU group the reported results will not
be drastically different from the ones reported in this study. Nevertheless, loss
to follow-up in TB patient cohorts is still a big concern in many sub-Saharan
countries. More importantly TB patients who default on their treatment pose a
great danger of infecting other people in their communities. Poor adherence to
TB treatment can lead to developing resistance to standard first line drugs. Many
TB programs in Africa are doing commendable efforts to address this issue, with
a more recent concerns for TB patients detained in prisons (Mburu et al., 2016;
Puchalski Ritchie et al., 2015; Loveday et al., 2015; Feasey et al., 2013).
The limitations of this study are mainly failure to account for the impact of dia-
gnostic tool (sputum smear versus X-ray) and type of TB (PTB, EPTB, MDR-
TB). Including these variables would help to measure they impact transition quant-
ities reported here. Also being a retrospective study, we were limited in terms of
socio-demographics and clinical variables to include in the models. Being an air-
borne disease, TB prevalence varies by social factors such as being in crowded
prisons and tobacco smoking. Inclusion of such social could provide an extra layer
of understanding TB in HIV populations. Another limitation of this analysis is
that the infection rate reported in this analysis could be lower than the rate in
the general population. This is because we only used TB cases in HIV clinic and
might have missed some TB cases in the general HIV population. Complete cap-
turing of TB cases in many settings like Malawi with poor surveillance systems
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is challenging. Lastly, the issue of loss to follow-up could also have an impact on
the true outcomes of patients who did not die. Although the majority (>90%) of
patients were alive and were in active follow-up, the other 10% of patients’ statues
were based on their last known clinic visit (a lag of 3 months). This could po-
tentially underestimate the number of deaths not Tb infections due to its public
health importance. Despite these limitations, the results of this analysis are con-
sistent with results reported in other studies in the region. In additional, by using
multistate models we have demonstrated how presenting different transitions in
TB can improve our understanding of TB epidemiology in HIV cohorts. In our
literature review, we noted that multistate models are widely applied in oncology
and pharmacology (Svensson and Simonsson, 2016; Andersen and Keiding, 2002;
Anderson, Cain and Gelber, 1983).
Further areas of research extending this work can be considered in the following
areas. Firstly, it will be interesting to investigate if the introduction of the uni-
versal provision of ART to all HIV patients regardless of their CD4 levels will
have an impact on incidences of TB episodes in HIV populations. As part of as-
sessing the impact of this universal ART treatment policy, it will be of interest
to see how transitions in TB states will be affected in the long run. Secondly, a
possible methodology work is to extend the present work to include spatial effects
(spatial multistate models). This could help to understand regional effects on the
transition probabilities: geography is increasingly becoming an important element
in the planning process of health programmes. With increasing development of
computational tools and software, these more complicated models can be fitted
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although this is not straight-forward.
In conclusion, the results in this analysis provide clear pathways taken by patients
as they move from one state to another. It is noted that the following pathways
were common; remaining TB free, no TB to death, TB infection to cure, no TB
then TB then cure, no TB then TB then died. Cumulatively, we noted that there
was a high probability that TB-free patients would die than TB infection as their
immediate state. Also significant gender differences were noted in TB-free to death
transitions and being diagnosed with TB significantly varied with the period of
starting a lifelong HIV treatment. Although mortality among TB patients was
low compared to other cohort studies in the region, continued efforts for early TB
diagnosis and treatment initiation are crucial for public health reasons. In HIV
cohorts, patients with long follow-up time should be given the necessary attention
as they tend have a higher risk of TB infection. The methods presented in this
chapter are a complementary way of interpreting results from comparable models.
Apart from reporting the traditional hazards and time ratios in survival analysis,
transition probabilities and intensities are also reported here. As argued, this could
potentially increase in the way in which the public health readership community
can understand the epidemiology of a particular disease. Continued operations
research and best practices research in TB epidemiology is vital to inform the
overall public health interventions for controlling TB, especially in this rapidly
changing era of the lifelong antiretroviral therapy.
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Part III
General Discussion and Further
Research
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The work in this thesis has addressed some of the most important research ques-
tions in HIV epidemiology: survival, geographical variation in risk and TB co-
infection. As such, the purpose of this Part III is to summarise the discussion
and conclusion points from presented in the three (3) results chapters: Chapter 5,
Chapter 6 and Chapter 7.
In Chapter 5, we have reported risk factors associated with mortality in ART
cohorts. In addition, we have provided a novel way of identifying the lower bound
for the proportion of loss to follow-up (LTFU) patients that are really deaths. In
summary, we found that the time of starting ART was associated with reduced
hazards of death, while patients diagnosed with TB were twice at greater risk
of death compared to those without TB. These results were also echoed in some
results from sensitivity analysis of our approach of addressing LTFU. Our approach
of addressing LTFU in HIV cohorts is one of the major contributions of this thesis
as a whole. However, we hasten that to caution the reader that our approach is not
the ideal method for correcting parameter estimates in the model using data with
high LTFU. The methods for that purpose are available: see Kiragga et al., (2013)
and Henriques et al., (2012) and also a dedicated HIV research group in South
Africa, see http://www.iedea-sa.org/ for details. The key public health message
in this chapter concerns advocating for continued funding for HIV programs to
better trace individuals who are lost from HIV/AIDS care.
In Chapter 6, we extended the analysis in Chapter 5 by addressing the aspect
of geographical epidemiology. With the use of exceedance probability maps, we
noted that the northern and southern parts of Zomba district had unusually high
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probability of having greater hazards for death. The key contribution of this study
to the general HIV epidemiology is the intuitive way of interpretive the risk in
space. Identifying areas with poor survival outcomes becomes easy and this could
facilitate knowledge sharing among policymakers and health practitioners. Such
information could be used in the planning and distribution of resources targeting
areas with high disease burden. By highlighting geographical variation in risk,
this could also inform the global HIV/AIDS campaigns such as the 90-90-90 HIV
treatment goals aimed at eradicating AIDS by 2030 (UNAIDS, 2014).
In Chapter 7, we have addressed another important opportunistic disease in HIV
and AIDS cohorts. Due to compromised immunity, HIV patients are often vul-
nerable to attacks from several opportunistic illnesses including from TB infection
(CDC, 2016; Chu, Mahlangeni et al., 2010). In this analysis, we noted that (all-
cause) mortality was three times higher in HIV patients that contracted TB after
they had started ART compared to those that were already on TB treatment. This
result is indicative of worsening prognosis in patients that were diagnosed with TB
after recruitment. Few relapses (7) were observed among the TB patients that suc-
cessfully completed TB treatment at some time point. This low number of relapses
is encouraging finding highlighting the effect of ART (by boosting immunity) and
similar findings have been reported from studies in sub-Saharan Africa (Belayneh,
Giday and Lemma, 2015; Johansson, Robberstad and Norheim, 2010). Also, we
noted that once patients were on TB treatment, they were more likely to complete
the treatment than to die while on TB treatment. This is good because to gives
hope to the fight against TB. Lastly, we observed gender differences in mortality
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risk, with men having high risk of death: should continue to worry clinicians and
public health specialists. This undermines the continued efforts to eradicate TB
and gender mainstreaming in TB treatment programmes could provide vital. We
anticipate that the findings in this study will help to inform the current global
campaigns to end TB by 2030: WHO End TB Strategy, with a target of 35%
reduction in TB cases by 2020; Towards Zero campaigns by 2030- TB, AIDS,
Malaria, Poverty etc (WHO, 2016)
A number of future research studies could be considered for both epidemiology and
methodology purposes. For epidemiology research, future operational studies are
needed to study geographical differences in KS epidemiology and treatment out-
comes. Similar analyses at regional and nation-level to study KS epidemiology and
other types of cancer in HIV programmes could inform current efforts to improve
HIV programming in resource-limited settings. Also, there is need to find better
metrics for distance from Zomba Clinic to the patient’s location. Operational and
best practices research should be encouraged in HIV and TB epidemiology in order
to inform the overall public health interventions for controlling TB, especially in
this rapidly changing era of HIV treatment. For methodology, a possible meth-
odology work is to extend the present multistate models to include spatial effects
(spatial multistate models) and their computation to supplement current work
by Nathoo and Dean, (2008) and Brezger, Kneib and Lang, (2005). This could
help to understand regional effects on the transition probabilities as geography is
increasingly becoming an important element in epidemiology as a whole.
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